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RESUMEN 
CAPÍTULO I: NUEVOS INHIBIDORES DE ANGIOGÉNESIS CON ACTIVIDAD ANTITUMORAL IN 
VIVO
La angiogénesis, el proceso de formación de nuevos vasos sanguíneos, es un requerimiento 
esencial para la supervivencia y proliferación de los tumores sólidos.1 Por consiguiente, la búsqueda
de inhibidores de la angiogénesis se ha convertido en una importante línea de investigación en el 
área de cáncer, y se ha traducido en la presencia de múltiples fármacos en el mercado que han
mejorado claramente los resultados en pacientes con distintos tipos de tumores y metástasis. Sin 
embargo, todavía existen limitaciones, como la falta de eficacia en algunos pacientes, y la aparición
de efectos adversos o de resistencia al tratamiento.2-4 Se considera que cuando se bloquea
farmacológicamente la señalización del factor de crecimiento vascular endotelial (VEGF), otros 
factores proangiogénicos -especialmente el factor de crecimiento de fibroblastos (FGF)- cumplen su 
función, favoreciendo la angiogénesis tumoral.2,5,6 Además, se ha descrito que el aumento de la
hipoxia tumoral causado por la terapia antiangiogénica potencia la supervivencia celular al estimular 
varios factores, particularmente el factor inducible por hipoxia-1α (HIF-1α).7 
En este contexto, el principal objetivo del presente trabajo es la identificación de nuevas 
estructuras químicas capaces de bloquear la angiogénesis afectando varios factores 
proangiogénicos (especialmente VEGF y FGF), así como de inducir una inhibición sostenida de la
señalización proangiogénica generada por la hipoxia. Este objetivo general supone llevar a cabo los 
siguientes pasos: 
1. Identificación de un hit y proceso hit to lead. 
2. Caracterización biológica de los compuesto(s) seleccionado(s) en relación a su capacidad
para bloquear la señalización proangiogénica ante la hipoxia.
3. Estudio del efecto antitumoral de los compuesto(s) seleccionado(s). 
Por tanto, en este capítulo describimos una nueva serie de compuestos antiangiogénicos.8 Entre
ellos, el compuesto óptimo 22 (UCM-2711) inhibe la señalización proangiogénica en hipoxia en 
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células de cáncer de mama. Más concretamente, la administración de 22 disminuye los niveles de
las moléculas proangiogénicas VEGF, FGF, y óxido nítrico (NO). Además, este compuesto inhibe
las formas activas de los receptores correspondientes a los mencionados factores (las formas 
fosforiladas de VEGFR y FGFR) y baja los niveles de la enzima óxido nítrico sintasa inducible (iNOS).
Dichos efectos se correlacionan con un bloqueo en las vías de señalización MEK/ERK y PI3K/AKT,
así como de la migración celular; y están mediados por HIF-1α, puesto que los efectos del compuesto
22 prácticamente desaparecen cuando su expresión se reduce mediante un knock-down genético.
Adicionalmente, la evaluación del perfil genético ha permitido identificar un conjunto de genes 
relacionados con la angiogénesis cuya expresión se altera con el compuesto 22. Finalmente, la 
administración del compuesto 22 a un modelo xenograft produjo reducciones en el crecimiento
tumoral entre el 46 y el 55% en un 38% de los animales tratados. Cabe destacar que en los tumores
que respondieron al tratamiento, se observó además una reducción significativa del número de vasos 
sanguíneos y de los niveles de VEGF, apoyando así el mecanismo de acción del compuesto. Aunque
sería deseable una mayor eficacia, el hecho de que el compuesto 22 no indujese toxicidad alguna
in vivo, y que fuese capaz de bloquear de forma efectiva la angiogénesis en los tumores que
respondieron al tratamiento, refuerza el potencial del compuesto como un lead para el desarrollo de
nuevos agentes antiangiogénicos aptos para el tratamiento del cáncer, ya sea solos o en 
combinación con otros fármacos de referencia. 
Migración
celular
CAPÍTULO II: PROCESO DE OPTIMIZACIÓN Y CARACTERIZACIÓN BIOLÓGICA DE UN
NUEVO INHIBIDOR DE ICMT CON ACTIVIDAD ANTITUMORAL 
Las mutaciones puntuales del gen ras llevan a la producción de una proteína Ras
constitutivamente activa, resultando así en una estimulación constante de la proliferación celular y 
la inhibición de la señalización intracelular que conduce a la apoptosis. Sin embargo, pese a más de 
tres décadas de intenso esfuerzo, ningún fármaco que inhiba eficazmente las oncoproteínas Ras ha 
llegado a fase clínica, lo cual ha motivado la amplia creencia de que las proteínas Ras son
‘undruggable’.9,10 Por ello, la posibilidad de bloquear la actividad de Ras interfiriendo con las 
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modificaciones post-traduccionales responsables de su activación ha ganado atención en los últimos 
años.  
Ras es un miembro de una gran clase de proteínas conocidas como las proteínas CAAX, donde 
C es cisteína, A es normalmente un aminoácido alifático, y X es cualquier aminoácido. Su producto 
primario tras la traducción contiene una secuencia CAAX, que sirve como sustrato de tres enzimas
que la modifican de manera secuencial para crear un dominio lipídico e hidrofóbico que media la
asociación con membranas celulares. Primero, la secuencia CAAX intacta sirve de sustrato para su 
prenilación por la geranilgeranilasa tipo I (GGTase I) o la farnesiltransferasa (FTasa).11  A
continuación, se da la proteólisis de los tres últimos aminoácidos AAX, gracias a la enzima 
convertidora de Ras (Rce1).12,13 Y por último, la nueva prenilcistína C-terminal sirve como sustrato 
para una enzima metiltransferasa específica, la isoprenilcisteína carboximetiltransferasa (ICMT), que
metila el grupo carboxilo libre, neutralizando la carga negativa de la prenilcisteína y aumentando así
su afinidad por la membrana.14 
En ausencia de cualquiera de estas modificaciones post-traducccionales, Ras pierde su habilidad
para inducir transformación tumoral. Sin embargo, hasta el momento los intentos de bloquear los
primeros dos pasos de estas modificaciones post-traduccionales han fracasado.15-18 Además, el
hecho de que los genomas de mamíferos codifiquen únicamente para un miembro de la clase ICMT 
de las metiltransferasas, y que ésta no presente homología con ninguna otra metiltransferasa, 
convierte la inhibición de ICMT en una prometedora alternativa para las terapias antitumorales. En
este contexto, en nuestro grupo de trabajo hemos iniciado un proyecto orientado al diseño, síntesis 
y desarrollo de nuevos inhibidores de ICMT. Esto nos ha llevado al nuevo lead UCM-1325, que
mostró el mejor perfil en términos de capacidad inhibitoria de ICMT. Así pues, los principales
objetivos del presente trabajo son: 
1. Optimización del lead UCM-1325. 
2. Estudio del mecanismo de acción de los compuesto(s) seleccionado(s). 
Por consiguiente, en este capítulo describimos el proceso de optimización del lead UCM-1325 
hasta llegar al lead optimizado UCM-1336 (3), que mostró una inhibición de ICMT del 93% a 50 μM 
(CI50  =  2 μM), siendo por tanto seleccionado para su estudio biológico y caracterización del 
mecanismo de acción. Este nuevo compuesto potencia la muerte celular programada, afectando
especialmente a aquellas líneas celulares que expresan K-Ras mutante oncogénica; e induce una
deslocalización de todas las isoformas de Ras. Además, UCM-1336 (3) reduce significativamente la
actividad de Ras, bloquea la activación de las vías de señalización MEK/ERK y PI3K/AKT, y afecta 
la capacidad de migración de las células tumorales. Cabe destacar que UCM-1336 (3) ha mostrado
una mayor potencia que el ya validado inhibidor de ICMT cysmethynil en todos los ensayos
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realizados, sugiriendo que podría funcionar como un nuevo inhibidor de ICMT que contribuiría a la 
definitiva validación de dicha enzima desde un punto de vista mecanístico, como una diana de interés 
terapéutico para el tratamiento de cánceres caracterizados por una elevada activación de Ras. 
Todos estos prometedores resultados nos han llevado a estudiar la eficacia in vivo del compuesto
UCM-1336 (3) en un modelo xenograft de cáncer de páncreas en ratón, experimentos que se están
realizando actualmente.
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SUMMARY 
CHAPTER I: NEW INHIBITORS OF ANGIOGENESIS WITH ANTITUMOR ACTIVITY IN VIVO 
Angiogenesis, the process of new blood vessel formation, is an essential requirement for the survival
and proliferation of solid tumors.1 Accordingly, the search for angiogenesis inhibitors has become a  
leading line of investigation in anticancer research, and it has translated into several drugs in the market 
that have clearly improved outcomes in patients with different tumor types and metastatic disease. 
However, several limitations still exist, such as the lack of efficacy in some patients, the appearance of 
adverse effects, and drug resistance.2-4 It has been suggested that when the vascular endothelial growth 
factor (VEGF) signaling is pharmacologically blocked, other proangiogenic factors -especially the
fibroblast growth factor (FGF)- take over its signaling, thereby supporting tumor angiogenesis.2,5,6
Besides, it has been described that increasing tumor hypoxia during antiangiogenic therapy enhances 
cell survival through the stimulation of several factors, particularly the hypoxia-inducible factor-1α (HIF-
1α).7 
In this context, the main objective of the present work is the identification of new small molecules able 
to block angiogenesis affecting various proangiogenic factors (especially VEGF and FGF signaling 
pathways), and to induce a sustained inhibition of the proangiogenic signaling generated by hypoxia. This
overall objective involves the following steps:
1. Hit identification and hit to lead process.
2. Biological characterization of selected compound(s) in terms of impairment of proangiogenic 
signaling under hypoxia.
3. Antitumor effect of selected compound(s). 
Hence, in this chapter we describe a new series of antiangiogenic compounds.8 Among them, the optimal 
compound 22 (UCM-2711) inhibits the proangiogenic signaling under hypoxic conditions in breast cancer
cells. Specifically, administration of 22 decreases the levels of the proangiogenic molecules VEGF, FGF,
and nitric oxide (NO). Moreover, this compound inhibits the active forms of the corresponding receptors 
of these factors (phosphorylated forms of VEGFR and FGFR) and the levels of the inducible nitric oxide
11
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synthase (iNOS) enzyme. These effects correlate with a blockade of the MEK/ERK and PI3K/AKT
pathways and the inhibition of cellular migration; and they are mediated by HIF-1α, since the effects of 
compound 22 mostly disappear when its expression is knocked-down. Additionally, gene profiling
identified a set of genes related to angiogenesis whose expression is altered by compound 22 and that
might contribute to the antiangiogenic effects. Furthermore, administration of compound 22 in a xenograft 
model produced tumor growth reductions ranging from 46 to 55% in the 38% of the treated animals. 
Importantly, in the responding tumors, a significant reduction in the number of blood vessels and in the
levels of VEGF was observed, further supporting the mechanism of action of the compound. Although
better efficacy would be desirable, the fact that compound 22 did not induce any toxic effects in vivo and 
that it was able to effectively block angiogenesis in the tumors of responding animals strongly support the
potential of this compound as a lead for the development of new antiangiogenic agents suitable for the 
treatment of cancer either alone or in combination with other benchmark drugs. 
CHAPTER II: LEAD OPTIMIZATION PROCESS AND BIOLOGICAL CHARACTERIZATION OF A 
NOVEL INHIBITOR OF ICMT WITH ANTITUMOR ACTIVITY
Single-point mutations of ras gene can lead to the production of constitutively activated Ras protein,
resulting in a continuous stimulation of cell proliferation and inhibition of apoptotic signaling, thus 
promoting cancer. However, despite more than three decades of intensive effort, no effective
pharmacological inhibitors of the Ras oncoproteins have reached the clinic, prompting the widely held
perception that Ras proteins are ‘undruggable’.9,10 Hence, the possibility of blocking Ras activity by 
interfering with the post-translational modifications responsible for its activation has gained an increasing 
attention within the last years.
Ras is a member of a large class of proteins known as CAAX proteins, where C is cysteine, A is usually
an aliphatic amino acid and X is any amino acid. Their primary translation product ends with a CAAX 
sequence, which serves as a substrate for three enzymes that modify the sequence in a step-wise manner 
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to create a lipidated, hydrophobic domain that mediates the association with cellular membranes. First, 
unmodified CAAX sequences serve as substrates for prenylation by geranylgeranyltransferase type I 
(GGTase I) or farnesyltransferase (FTase).11 Second, there is a specific proteolytic removal of the last
three amino acids AAX, carried out by the Ras-converting enzyme 1 (Rce1).12,13 And finally, the newly
formed C-terminal prenylcysteine becomes a substrate for a specific protein carboxyl methyltransferase, 
isoprenylcysteine carboxyl methyltransferase (ICMT), which methylates the free carboxyl group, 
neutralizing the negative charge of the prenylcysteine and thereby increasing membrane affinity.14 
In absence of any of these post-translational modifications, Ras losses its ability to induce tumor 
transformation. However, thus far attempts to abrogate the first two steps of the post-translational 
modifications have failed.15-18 Besides, the fact that mammalian genomes encode only one member of
the ICMT class of methyltransferases and that it lacks homology to other protein methyltransferases, turns
the inhibition of ICMT into a promising alternative for anticancer therapies. In this context, in our research 
group we have started a project aimed at the design, synthesis and development of new ICMT inhibitors.
This has led us to the new lead UCM-1325, which showed the best overall profile in terms of ICMT
inhibitory capacity. Thus, the main objectives of the present work are:
3. Optimization of the lead UCM-1325. 
4. Study of the mechanism of action of the selected compound(s). 
Hence, in this chapter we describe the lead optimization process of UCM-1325 that has led us to the
new lead UCM-1336 (3), which showed an ICMT inhibition of 93% at 50 μM (IC50 = 2 μM), hence being
selected for in depth biological studies and characterization of its mechanism of action. This new 
compound enhances programmed cell death, affecting specially those cell lines expressing oncogenic
mutant K-Ras; and induces mislocalization of all Ras isoforms. Besides, UCM-1336 (3) significantly
reduces Ras activity, blocks the activation of the downstream MEK/ERK and PI3K/AKT signaling
pathways, and impairs the migratory capacity of tumor cells. Noteworthy, UCM-1336 (3) has shown to be
more potent than the already validated ICMT inhibitor cysmethynil in all performed assays, suggesting
that it could work as a new ICMT inhibitor that would help to definitively validate this enzyme from a
mechanistic standpoint as a therapeutic target of interest for the treatment of cancers characterized by
high Ras overactivation. All these promising results have prompted us to study the in vivo efficacy of 
compound UCM-1336 (3) in a xenograft mouse model of pancreatic cancer, experiments that are currently 
ongoing.  
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1. INTRODUCTION AND OBJECTIVES 
Solid tumors initially grow as avascular nodules by absorbing nutrients and removing waste
through simple diffusion, but once they grow beyond approximately 1 mm in diameter, they need to
develop a novel network of blood vessels to satisfy their increasing need for nutrients and oxygen, 
and to remove waste products.1 Angiogenesis, the process of new blood vessel formation, is then an 
essential requirement for the survival and proliferation of solid tumors. 
The angiogenic process starts when a cell activated by a lack of oxygen releases proangiogenic 
factors that attract and promote the proliferation of inflammatory cells, which intensify the angiogenic
call; and of endothelial cells from existing blood vessels, which proliferate and secrete proteases that 
break the blood-vessel wall, allowing their migration toward the angiogenic stimuli (Figure 1). 
Furthermore, one characteristic feature of new tumor vessels is that they fail to become quiescent, 
enabling the constant growth of tumor vasculature, which consequently becomes distinct from the 
normal blood supply system, showing irregularly shaped, dilated and tortuous vessels. 
Figure 1. The development of new vessels in tumor angiogenesis (from Siemann, D.W. Vascular targeting
agents. Horizons in Cancer Therapeutics 2002, 3, 4-15).
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Accordingly, the search for angiogenesis inhibitors has become a leading line of investigation in 
anticancer research, and it has translated into several drugs in the market that have clearly improved
outcomes in patients with different tumor types and metastatic disease. 
There are many proangiogenic factors supporting tumor growth, such as vascular endothelial
growth factors (VEGF), platelet derived growth factors (PDGF), fibroblast growth factors (FGF),
tyrosine-protein kinase KIT (c-KIT or CD117), etc. And consequently, there are a number of 
possibilities to obtain an angiogenesis blockade. In fact, there are thirteen antiangiogenic drugs 
approved by the Food and Drug Administration (FDA), categorized as a) monoclonal antibodies or 
fusion proteins designed against the specific proangiogenic growth factors and/or their receptors; b) 
tyrosine kinase inhibitors (TKIs) of multiple proangiogenic growth factor receptors; and c) inhibitors 
of mammalian target of rapamycin (mTOR) (Figure 2).2 
PDGFR VEGFR c-KIT FGFR 
PI3K 
AKT 
mTOR 
Ras 
Raf 
MEK 
ERK 
Cell survival 
Angiogenesis
Tumor growth 
mTOR inhibitors 
(everolimus, 
pazopanib) 
TKIs 
(sorafenib, 
sunitinib, 
regorafenib) 
VEGF inhibitors 
(bevacizumab, 
aflibercept) 
Figure 2. Summary of the mode of action of some proangiogenic factors and of major therapeutic agents
designed against them (in red boxes).
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Among these agents, bevacizumab (Avastin®, Genentech Ltd.) was the first antiangiogenic drug
approved by the FDA in 2004.3 Bevacizumab is a monoclonal antibody that targets VEGF -also known 
as VEGFA- and hinders it from binding to its corresponding receptor, thus blocking its signaling.
Initially considered a first-line treatment for metastatic colorectal cancer, it is also prescribed for the
treatment of other types of cancer, and its development still stands out as one of the landmark 
achievements of anticancer research.4 With this same target, aflibercept (Zaltrap®, 
Sanofi/Regeneron), a soluble recombinant fusion receptor composed of VEGFR1 and VEGFR2 
fragments, has recently been approved for the second-line treatment of patients with metastatic 
colorectal cancer in combination with chemotherapy.5 
On the other hand, some TKIs (Figure 3) have also been approved by the FDA for the treatment
of cancer angiogenesis. These compounds exert their effect at the intracellular level, inhibiting the 
kinase activity of receptors and/or downstream signa transducers of important angiogenic signaling 
systems. For instance, sorafenib tosylate (Nexavar®, Bayer) inhibits the kinase activity of certain
receptors and the downstream transducer rapidly accelerated fibrosarcoma (RAF) blocking both
angiogenesis and tumor proliferation, and it was approved for hepatocellular carcinoma and kidney 
cancer.6,7 With similar mechanism of action, sunitinib malate (Sutent®, Pfizer) was approved for 
gastrointestinal stromal tumors and advanced kidney cancer,8 and regorafenib (Stivarga®, Bayer) 
has been recently approved for patients with refractory advanced colorectal cancer.9 However, the 
main problem of these TKIs is their relatively low specificity, which allows them to inhibit multiple 
pathways, but with lower efficiency and potential arise of adverse effects.2 
Besides, some mTOR inhibitors (Figure 3) have been approved by the FDA as antiangiogenic 
agents for the treatment of cancer, such as everolimus (Afinitor®, Novartis) for both kidney cancer
and neuroendocrine tumors, and pazopanib (Votrient®, GlaxoSmithKline/ Novartis) for kidney 
cancer. However, the activation of phosphoinositide 3-kinase/protein kinase B, also known as Akt-
(PI3K/AKT) signaling pathway through the inhibition of mTOR, which could lead to outgrowth of more
aggressive lesions; together with the lack of predictive biomarkers of efficacy for tumors treated with
these inhibitors is an important concern that limits their clinical applications.10,11 
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Figure 3. Representative examples of antiangiogenic compounds approved by the FDA. 
Although the previously mentioned, as well as other drugs with similar mechanisms of action, 
have progressed into the clinic,2,12,13 several limitations still exist, such as the lack of efficacy in some 
patients, the appearance of adverse effects, and drug resistance. Among them, this last one is 
perhaps the most important efficacy-limiting factor of the current antiangiogenic therapies. This effect 
has been observed especially for angiogenesis inhibitors targeting VEGF signaling pathways, which
24
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have been clinically used for a longer period of time and in a larger number of patients, thus providing 
us with more clinical data. Results obtained up to day show that, although they are affording 
demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human
cancers, the benefits achieved in both preclinical and clinical studies are at best transitory and are
followed by a restoration of tumour growth and progression.14 A number of factors are behind the
appearance of this resistance. For example, it has been suggested that when VEGF signaling is 
pharmacologically blocked, other proangiogenic factors take over its signaling thereby supporting
tumor angiogenesis.2,15,16 Amid these compensatory angiogenesis pathways, FGF seems to play an 
integral role in the resistance to anti-VEGF therapy, and different studies have suggested a critical
role of the FGF signaling in clinical tumor progression.17-19 Besides, it has been described that 
increasing tumor hypoxia during antiangiogenic therapy enhances cell survival through the
stimulation of several factors, especially the key regulator hypoxia-inducible factor-1α (HIF-1α). Its
activation leads to an increase in transcription levels of the VEGF gene, making it even more difficult 
for the antiangiogenic drugs to achieve their goal.20 
Although targeting FGF signaling has lagged behind that of other receptor tyrosine kinases, there 
is now substantial evidence for the importance of FGF signaling in the pathogenesis of diverse tumor 
types. Hence, the development of compounds that inhibit the FGF pathway is receiving much
attention although they are still early in development.21-23 Among the different FGFs, FGF-2, also 
known as basic FGF (bFGF), has been functionally implicated in tumor angiogenesis and it is an
important target of antiangiogenic therapies.17,21,23,24 Notwithstanding the importance of blocking 
angiogenesis for antitumor therapies, it has been shown that prolonged antiangiogenic treatments 
eventually lead not only to drug resistance but also to enhanced tumor migration and metastasis.25-
27 A main reason for this is that an antiangiogenic compound will eventually generate a hypoxic 
microenvironment, fact that turns on all pro-anginogenic signaling increasing the levels of factors that 
promote the acquisition of an invasive and metastatic tumor phenotype such as nitric oxide (NO), 
VEGF and FGF. In addition, the same cells often express the cognate membrane receptors for these
factors, resulting in autocrine signaling.20 Accordingly, the development of new antitumor compounds 
that simultaneously block angiogenesis and induce a sustained inhibition of the proangiogenic 
signaling generated by hypoxia currently remains as an important unmet need, as these agents
should be more effective drugs than the ones currently in the clinic and should lack the associated 
more aggressive recurrence with metastasis and drug resistance.
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In this context, the main objective of this work is the identification of new small molecules able to 
block angiogenesis affecting various proangiogenic factors (especially VEGF and FGF signaling 
pathways), and inducing a sustained inhibition of the proangiogenic signaling generated by hypoxia.  
This overall objective involves the following steps:
1. 	 Hit identification and hit to lead process.
2. 	 Biological characterization of selected compound(s) in terms of impairment of 
proangiogenic signaling under hypoxia. 
3. 	 Antitumor effect of selected compound(s).
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2. RESULTS AND DISCUSSION 
2.1. Hit identification and hit to lead process
Selected representative compounds of our in-house library were screened in a bFGF-induced cell
proliferation assay using human umbilical vein endothelial cells (HUVECs) in order to identify a hit 
chemically tractable and with drug-like properties that could be amenable to further optimization.
From this screening, carbamate 1 emerged as an initial hit with an IC50 value of 317 M. 
Figure 4. Exploration of the scaffold of the initial hit 1.
We started the exploration of this scaffold (Figure 4) by introducing substituents in the carbamate
group and keeping constant the methyl ester moiety (as its removal led to complete inactivity of the
corresponding carboxylic acid, derivative 2, IC50 > 500 M) as well as the phenolic hydroxyl group
(compounds 3-10). Target compounds were synthesized as depicted in Scheme 1. 
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Scheme 1. Reagents and conditions: a) CSI, DCM, rt, o/n, 30-34%; b) H2, Pd(C), EtOH, rt, 3 h, 100%; c) R2NCO,
DIEA, THF, rt, 16 h, 70-71%; d) NaH, CH3CN, rt, 3 h, 14-64%; e) 4-nitrophenylchloroformate, DABCO, DCM, rt,
5 h, 40%; f) 1-methylpiperazine, DIEA, DCM, 0 °C to rt, 3 h, 67%; g) CH3I, CH3CN, rt, 24 h, 36%.
Reaction of methyl or benzyl 2,5-dihydroxybenzoate with chlorosulfonylisocyanate (CSI), followed 
by benzyl ester cleavage of intermediate 24 yielded carbamates 1 and 2, respectively.
N-monosubstituted carbamates 3 and 4 were obtained by addition of methyl 2,5-dihydroxybenzoate
to ethyl and phenyl isocyanate, in the presence of N,N-diisopropylethylamine (DIEA) as a base,
whereas reaction of methyl 2,5-hydroxybenzoate with the corresponding carbamoylchloride afforded
disubstituted carbamates 5-8. Piperazine derivative 9 was synthesized by nucleophilic substitution of 
4-nitrophenylchloroformate with methyl 2,5-dihydroxybenzoate, followed by treatment of the resultant 
carbonate with 1-methylpiperazine. Alternatively, acylation of methyl 2,5-dihydroxybenzoate with 
carbonylimidazol derivative 25 gave intermediate 26, which afforded final compound 10 by benzyl 
ether deprotection under palladium-catalyzed hydrogenation. Carbamates 2-10 were screened for
activity in the bFGF-induced proliferation assay (Table 1).  
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Table 1. Inhibition of bFGF-induced cell proliferation of HUVECs for compounds 1-10 

Cpd R1  R2  R3 IC50 (M)a 
1 Me H H 317
2 H H H >500 
3 Me Et H 17 
4 Me Ph H 165
5 Me Me Me >500 
6 Me Et Et >500 
7 Me Ph Me 48 
8 Me Ph Ph 35 
9 Me (CH2)2NCH3(CH2)2 >500 
10 Me p-hydroxyphenyl Me 96
aIC50 values are the means from two or three independent experiments performed in triplicate. The standard
error of the mean (SEM) is in all cases within a 10% of the mean value.
From the obtained results, the main conclusion is that the replacement of a hydrogen of the 
carbamate group by an ethyl or phenyl group gave active compounds (3 and 4), whereas 
disubstitution of the carbamate with alkyl chains is detrimental for the activity (compounds 5, 6, and 
9, IC50 >500 M). However, when one or both substituents are aromatic rings the antiproliferative
activity is restored (7, 8, and 10). Among this first series of compounds, carbamates 3, 7, and 8
deserve special attention as they show the highest potency in the inhibition of cell proliferation, with 
IC50 values of 17, 48, and 35 M, respectively. In order to select the best scaffold to continue with the
optimization process, we determined some pharmacokinetic parameters (Table 2).  
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Table 2. Pharmacokinetic properties of compounds 3, 7, 8, 21, and 22a 
Compound
	
Property 3 7 8 21 22
	
Aqueous solubility 

(PBS, pH 7.4, µM) ND 103.5 5.8 35 175.7
	
Partition coefficient
	
(LogD, n-octanol/PBS, pH 7.4) ND 3.13 4.46 4.19 2.95
	
Chemical stability pH 7.4 ND 67 24 93 108(remaining compound, %) 

A-B Permeability 

(TC7, pH 6.5/7.4, 10-6cm/s) ND 46.1 7.9 35.1 53.5
	
Human plasma stability 

(remaining compound, %) <5 94 105 87 111
	
Mouse plasma stability <5 83 89 78 99(remaining compound, %) 
aData are expressed as the means from two independent experiments performed in duplicate. The SEM in all
cases is within a 10% of the mean value. ND, not determined. For stability studies, the percentage of the
remaining compound after 1 h is given.
Although the most potent derivative 3 showed a disappointing low stability that disqualified it as a
suitable candidate for further optimization, compound 7 showed good properties, especially in terms 
of aqueous solubility, lipophilicity, permeability and stability. Therefore, it was selected for further 
structural exploration focused on whether the phenolic hydroxy group was required for activity and if 
it was possible to replace the methyl ester group without significant activity decrease (compounds 
11-23, Figure 4). These new derivatives were synthesized as depicted in Scheme 2. Disubstituted 
carbamates 11, 12 and 14-18 were prepared by reaction of the corresponding 5-hydroxybenzoates 
with N-methyl-N-phenylcarbamoyl chloride. Methyl ester 7 was transformed into amide 13 by reaction 
with methylamine. Finally, phenyl methyl carbamates 19-23 were obtained by condensation of 
carboxylic acid 28 with the corresponding alcohol or amine in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as coupling reagent. All these new compounds were
screened for activity (Table 3).  
32
	
	
 
 
	
	
 
 
 
 
 
 
 
 
 
 
 
  
  
Results and discussion
	
CO2R1CO2R1 R4OR4 a 
N OOHO
	 Ph
	N ClR1 = Me, Et, iPr, tBu, MeBn, pyridin-3-ylmethyl 11, 12, 14-18 
R4 = OH, OMe, H 
27a-e 
CO2Me CONHMe 
OH OHOO b
	
N
	 N OO 
7 13 
O X R1CO2R1 OHOH OO d 
N ON O 
X = O,  NH, NMe  14: R1 = Bn  c R1 = 1-pyridin-3-ylethyl, (1-methylpiperidin-3-yl)methyl, 28: R1 = H  Bn, pyridin-3-ylmethyl 
19-23 
Scheme 2. Reagents and conditions: a) NaH, CH3CN, rt, 3 h, 14-64%; b) CH3NH2, CH3OH, 0 ºC to rt, 3 h, 76%;
c) H2, Pd(C), EtOH, rt, 3 h, 100%; d) R1OH, R1NH2, or R1NHMe, EDC, DMAP, DMF, 0 ºC to rt, 16 h, 27-64%.  
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Table 3. Inhibition of bFGF-induced cell proliferation of HUVECs for compounds 11-23
	
Cpd X R1  R4 IC50 (M)a 
7 O Me OH 48
11 O Me OMe 118 
12 O Me H 290
13 NH Me OH 67
14 O Bn OH 17
15 O Et OH 28
16 O Isopropyl OH 26
17 O tert-Butyl OH 25
Bn 
OH 1618 O 
19 O OH 39
20 O OH 74
OH 22
	
22 NH
	
21 NH
14
OH 
23 N(Me) 90
aIC50 values are the means from two or three independent experiments performed in triplicate. The SEM is in all 
cases within a 10% of the mean value.
Our results suggest that the phenolic hydroxy group is essential for activity, since both its 
methylation (compound 11) or its removal (derivative 12) led to an important decrease in the activity 
(IC50 (7) = 48 M vs IC50 (11) = 118 M and IC50 (12) = 290 M, Table 3). Accordingly, the phenolic
hydroxy group was kept in carbamates 13-23 and different esters and amides were introduced trying
to replace the initial methyl ester group. Our first attempt was to prepare the amide 13, analogue to 
7, but this change led to a decrease in activity (IC50 value for 7 was 48 M whereas amide 13 showed
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an IC50 value of 67 M, Table 3). This result suggested that the substitution of the ester by an amide
probably would involve some reduction in biological activity, so we first kept the ester bond but
replaced the methyl group by other aliphatic and (hetero)aromatic groups searching for better 
activities. In this case, we could later substitute the ester by an amide group and still keep good 
activity values. With this idea in mind, esters 14-20 were prepared. Among them, the best results in 
terms of IC50 values were obtained for benzyl and 3-methylpyridinyl groups as R1 substituents, 
compounds 14 and 18, with IC50 values of 17 and 16 M, respectively (Table 3). Hence, these two 
R1 groups were selected and the analogue amides 21-23 were synthesized. The biological activity of 
these amides was similar to that of the corresponding esters, as shown, for example, by the IC50
values of esters 14 and 18 (17 M and 16 M, respectively) when compared with the IC50 values of 
amides 21 and 22 (22 M and 14 M, respectively). Hence, we determined their pharmacokinetic 
properties in order to select the best candidate to continue with the biological studies. Taking into 
account all these data (Table 2), amide 22 (UCM-2711) showed the best overall profile with the
highest solubility (175.7 M), stability (around 100% in the three assayed conditions), and 
permeability values. Accordingly, this compound was selected for in-depth characterization. 
2.2. Biological evaluation of compound 22 (UCM-2711) 
2.2.1. Proangiogenic signaling in hypoxic MCF7 cells  
Tumor hypoxia, a common feature of many solid tumors, has been identified as a key driver for 
angiogenic regulation mechanisms. Hence, we first explored whether compound 22 is able to inhibit 
the proangiogenic signaling generated by hypoxia in the MCF7 human breast adenocarcinoma cell
line that was chosen as a model. Our results show that compound 22 decreases the levels of
important proangiogenic factors VEGF and bFGF in hypoxic MCF7 cells (Figure 5A,B). In addition, 
this derivative also induces a decrease in the NO levels, which runs parallel to a strong inhibition of 
iNOS expression (Figure 5C,F).
Considering the importance of the enhancement of autocrine signaling under hypoxic conditions, 
especially in terms of activation of the corresponding receptors, VEGFR and FGFR,  we  also  
assessed whether compound 22 affected their activation. Remarkably, this derivative inhibits the 
activation of these two receptors, as it decreases their phosphorylated (active) forms (Figure 5D,E). 
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Figure 5. Compound 22 (UCM-2711) decreases the production of hypoxia-induced proangiogenic factors VEGF, 
bFGF, and NO and inhibits the activation of their corresponding receptors. Incubation of MCF7 cells with
compound 22 (50 M) under hypoxic conditions significantly reduces the levels of (A) VEGF, (B) bFGF, and (C)
NO, decreases the activation of the (D) VEGF and (E) FGF receptors, and decreases (F) iNOS expression (131
kDa band). β-actin (42 kDa) is shown as loading control. Data correspond to the average ± SEM of at least three
independent experiments, and representative gels are shown. The bar graphs in panels D and E represent the
optical density of the immunoreactive phosphorylated protein normalized to the total corresponding protein,
which is expressed as the percentage relative to normoxia. The bar graph in panel F represents the optical
density of the immunoreactive protein (iNOS) expressed as the percentage relative to normoxia *, P<0.05; **,
P<0.01; ***, P<0.001 (vs hypoxic vehicle-treated cells) (Student’s t test). 
The main effects of the activation of the FGFR pathway include the induction of proliferation, 
migration, and antiapoptotic signals. Proliferation enhancement is mainly achieved through activation 
of the MAPK cascade, whereas the induction of antiapoptotic signals is mediated by activation of the 
PI3K/AKT pathway.17,21 This latter cell survival pathway is also reinforced by VEGFR activation. 
Hence, we explored whether compound 22 was able to suppress the phosphorylation of the
downstream kinases AKT, MEK and ERK. As expected, hypoxia activated the AKT and the MEK and
ERK signaling pathways as demonstrated by the increased phosphorylation of these kinases and, 
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remarkably, incubation of the cells with compound 22 prevented this activation (Figure 6A).
Importantly, inhibition of these signaling pathways by compound 22 was accompanied by an 
impairment in hypoxia-stimulated cell migration (Figure 6B). 
Figure 6. Compound 22  (UCM-2711) inhibits hypoxia-activated signaling pathways and suppresses cell 
migration. (A) Representative western blots of phosphorylated (pAKT) and total AKT (T-AKT), phosphorylated
MEK1/2 (pMEK1/2) and total MEK1/2 (T-MEK1/2), and phosphorylated ERK1/2 (pERK1/2) and total ERK1/2 (T-
ERK1/2). Lysates were obtained from MCF7 cells treated with compound 22 (50 M) under hypoxic conditions.
Data correspond to the average ± SEM of at least three independent experiments. The bar graphs in panel A
represent the optical density of the immunoreactive phosphorylated protein normalised to the total corresponding 
protein, which is expressed as the percentage relative to normoxia. *, P<0.05; **, P<0.01 (Student’s t test). (B)
In vitro scratches (wounds) were made by scraping confluent cell monolayers with a sterile pipette tip and were
visualized by phase contrast microscopy. After 48 h under hypoxic conditions, the remaining wound area was
quantified. The bar graph represents the average ± SEM of at least three independent experiments and three
different fields. ***, P<0.001 (vs DMSO-treated cells) (Student’s t test). Bar, 250 m. 
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Figure 7. Compound 22  (UCM-2711) impairs cell migration without inducing general cytotoxicity. (A-C)
Compound 22 prevents cell migration but cells recover their ability to migrate in the absence of compound. In
vitro scratches (wounds) were made by scraping confluent cell monolayers with a sterile pipette tip and were
visualized by phase contrast microscopy. After the indicated time under hypoxic conditions, remaining wound 
area was quantified in cells treated with (A) vehicle, (B) 50 μM of compound 22 during 96 h, and (C) 50 μM of
compound 22 during 48 h and vehicle for additional 48h. Bar, 250 m. (D) The bar graph represents the average
± SEM of the remaining wound area of at least three independent experiments and three different fields. ***, 
P<0.001 (vs DMSO-treated cells) (Student’s t test). ###, P<0.001 (vs cells treated with 50 μM of compound 22
during 96 h) (Student’s t test). (E) Cell viability is not significantly affected by compound 22. Cells were incubated 
under hypoxic conditions and the number of viable cells determined after 96 h of incubation with vehicle (black
bar), 50 μM of compound 22 (grey bar) or 50 μM of compound 22 during 48 h and vehicle for additional 48 h
(white bar). 
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In order to determine whether the decrease in migration was due to general cytotoxicity, we carried
out a similar set of experiments in which cells were incubated with compound 22 for 48 h, after which 
the compound was removed and then the cells were incubated for an additional 48 h. The obtained 
results show that cells recover their ability to migrate after removal of the compound (Figure 7). In 
addition, the number of viable cells remains similar to that in the vehicle treated cells (Figure 7E).
Taken together, these data strongly suggest that compound 22 is mainly affecting cell migration and
not inducing general cytotoxicity. 
2.2.2. Proangiogenic signaling via hypoxia-inducible factor-1α (HIF-1α) 
Intratumoral hypoxia is one of the major factors that drive tumor angiogenesis, and hypoxia-driven
angiogenesis is primarily mediated by HIF-1α, often considered to be a master regulator of
angiogenesis under hypoxia.28 In addition, in MCF7 breast cancer cells, HIF-1α is the factor that 
mainly contributes to the expression of genes under hypoxic conditions.29 Therefore, we analyzed 
whether HIF-1α was involved in the antiangiogenic response elicited by compound 22. To this end, 
we knocked-down HIF-1α using selective small interfering RNAs (siRNAs) (Figure 8A). As shown in 
Figure 8B,C, hypoxia induced an increase in bFGF and VEGF levels in MCF7 cells transfected with 
a nontargeted (control) siRNA (C siRNA), and this effect was prevented by compound 22. 
Conversely, genetic silencing of HIF-1α abrogated the increase in these two proangiogenic factors 
upon hypoxia stimulus, and compound 22 did not enhance this effect. These results suggest that the
effect of compound 22 on bFGF and VEGF levels is mediated via HIF-1α. To further ascribe the
effects of compound 22 to HIF-1α modulation and not to other members of its family, mainly HIF-2α, 
we selected two proteins, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNip3) and
Angiopoietin 2 (Ang2), which have been described to be mainly regulated by HIF-1α and HIF-2α, 
respectively.30 As expected, and consistent with the literature, hypoxia increased the levels of both 
proteins, BNip3 and Ang2. Remarkably, compound 22 decreased only the levels of BNip3 (Figure
8D) without affecting the expression of Ang2 (Figure 8E). These results provide further support for 
the specific involvement of HIF-1α in the effects induced by compound 22. In addition, and to discard
potential effects of this derivative upstream of HIFs, we verified that compound 22 did not affect the 
expression levels either of HIF-1α or of HIF-2α (Figure 8F).
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Figure 8. Compound 22 (UCM-2711) inhibits the production of the hypoxia-induced proangiogenic factors via 
HIF-1α. (A) HIF-1α mRNA levels after transient transfection of MCF7 cells with a siRNA selectively targeting 
HIF-1α (HIF-1α siRNA) or with a nontargeted siRNA (C siRNA). Results are expressed in arbitrary units (au). 
bFGF (B) and VEGF (C) levels in MCF7 cells transiently transfected with the indicated siRNAs under normoxic
and hypoxic conditions and in the presence/absence of compound 22. Representative western blots of (D) BNip3
(22 kDa), (E) Ang2 (65 kDa), (F) HIF-1α (132 kDa) and HIF-2α (115 kDa). In all cases, β-actin (42 kDa), marked 
with an arrowhead, is used as a loading control. Lysates were obtained from MCF7 cells treated with compound 
22 (50 M) under normoxic or hypoxic conditions as indicated. Data correspond to the average ± SEM of at least 
three independent experiments. The bar graphs in panels D and E represent the optical density of the
immunoreactive protein (BNip3 or Ang2, respectively) expressed as the percentage relative to normoxia. Ns,
not significant; *, P<0.05; ***, P<0.001 (vs hypoxic vehicle-treated cells) (Student’s t test). 
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2.2.3. Antiangiogenic gene profile of hypoxic MCF7 cells  
To further confirm the antiangiogenic profile of compound 22, we analyzed the expression of 84
key genes involved in angiogenesis in hypoxic MCF7 cells treated with this compound. We identified 
12 genes that were significantly affected by compound 22 (fold change  2, Figure 9). As expected, 
several proangiogenic genes were down-regulated in the presence of compound 22. Among them 
are several cytokines such as CCL11, IL-1 or the chemokine-like PROK2 that have been linked to
angiogenesis in solid tumors31-33 as well as other known proangiogenic factors such as the vascular 
endothelial cadherin CDH5, and the receptors VEGFR-2 (also known as KDR) and Notch4.34 On the
other hand, up-regulation of several genes in response to compound 22 was also observed, including 
the chemokine CXCL9, which has been described to attenuate angiogenesis in some situations.35 
Surprisingly, we observed an increase in the transcript levels of certain proangiogenic factors such
as the cell adhesion molecules integrin ITGB3 and PECAM1, the angiopoietin receptor TIE1 and the 
proangiogenic factors FGF1 and FGF2. These apparently contradictory results may be due to
differential regulation at the transcriptional and translational levels. In this regard, for example, it is
worth noting that although some increase is observed at the transcriptional level (Figure 9), 
compound 22 reduces the protein levels of FGF2 (bFGF) as shown in Figure 5B. 
Figure 9. Compound 22 (UCM-2711) regulates the expression of angiogenesis-related genes. An angiogenesis 
PCR array was performed in hypoxic MCF7 cells challenged with compound 22 or the corresponding vehicle.
The graph shows the 12 genes that were modulated (threshold = 2 fold increase/decrease) in compound 22-
treated cells vs control cells. Results are expressed as fold regulation. 
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2.2.4. In vivo antitumor effect  
In order to assess the in vivo efficacy of compound 22 we used a breast cancer xenograft model. 
Tumor-bearing mice were injected intraperitoneally with compound 22 (25 mg/kg) once a day for 28
days and tumor volumes were routinely measured (Figure 10A). In vehicle-treated animals, tumors 
grew in an exponential manner. Treatment of mice with compound 22 produced no effect in 62% of 
them (5 out of 8), but we observed a significant reduction in tumor growth (ranging from 46% to 55%)
in the remaining 38% (3 out of 8) (Figure 10B). 
To analyze the in vivo inhibition of angiogenesis, we quantified the number of blood vessels within
the tumors by immunofluorescence staining of CD31 (a marker of endothelial cells) in vehicle-treated 
animals as well as in responding and not-responding individuals (Figure 10C). Significant inhibition
of angiogenesis was not detected in non-responding animals. In contrast, in the tumors of compound-
responding individuals, a marked reduction in the number of blood vessels was observed. 
Remarkably, this result correlates with the expression levels of VEFG (Figure 10D). Importantly, the
inhibition of angiogenesis and tumor growth induced by compound 22 was not accompanied by any 
sign of toxicity, as assessed by histopathological analysis of liver, lungs, spleen and heart of 
compound-treated animals (data not shown). The degree of interindividual variability in the response
to compound 22 might be related to a different bioavailability of the compounds caused by the distinct 
growth and size of each individual tumor or by the existence of clonal variability of xenograft cells, 
something that has been previously observed for other antitumor targets36 and also in the clinic after 
treatment with other angiogenesis inhibitors. In this case, it is possible that increasing the number of 
individuals would also augment the number of positive cases. In addition, it is important to note that 
a tumor is a heterogeneous entity, with hypoxic portions but also with other zones, near the blood
vessel, which are not hypoxic and each may have different signaling factors. In this context, Figure 9
suggests up-regulation of some proangiogenic genes even in the presence of compound 22. Hence,
it is possible that in the mice in which the drug decreased tumor size the effects of the down-regulated 
proangiogenic genes predominated, while the increase in tumor size observed in the other mice was 
dominated by the effect of the proangiogenic genes that remained upregulated even in the presence
of the compound.
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Figure 10. Antitumor effects of compound 22 (UCM-2711) in a breast cancer xenograft model. (A) Tumor growth
in vehicle-treated (represented as mean ± SEM, grey dashed line, n=8) and compound 22-treated animals
(represented individually, n=8, solid grey lines). (B) Tumor weight at the end of the treatment for vehicle-treated
animals (white bar), compound 22-responding animals (black bar) and compound 22-treated not-responding
animals (grey bar). (C) Compound 22 significantly reduces angiogenesis in responding animals (22-R) whereas
it does not affect the number of blood vessels in treated but not-responding animals (22-NR). Images correspond
to representative immunofluorescence stainings of tumor sections of each experimental group. Blood vessels
are stained with an antibody against CD31 (in green), and nuclei are shown in blue. Scale bar, 100 m. The bar
graph represents the number of blood vessels (mean ± SEM, 3 tumors/experimental group and 4 sections/tumor)
for vehicle-treated animals (white bar), compound 22-responding animals (black bar) and not-responding
animals (grey bar). *, P<0.05; ***, P<0.001 (vs compound 22-treated non-responding mice) (Student’s t test).
(D) Compound 22 significantly reduces VEGF mRNA levels in responding animals (22-R) compared to vehicle-
treated mice or to mice treated with compound 22 that are not responding (22-NR). Images correspond to
representative data obtained from independent samples of tumor sections from each experimental group.
Controls include lack of RNA (right lane, labelled -) and GAPDH as housekeeping gene. 
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3. CONCLUSIONS
In conclusion, in this work, we describe a new series of antiangiogenic compounds.37 Among 
them, the optimal compound 22 (UCM-2711) inhibits proangiogenic signaling under hypoxic 
conditions in breast cancer cells. Specifically, administration of  22 decreases the levels of the
proangiogenic molecules VEGF, bFGF, and NO. Moreover, this compound inhibits the active forms 
of the corresponding receptors of these factors (phosphorylated forms of VEGFR and bFGFR) and
the levels of the iNOS enzyme. These effects correlate with a blockade of the MEK/ERK and 
PI3K/AKT pathways and the inhibition of cellular migration, and they are mediated by HIF-1α, since 
the effects of compound 22 mostly disappear when its expression is knocked-down. Additionally, 
gene profiling identified a set of genes related to angiogenesis whose expression is altered by 
compound 22 and that might contribute to the antiangiogenic effects. Furthermore, administration of 
compound 22 in a xenograft model produced tumor growth reductions ranging from 46 to 55% in the 
38% of the treated animals. Importantly, in the responding tumors, a significant reduction in the 
number of blood vessels and in the levels of VEGF was observed, further supporting the mechanism
of action of the compound. Although better efficacy would be desirable, the fact that compound 22
did not induce any toxic effects in vivo and that it was able to effectively block angiogenesis in the 
tumors of responding animals strongly support the potential of this compound as a lead for the
development of new antiangiogenic agents suitable for the treatment of cancer either alone or in 
combination with other benchmark drugs.  
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4. EXPERIMENTAL SECTION 
4.1. Chemistry
Unless stated otherwise, starting materials, reagents and solvents were purchased as high-grade 
commercial products from Sigma-Aldrich, Acros, Fluorochem, Abcr, Scharlab or Panreac, and were
used without further purification. Anhydrous tetrahydrofuran (THF) and diethyl ether (Et2O) were 
distilled from sodium benzophenone ketyl and used immediately, dichloromethane (DCM) was 
distilled from CaH2. All reactions were carried out under an argon atmosphere in oven-dried
glassware. Flash chromatography was performed on a Varian 971-FP flash purification system using
silica gel cartridges (Varian, particle size 50 µm, for final compounds). Analytical thin-layer 
chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-254) with detection by UV
light (254 nm), ninhydrin solution, or 10% phosphomolybdic acid solution in ethanol. Melting points 
(mp, uncorrected) were determined on a Stuart Scientific electrothermal apparatus. Infrared (IR)
spectra were measured on a Shimadzu-8300 or Bruker Tensor 27 instrument; frequencies () are 
expressed in cm-1. Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker Avance 
300-AM (1H, 300 MHz; 13C, 75 MHz) at the UCM’s NMR facilities. Chemical shifts () are expressed 
in parts per million relative to internal tetramethylsilane; coupling constants (J) are in hertz (Hz). The
following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet),
t (triplet), q (quartet), qt (quintet), sept (septuplet), m (multiplet), br (broad), dd (doublet of doublets),
td (triplet of doublets). 2D NMR experiments (HMQC and HMBC) of representative compounds were 
carried out to assign protons and carbons of the new structures. Elemental analyses (C, H, N) were
obtained on a LECO CHNS-932 apparatus at the UCM’s analysis services and were within 0.4% of 
the theoretical values. High Pressure Liquid Chromatography-Mass Spectrometry (HPLC-MS)
analysis was performed using an Agilent 1200LC-MSD VL. LC separation was achieved with an 
Eclipse XDB-C18 column (5 µm, 4.6 mm x 150 mm) together with a guard column (5 µm, 4.6 mm x
12.5 mm). The gradient mobile phases consisted of A (95:5 water/MeOH) and B (5:95 water/MeOH) 
with 0.1% ammonium hydroxide and 0.1% formic acid as the solvent modifiers. MS analysis was
performed with an ESI source. The capillary voltage was set to 3.0 kV and the fragmentor voltage
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was set at 70 eV. The drying gas temperature was 350 ºC, the drying gas flow was 10 L/min, and the
nebulizer pressure was 20 pounds per square inch (psi). Spectra were acquired in positive and
negative ionization mode from 100 to 1000 m/z and in UV-mode at four different wavelengths (210,
230, 254, and 280 nm). Spectroscopic data of all described compounds were consistent with the
proposed structures. Satisfactory HPLC chromatograms and elemental analyses (C, H, N) were 
obtained for the final compounds, confirming a purity of at least 95% for all tested compounds. 
Pharmacokinetic properties of selected compounds 3, 7, 8, 21, and 22 (UCM-2711) were determined
at CEREP (www.cerep.fr).
The free amines 9, 18-20, 22, and 23 were characterized (yield, Rf, IR, NMR), dissolved in
anhydrous DCM (6 mL/mmol) and a commercial 1 M HCl(g)/Et2O solution (1 mL/mmol) was added. 
The hydrochloride salts were isolated by filtration or evaporation of the solvents, washed with 
anhydrous Et2O, dried under high vacuum, and characterized (Mp, elemental analysis).  
4.1.1 Synthesis of final compounds 1- 23 
General procedure for the synthesis of esters 27a and 27b. A solution of 2,5-dihydroxybenzoic
acid (1 g, 6.5 mmol) and 1,1’-carbonyldiimidazole (CDI, 1 g, 6.5 mmol) in anhydrous DMF (16 mL) 
was heated at 40 ºC for 1 h under an argon atmosphere. Then, isopropanol or tert-butanol (13 mmol) 
and 1,8-diazabicyclo[5.4.0.]undec-7-ene (DBU, 1 mL, 6.5 mmol) were added and the reaction mixture 
was stirred at 40 ºC for additional 24 h. After cooling to rt, Et2O (60 mL) was added and the mixture 
was washed with an aqueous saturated solution of NaHCO3 (3 x 40 mL). The organic layers were
dried (Na2SO4) and evaporated. The residue was purified by column chromatography to afford the
title esters. 
Isopropyl 2,5-dihydroxybenzoate (27a). Obtained from 2,5-dihydroxybenzoic acid (1 g, 6.5 
mmol) and isopropanol (1 mL, 13 mmol) in 17% yield. Chromatography: hexane/EtOAc, 7:3; oil. Rf
(hexane/EtOAc, 7:3) 0.48. 1H NMR (300 MHz, CDCl3) 1.38 (d, 6H, J = 6.3 Hz, 2CH3), 4.63 (br s, 
1H, OH), 5.27 (sept, 1H, J = 6.3 Hz, CH(CH3)2), 6.87 (d, 1H, J = 8.9 Hz, H3), 6.99 (dd, 1H, J = 8.9, 
3.1 Hz, H4), 7.29 (d, 1H, J = 3.1 Hz, H6), 10.48 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3) 22.0
(2CH3), 69.5 (CH), 112.9 (C), 115.0, 118.6, 123.9 (3CH), 147.7, 156.1, 169.4 (3C). The spectroscopic 
data are in agreement with those previously described.38 
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tert-Butyl 2,5-dihydroxybenzoate (27b). Obtained from 2,5-dihydroxybenzoic acid (1 g, 6.5 
mmol) and tert-butanol (1.2 mL, 13 mmol) in 61% yield. Chromatography: hexane/EtOAc, 8:2. Mp
76-77 ºC (Lit.39 77-78 ºC). Rf (hexane/EtOAc, 7:3) 0.50. 1H NMR (200 MHz, CDCl3) 1.53 (s, 9H, 
3CH3), 4.47 (br s, 1H, OH), 6.78 (d, 1H, J = 8.9 Hz, H3), 6.90 (dd, 1H, J = 8.9, 3.1 Hz, H4), 7.16 (d, 
1H, J = 3.1 Hz, H6), 10.54 (br s, 1H, OH). 13C NMR (50 MHz, CDCl3) 28.2 (3CH3), 83.2, 113.9 (2C),
115.4, 118.3, 123.6 (3CH), 147.8, 155.4, 169.5 (3C). The spectroscopic data are in agreement with 
those previously described.39 
Synthesis of benzyl 2,5-dihydroxybenzoate (27c). To a solution of 2,5-dihydroxybenzoic acid 
(2 g, 13 mmol) in anhydrous DMF (17 mL), KHCO3 (1.6 g, 16 mmol) was added, under an argon
atmosphere, and the reaction mixture was stirred at rt for 15 min. Then, benzyl bromide (2.3 mL, 19 
mmol) was added and the reaction was heated at 40 ºC for 3 h. After cooling to rt, H2O (10 mL) was 
added and the mixture was extracted with EtOAc (3 x 40 mL). The organic layers were washed with
a saturated aqueous solution of NaHCO3 and brine successively, dried (Na2SO4) and evaporated to 
afford the title ester 27c in 88% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc,
7:3) 0.57. 1H NMR (200 MHz, CDCl3) 4.62 (br s, 1H, OH), 5.36 (s, 2H, CH2), 6.88 (d, 1H, J = 8.9
Hz, H3), 7.01 (dd, 1H, J = 8.9, 2.9 Hz, H4), 7.31 (d, 1H, J = 2.9 Hz, H6), 7.36-7.44 (m, 5H, Ar), 10.34
(br s, 1H, OH). 13C NMR (75 MHz, CDCl3) 67.1 (CH2), 112.2 (C), 114.9, 118.6, 124.2 (3CH), 128.3
(2CH), 128.6 (CH), 128.8 (2CH), 135.2, 147.7, 156.0, 169.5 (4C). The spectroscopic data are in 
agreement with those previously described.40 
Synthesis of pyridin-3-ylmethyl 2,5-dihydroxybenzoate (27d). To a solution of 2,5-
dihydroxybenzoic acid (700 mg, 4.5 mmol) in DMF (20 mL), pyridin-3-ylmethanol (491 mg, 4.5 mmol), 
EDC (1.30 g, 6.8 mmol) and DMAP (832 mg, 6.8 mmol) were added. The reaction was warmed to
50 ºC and stirred for 12 h. The mixture was evaporated and the residue was purified by
chromatography (DCM/MeOH, 98:2) to afford the title ester as a solid in 27% yield. Mp 173-174 ºC. 
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Rf (DCM/MeOH, 95:5) 0.33. IR (KBr, cm-1) 3429, 3245 (OH), 1678 (COO), 1627, 1589, 1485 (Ar). 
1H NMR (300 MHz, CD3OD) 5.35 (s, 2H, CH2), 6.71 (d, 1H, J = 8.9 Hz, H3), 6.89 (dd, 1H, J = 8.9,
3.0 Hz, H4), 7.15 (d, 1H, J = 3.0 Hz, H6), 7.40 (dd, 1H, J = 7.8, 4.9 Hz, H5’), 7.89 (d, 1H, J = 7.8 Hz,
H4’), 8.45 (dd, 1H, J = 4.9, 1.4 Hz, H6’), 8.58 (d, 1H, J = 1.4 Hz, H2’). 13C NMR (75 MHz, CD3OD) 
65.3 (CH2), 113.0 (C), 115.2, 119.2, 125.4, 125.5 (4CH), 133.9 (C), 138.4 (CH), 150.1 (2CH), 150.9, 
156.3, 170.8 (3C).
Methyl 5-hydroxy-2-methoxybenzoate (27e). a solution of methyl 5-(benzyloxy)-2-
hydroxybenzoate41 (460 mg, 1.8 mmol) in DMF (14 mL), K2CO3 (738 mg, 5.3 mmol) and methyl iodide
(0.1 mL, 1.8 mmol) were added and the mixture was stirred at 80 ºC for 2 h. Then, additional amounts 
of K2CO3 (246 mg, 1.8 mmol) and methyl iodide (0.1 mL, 1.8 mmol) were added and the reaction was 
stirred at 60 ºC for 2 h. The mixture was quenched with H2O (15 mL) and extracted with DCM (5 x 30
mL). The combined organic layers were dried (Na2SO4) and evaporated to afford methyl 5-
(benzyloxy)-2-methoxybenzoate as an oil in quantitative yield. Rf (hexane/EtOAc, 8:2) 0.20. IR (neat, 
cm-1) 1728 (COO), 1583, 1528, 1499 (Ar). 1H NMR (300 MHz, CDCl3) 3.90 (s, 3H, OCH3), 3.93
(s, 3H, OCH3), 5.08 (s, 2H, CH2), 6.95 (d, 1H, J = 9.1 Hz, H3), 7.13 (dd, 1H, J = 9.1, 3.2 Hz, H4), 7.36-
7.49 (m, 6H, H6, H2’-H6’).13C NMR (75 MHz, CDCl3)  52.2, 56.8 (2CH3), 70.8 (CH2), 113.8, 117.4 
(2CH), 120.5 (C), 120.6 (CH), 127.6 (2CH), 128.1 (CH), 128.7 (2CH), 136.9, 152.2, 153.8, 166.5
(4C).
To a solution of methyl 5-(benzyloxy)-2-methoxybenzoate (478 mg, 1.8 mmol) in EtOH (20 mL), 
10% Pd(C) (273 mg) was added and the mixture was hydrogenated at rt for 5 h, with an initial 
hydrogen pressure of 37 psi The reaction was filtered through celite and the solvent was evaporated
to afford pure title compound 27e as a solid in quantitative yield. Mp 75-76 ºC. Rf (hexane/EtOAc, 
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9:1) 0.21. IR (KBr, cm-1)  3370 (OH), 1710 (COO), 1589, 1502, 1441 (Ar). 1H NMR (300 MHz, CDCl3) 
 3.86 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.88 (d, 1H, J = 8.9 Hz, H3), 7.00 (dd, 1H, J = 9.0, 3.2 Hz,
H4), 7.33 (d, 1H, J = 3.2 Hz, H3). 13C NMR (CDCl3)  52.3, 56.9 (2CH3), 114.2, 118.3, 120.6 (3CH), 
149.2 (2C), 153.7, 166.7 (2C).
General procedure for the synthesis of compounds 1 and 24. To a solution of methyl or benzyl 
2,5-dihydroxybenzoate (1 equiv) in anhydrous DCM, CSI (1 equiv) was added dropwise and the
reaction was stirred at rt for 2 h. Then, the resultant solid was separated by filtration and treated with
cold H2O. The solution was stirred overnight to afford a white precipitate which was filtered and
washed with H2O to afford the title compounds, which were purified by chromatography.
Methyl 5-[(aminocarbonyl)oxy]-2-hydroxybenzoate (1). Obtained from methyl 2,5-
dihydroxybenzoate (1.8 mmol) and CSI (1.8 mmol) in 30% yield. Chromatography: hexane/EtOAc, 
8:2. Mp 194-196 ºC. Rf (DCM/EtOH, 9:1) 0.39. IR (KBr, cm-1)  3423, 3305 (OH, NH2), 1728, 1705 
(NH2COO, COO), 1610, 1560, 1493, 1443 (Ar). 1H NMR (300 MHz, acetone-d6)  3.75 (s, 3H, CH3), 
6.65 (d, 1H, J = 8.9 Hz, H3), 6.89 (dd, 1H, J = 8.9, 3.0 Hz, H4), 7.09 (d, 1H, J = 3.0 Hz, H6), 7.96 (br 
s, 2H, NH2), 10.01 (br s, 1H, OH). 13C NMR (75 MHz, acetone-d6) 51.9 (CH3), 123.4 (CH), 124.5
(C), 124.7, 126.8 (2CH), 146.8, 147.5, 154.3, 164.2 (4C). MS (ESI): [(M-H)-] 210.2. 
Benzyl 5-[(aminocarbonyl)oxy]-2-hydroxybenzoate (24). Obtained from benzyl 2,5-
dihydroxybenzoate (4.1 mmol) and CSI (4.1 mmol) in 34% yield. Chromatography: hexane/EtOAc, 
7:3. Mp 153-154 ºC. Rf (hexane/EtOAc, 6:4) 0.36. IR (KBr, cm-1)  3429, 3310 (OH, NH2), 1709, 1677
(NH2COO, COO), 1610, 1490, 1430 (Ar). 1H NMR (300 MHz, CDCl3)  5.04 (br s, 2H, NH2), 5.29 (s, 
2H, CH2), 6.90 (d, 1H, J = 9.0 Hz, H3), 7.16 (dd, 1H, J = 9.0, 2.8 Hz, H4), 7.31-7.36 (m, 5H, Ph), 7.54 
(d, 1H, J = 2.8 Hz, H6), 10.60 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  67.2 (CH2), 112.2 (C),
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118.4, 122.2 (2CH), 128.4 (2CH), 128.6 (2CH), 128.7, 129.7 (2CH), 134.9, 142.4, 155.1, 159.3, 169.2
(5C). 
Synthesis of 5-[(aminocarbonyl)oxy]-2-hydroxybenzoic acid (2). To a solution of benzyl ester 
24 (117 mg, 0.41 mmol) in absolute EtOH (15 mL), 10% Pd(C) (25 mg) was added and the mixture
was hydrogenated at rt for 3 h, with an initial hydrogen pressure of 10 psi. The reaction was filtered 
over celite and the solvent was evaporated to afford pure title acid 2 as a white solid in quantitative 
yield. Mp 216-217 ºC. Rf (DCM/EtOH, 8:2) 0.28. IR (KBr, cm-1)  3450, 3305 (OH, NH2), 1708, 1673
(NH2COO, COO), 1602, 1485, 1400 (Ar).1H NMR (300 MHz, DMSO-d6)  6.90 (d, 1H, J = 8.9 Hz,
H3), 7.15 (br s, 2H, NH2), 7.20 (dd, 1H, J = 8.9, 2.9 Hz, H4), 7.41 (d, 1H, J = 2.9 Hz, H6). 13C NMR (75
MHz, DMSO-d6)  113.6 (C), 117.2, 122.3, 128.9 (3CH), 142.3, 154.9, 158.1, 171.0 (4C). Elemental
analysis: calcd. for C8H7NO5: %C: 48.74, %H: 3.58, %N: 7.10; found, %C: 48.49, %H: 3.66, %N: 
6.88. 
General procedure for the synthesis of final compounds 3 and 4. To a solution of methyl 2,5-
dihydroxybenzoate (1 equiv) in anhydrous THF (4 mL/mmol), DIEA (1 equiv) and the proper 
isocyanate (1 equiv) were added dropwise, and the reaction mixture was stirred at rt for 16 h. The
solvent was evaporated and the residue was purified by chromatography to afford the title final 
compounds as white solids. 
Methyl 5-{[(ethylamino)carbonyl]oxy}-2-hydroxybenzoate (3). Obtained from methyl 2,5-
dihydroxybenzoate (3.9 mmol) and ethyl isocianate (3.9 mmol) in 70% yield. Chromatography: 
hexane/EtOAc, 8:2. Mp 84-85 ºC. Rf (hexane/EtOAc, 8:2) 0.34. IR (KBr, cm-1) 3331, 3254 (NH), 
1697 (NHCOO), 1653 (COO), 1622, 1593, 1533, 1488 (Ar). 1H NMR (300 MHz, CDCl3)  1.15 (t, 3H, 
J = 7.2 Hz, CH3), 3.25 (qt, 2H, J = 7.2 Hz, CH2), 3.87 (s, 3H, OCH3), 4.89 (br s, 1H, NH), 6.91 (d, 1H, 
J = 9.0 Hz, H3), 7.15 (dd, 1H, J = 9.0, 2.9 Hz, H4), 7.54 (d, 1H, J = 2.9 Hz, H6), 10.56 (br s, 1H, 
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OH).13C NMR (75 MHz, CDCl3)  15.2 (CH3), 36.3 (CH2), 52.5 (CH3), 112.3 (C), 118.4, 122.4, 129.7
(3CH), 142.9, 150.1, 159.1, 170.1 (4C). Elemental analysis: calcd. for C11H13NO5: %C: 55.23, %H: 
5.48, %N: 5.86; found, %C: 54.90, %H: 5.32, %N: 5.58. 
Methyl 5-{[(phenylamino)carbonyl]oxy}-2-hydroxybenzoate (4). Obtained from methyl 2,5-
dihydroxybenzoate (3.1 mmol) and phenyl isocianate (3.1 mmol) in 71% yield. Chromatography: 
hexane/EtOAc, 8:2. Mp 129-130 ºC. Rf (hexane/EtOAc, 7:3) 0.44. IR (KBr, cm-1)  3354, 3325 (NH), 
1724 (NHCOO), 1683 (COO), 1602, 1541, 1485, 1439 (Ar). 1H NMR (300 MHz, CDCl3)  3.96 (s, 3H,
CH3), 6.92 (br s, 1H, NH), 7.02 (d, 1H, J = 9.0 Hz, H3), 7.12 (t, 1H, J = 7.9 Hz, H4’), 7.29 (dd, 1H, J =
9.0, 2.9 Hz, H4), 7.34 (t, 2H, J = 7.9 Hz, H3’, H5’), 7.44 (d, 2H, J = 7.9 Hz, H2’, H6’), 7.68 (d, 1H, J = 2.9
Hz, H6), 10.69 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  52.4 (CH3), 112.2 (C), 118.3 (CH), 118.4
(2CH), 122.3, 123.9 (2CH), 129.0 (2CH), 129.4 (CH), 137.1, 142.1, 151.7, 159.1, 169.8 (5C). 
Elemental analysis: calcd. for C15H13NO5: %C: 62.72, %H: 4.56, %N: 4.88; found, %C: 62.56, %H: 
4.55, %N: 4.94. 
General procedure for the synthesis of final compounds 5-8, 11, 12, and 14-18. To a solution 
of 1 equiv of the corresponding ester (commercially available or 27a-e) in anhydrous acetonitrile (4 
mL/mmol), 1.3 equiv of NaH (60% in mineral oil) and 1 equiv of the appropriate carbamoyl chloride
were added. The reaction mixture was stirred at rt for 3 h and the solvent was evaporated. The 
residue was purified by chromatography to afford the title final pure compounds. 
Methyl 5-{[(dimethylamino)carbonyl]oxy}-2-hydroxybenzoate (5). Obtained from methyl 2,5-
dihydroxybenzoate (500 mg, 3 mmol) and dimethylcarbamoyl chloride (0.3 mL, 3 mmol) in 21% yield. 
Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.24. IR (neat, cm-1)  3173 (OH),
1725 (NCOO), 1681 (COO), 1621, 1483 (Ar).1H NMR (300 MHz, CDCl3)  3.02 (s, 3H, NCH3), 3.10 
(s, 3H, NCH3), 3.94 (s, 3H, OCH3), 6.97 (d, 1H, J = 9.0 Hz, H3), 7.22 (dd, 1H, J = 9.0, 3.0 Hz, H4), 
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7.61 (d, 1H, J = 3.0 Hz, H6), 10.62 (s, 1H, OH). 13C NMR (75 MHz, CDCl3)  36.8, 37.1, 52.8 (3CH3), 
112.5 (C), 118.5, 122.8, 130.2 (3CH), 143.7, 155.4, 159.3, 170.4 (4C). MS (ESI): [(M-H)-] 238.1. 
COOMe 
OH 
O 
1 2 
3 
45 
6 
N 
O 
5 
Methyl 5-{[(diethylamino)carbonyl]oxy}-2-hydroxybenzoate (6). Obtained from methyl 2,5-
dihydroxybenzoate (500 mg, 3 mmol) and diethylcarbamoyl chloride (0.4 mL, 3 mmol) in 16% yield. 
Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.46. IR (KBr, cm-1)  3191 (OH),
1719 (NCOO), 1683 (COO), 1620, 1480 (Ar).1H NMR (300 MHz, CDCl3)  1.18-1.28 (m, 6H, 2CH3), 
3.38-3.45 (m, 4H, 2CH2), 3.94 (s, 3H, OCH3), 6.97 (d, 1H, J = 9.0 Hz, H3), 7.23 (dd, 1H, J = 9.0, 2.9
Hz, H4), 7.60 (d, 1H, J = 2.9 Hz, H6), 10.62 (s, 1H, OH). 13C NMR (75 MHz, CDCl3)  13.8, 14.6
(2CH3), 42.2, 42.7 (2CH2), 52.8 (CH3), 112.5 (C), 118.5, 122.8, 130.2 (3CH), 143.7, 154.7, 159.2, 
170.4 (4C). MS (ESI): [(M-H)-] 266.1.
Methyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (7).  Obtained from
methyl 2,5-dihydroxybenzoate (400 mg, 2.4 mmol) and N-methyl-N-phenylcarbamoyl chloride (404 
mg, 2.4 mmol) in 46% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.38. 
IR (neat, cm-1) 3168 (OH), 1724 (NCOO), 1680 (COO), 1620, 1597, 1487 (Ar). 1H-NMR (300 MHz, 
CDCl3) 3.43 (s, 3H, NCH3), 3.94 (s, 3H, OCH3), 6.96 (d, 1H, J = 9.0 Hz, H3), 7.27-7.45 (m, 7H, H4, 
H2’- H6’), 7.53 (m, 1H, H6), 10.62 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  38.7, 52.8 (2CH3), 112.6
(C), 118.6 (2CH), 122.7, 126.3, 127.1, 129.5 (4CH), 130.0 (2CH), 143.2, 143.5, 154.5, 159.4, 170.4
(5C). MS (ESI): [(M-H)-] 300.1. 
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Methyl 5-{[(diphenylamino)carbonyl]oxy}-2-hydroxybenzoate (8). Obtained from methyl 2,5-
dihydroxybenzoate (500 mg, 3 mmol) and diphenylcarbamoyl chloride (688 mg, 3 mmol) in 36% yield. 
Chromatography: hexane/EtOAc, 9:1. Mp 121-123 ºC. Rf (hexane/EtOAc, 8:2) 0.24. IR (KBr, cm-1) 
3179 (OH), 1729 (NCOO), 1682 (COO), 1594, 1488 (Ar).1H NMR (300 MHz, CDCl3)  3.95 (s, 3H, 
OCH3), 6.97 (d, 1H, J = 9.0 Hz, H3), 7.23-7.30 (3H, m, H4, Ph), 7.35-7.42 (8H, m, Ph), 7.66 (d, 1H, J 
= 2.9 Hz, H6), 10.64 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  52.9 (CH3), 112.6 (C), 118.7, 122.6 
(2CH), 127.1 (2CH), 127.3 (4CH), 129.6 (4CH), 129.9 (CH), 142.6 (C), 143.3 (2C), 153.7, 159.6, 
170.4 (3C). Elemental analysis: calcd. for C21H17NO5: %C: 69.41, %H: 4.72, %N: 3.85; found, %C: 
68.99, %H: 4.76, %N: 3.90. 
Methyl 2-methoxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (11).  Obtained from
methyl ester 27e (273 mg, 1.5 mmol) and N-methyl-N-phenylcarbamoyl chloride (254 mg, 1.5 mmol)
in 58% yield. Chromatography: DCM/EtOAc, 9:1; oil. Rf (DCM/EtOAc, 9.5:0.5) 0.37. IR (neat, cm-1)
1723 (NCOO, COO), 1596, 1497, 1437 (Ar).1H NMR (300 MHz, CDCl3)  3.43 (s, 3H, NCH3), 3.88 
(s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.95 (d, 1H, J = 9.0 Hz, H3), 7.27-7.44 (m, 6H, H4, H2’-H6’), 7.58 
(m, 1H, H6). 13C NMR (75 MHz, CDCl3) 38.3, 52.1, 56.5 (3CH3), 112.8 (CH), 120.3 (C), 124.8 (CH), 
125.9 (2CH), 126.8 (CH), 129.1 (3CH), 142.8, 144.1, 154.0, 156.7, 165.7 (5C). MS (ESI): [(M+Na)+] 
338.1.
Methyl 3-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (12). Obtained from methyl 5-
hydroxybenzoate (477 mg, 3.1 mmol) and N-methyl-N-phenylcarbamoyl chloride (533 mg, 3.1 mmol) 
in 64% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 9:1) 0.23. IR (neat, cm-
1) 1723 (NCOO, COO), 1593, 1495 (Ar). 1H NMR (300 MHz, CDCl3)  3.47 (s, 3H, NCH3), 3.94 (s,
3H, OCH3), 7.30-7.48 (m, 7H, H3, H4, H2’-H6’), 7.81 (m, 1H, H6), 7.91 (d, 1H, J = 7.6 Hz, H2). 13C NMR
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Benzyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (14).  
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(75 MHz, CDCl3)  38.3, 52.2 (2CH3), 122.9, 126.0, 126.4, 126.5, 126.8 (5CH), 129.1 (3CH), 129.2 
(CH), 131.5, 142.8, 151.3, 153.6, 166.2 (5C). MS (ESI): [(M-CH3+Na)+] 293.2.
Obtained from
benzyl ester 27c (630 mg, 2.6 mmol) and N-methyl-N-phenylcarbamoyl chloride (437 mg, 2.6 mmol) 
in 28% yield. Chromatography: hexane/EtOAc, 9:1. Mp 103-105 ºC. Rf (hexane/EtOAc, 7:3) 0.80. IR 
(KBr, cm-1) 3194 (OH), 1726 (NCOO), 1679 (COO), 1622, 1599, 1489 (Ar). 1H NMR (300 MHz,
CDCl3)  3.41 (s, 3H, NCH3), 5.38 (s, 2H, CH2), 6.96 (d, 1H, J = 9.0 Hz, H3), 7.20-7.46 (m, 11H, H4, 
H2’-H6’, H2’’-H6’’), 7.60 (m, 1H, H6), 10.66 (s, 1H, OH).13C NMR (75 MHz, CDCl3)  38.3 (CH3), 67.3
(CH2), 112.2 (C), 118.3, 122.3, 126.0, 126.7 (4CH), 128.6 (2CH), 128.7 (CH), 128.8 (3CH), 129.1
(2CH), 129.9 (CH), 135.1, 142.9, 143.2, 154.2, 159.3, 169.5 (6C). MS (ESI): [(M-H)-] 376.1.
Ethyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (15). Obtained from ethyl
2,5-dihydroxybenzoate (433 mg, 2.4 mmol) and N-methyl-N-phenylcarbamoyl chloride (404 mg, 2.4
mmol) in 14% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.55. IR (neat, 
cm-1)  3163 (OH), 1726 (NCOO), 1677 (COO), 1619, 1597, 1487 (Ar). 1H NMR (300 MHz, CDCl3) 
1.44 (t, 3H, J = 7.1 Hz, CH3), 3.46 (s, 3H, NCH3), 4.43 (q, 2H, J = 7.1 Hz, CH2), 6.96 (d, 1H, J = 8.9 
Hz, H3), 7.19-7.45 (m, 6H, H4, H2’-H6’), 7.62 (m, 1H, H6), 10.77 (s, 1H, OH). 13C NMR (75 MHz, CDCl3) 
 14.2, 38.3 (2CH3), 61.7 (CH2), 112.4 (C), 118.2, 122.3, 125.9, 126.7 (4CH), 129.1 (3CH), 129.5
(CH), 142.9, 143.0, 154.2, 159.2, 169.6 (5C). MS (ESI): [(M-H)-] 314.1. 
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Isopropyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (16). Obtained from 
isopropyl ester 27a (211 mg, 1.1 mmol) and N-methyl-N-phenylcarbamoyl chloride (183 mg, 1.1
mmol) in 28% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.57. IR (neat, 
cm-1) 3178 (OH), 1728 (NCOO), 1675 (COO), 1622, 1599, 1489 (Ar). 1H NMR (300 MHz, CDCl3) 
1.42 (d, 6H, J = 6.3 Hz, 2CH3), 3.47 (s, 3H, NCH3), 5.30 (sept, 1H, J = 6.3 Hz, CH), 6.98 (d, 1H, J 
= 9.0 Hz, H3), 7.23-7.33 (m, 2H, Ar), 7.39-7.48 (m, 4H, Ar), 7.61 (m, 1H, H6), 10.97 (br s, 1H, OH). 
13C NMR (75 MHz, CDCl3)  21.8, 38.3 (2CH3), 69.6 (CH), 112.8 (C), 118.2, 122.3, 126.0, 126.7
(4CH), 129.1 (3CH), 129.5 (CH), 142.9, 143.0, 154.2, 159.3, 169.2 (5C). MS (ESI): [(M-H)-] 328.1. 
tert-Butyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (17).  Obtained from 
tert-butyl ester 27b (500 mg, 2.4 mmol) and N-methyl-N-phenylcarbamoyl chloride (404 mg, 2.4
mmol) in 32% yield. Chromatography: hexane/EtOAc, 9:1; oil. Rf (hexane/EtOAc, 7:3) 0.61. IR (neat, 
cm-1)  3070 (OH), 1727 (NCOO), 1673 (COO), 1620, 1599, 1457 (Ar). 1H NMR (300 MHz, CDCl3) 
1.61 (s, 9H, 3CH3), 3.43 (s, 3H, NCH3), 6.93 (d, 1H, J = 8.9 Hz, H3), 7.17-7.19 (m, 1H, H4), 7.26-7.30
(m, 2H, Ar), 7.36-7.45 (m, 3H, Ar), 7.49 (m, 1H, H6), 10.95 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3) 
 28.1 (3CH3), 38.2 (CH3), 83.2 (C), 113.6 (C), 118.1, 122.4, 125.8, 126.6 (4CH), 129.0 (3CH), 129.1
(CH), 142.8 (2C), 154.2, 159.3, 169.1 (3C). MS (ESI): [(M-H)-] 342.1. 
Pyridin-3-ylmethyl (2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (18).
Obtained from pyridinyl ester 27d (272 mg, 1.1 mmol) and N-methyl-N-phenylcarbamoyl chloride 
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(188 mg, 1.1 mmol) in 22% yield. The free amine was characterized (yield, Rf, IR, NMR), dissolved 
in anhydrous Et2O (4 mL) and treated with a commercial 1 M HCl(g)/Et2O solution (0.6 mL). The 
hydrochloride salts was isolated by evaporation of the solvents and characterized (Melting point, 
elemental analysis). Chromatography: DCM/MeOH, 99:1. Mp 183-185 ºC.  Rf (DCM/MeOH, 95:5)
0.56; IR (KBr, cm-1) 3170 (OH), 1724 (NCOO), 1680 (COO), 1595, 1488 (Ar). 1H-NMR (300MHz, 
CDCl3)  3.42 (s, 3H, NCH3), 5.40 (s, 2H, CH2), 6.97 (d, 1H, J = 9.0 Hz, H3), 7.22-7.44 (m, 7H, H4, 
H2’-H6’, H5’’), 7.58 (m, 1H, H6), 7.84 (d, 1H, J = 7.8 Hz, H4’’), 8.66 (m, 1H, H2’’/H6’’), 8.76 (m, 1H, H2’’/H6’’),
10.51 (s, 1H, OH). 13C-NMR (75 MHz, CDCl3)  38.8 (CH3), 64.9 (CH2), 112.1 (C), 118.8, 122.6, 
124.3, 126.3, 127.2 (5CH), 129.5 (3CH), 130.6 (CH), 132.0 (C), 137.4 (CH), 143.1, 143.5 (2C), 149.7, 
149.8 (2CH), 154.5, 159.7, 169.6 (3C). Elemental analysis: calcd. for C21H18N2O5·HCl·H2O: %C:
58.27, %H: 4.89, %N: 6.47; found, %C: 58.64, %H: 5.28, %N: 6.62. 
Synthesis of 3-(methoxycarbonyl)phenyl 4-methylpiperazine-1-carboxylate (9). To a
solution of methyl 2,5-dihydroxybenzoate (550 mg, 3.3 mmol) and 4-nitrophenyl chloroformate (659
mg, 3.3 mmol) in anhydrous DCM, 1,4-diazabicyclo[2.2.2]octane (DABCO, 734 mg, 6.5 mmol) was 
added dropwise at 0 ºC and the reaction mixture was stirred for 5 h. The solvent was evaporated and
the residue was purified by chromatography (hexane/EtOAc, 9:1) to afford methyl 2-hydroxy-5-{[(4-
nitrophenoxy)carbonyl]oxy}benzoate in 40% yield. Rf (hexane/AcOEt, 7:3): 0.57. 1H NMR (300 MHz,
CDCl3) 3.97 (s, 3H, OCH3), 6.89 (d, 2H, J = 9.1 Hz, H2’, H6’), 7.03 (d, 1H, J = 9.1 Hz, H3), 7.37 (dd, 
1H, J = 9.1, 3.0 Hz, H4), 7.77 (d, 1H, J = 3.0 Hz, H6), 8.13 (d, 2H, J = 9.1 Hz, H3’, H5’). 
To a solution of methyl 2-hydroxy-5-{[(4-nitrophenoxy)carbonyl]oxy}benzoate (130 mg, 0.4 mmol) 
and 1-methylpiperazine (0.07 mL, 0.6 mmol) in anhydrous DCM (6 mL), DIEA (0.3 mL, 1.6 mmol) 
was added dropwise at 0 ºC and the reaction mixture was stirred for 3 h at  rt.  The  solvent  was  
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evaporated and the residue was purified by column chromatography (EtOAc/EtOH, 8:2) to afford the
title final compound 9 as a solid in 67% yield. Mp 218-219 ºC. Rf (EtOAc/EtOH, 7:3) 0.32. IR (KBr, 
cm-1) 3197 (OH), 1724 (NCOO), 1683 (COO), 1621, 1489 (Ar). 1H NMR (300 MHz, CDCl3)  2.28
(s, 3H, NCH3), 2.39 (t, 4H, J = 5.1 Hz, 2H3’, 2H5’), 3.52 (m, 2H, 2H2’/2H6’), 3.61 (m, 2H, 2H2’/2H6’),
3.87 (s, 3H, OCH3), 6.90 (d, 1H, J = 9.0 Hz, H3), 7.15 (dd, J = 9.0, 2.9 Hz, H4), 7.53 (d, 1H, J = 2.9 
Hz, H6), 10.56 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  43.9, 44.4 (2CH2), 46.2, 52.4 (2CH3), 54.6, 
54.8 (2CH2), 112.2 (C), 118.3, 122.4, 129.7 (3CH), 143.1, 153.8, 159.0, 170.0 (4C). Elemental 
analysis: calcd. for C14H18N2O5·HCl: %C: 50.84, %H: 5.79, %N: 8.47; found, %C: 50.47, %H: 5.61, 
%N: 8.68. 
Synthesis of N-[4-(benzyloxy)phenyl]-N-methyl-1-imidazole-1-carboxamide (25). To a
suspension of CDI (750 mg, 3.5 mmol) in anhydrous THF (20 mL), 4-(benzyloxy)-N–methylaniline 
(627 mg, 3.9 mmol) was added. The mixture was refluxed for 16 h. The solvent was evaporated and
the residue was dissolved in DCM (20 mL) and washed with H2O (2 x 30 mL). The organic layers 
were dried (Na2SO4) and evaporated to afford the title carbamoylimidazole as a solid in 85% yield.
Rf (hexane/ EtOAc, 7:3) 0.37. IR (KBr, cm-1) 1697 (NCON), 1608, 1510, 1460 (Ar).1H-NMR (300 
MHz, CDCl3)  3.46 (s, 3H, NCH3), 5.06 (s, 2H, CH2), 6.83-6.84 (m, 1H, H4’’/H5’’), 6.89-6.90 (m, 1H, 
H4’’/H5’’), 6.97 (d, 2H, J = 9.0 Hz, H2,H6/H3,H5), 7.07 (d, 2H, J = 9.0 Hz, H2,H6/H3,H5), 7.38-7.45 (m, 
5H, H2’-H6’), 7.58 (br s, 1H, H2’’). 
Synthesis of methyl 5-({[[4-(benzyloxy)phenyl](methyl)amino]carbonyl}oxy)-2-
hydroxybenzoate (26). To a solution of 25 (937 mg, 3.1 mmol) in acetonitrile (8 mL), methyl iodide
(0.9 mL, 12.2 mmol) was added and the mixture was stirred at rt for 24 h. The solvent was evaporated, 
the residue was dissolved in acetonitrile and methyl 2,5-dihydroxybenzoate (506 mg, 3 mmol) and 
triethyl amine (0.4 mL, 3 mmol) were added dropwise. The reaction was refluxed for 18 h. The solvent 
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was evaporated, the residue was dissolved in DCM and an aqueous solution of 0.1 M HCl (50 mL)
was added. The aqueous layer was extracted with DCM (3 x 50 mL). The organic layers were dried 
(Na2SO4) and evaporated, and the residue was purified by chromatography (hexane/EtOAc, 8:2) to
afford the title compound as an oil in 36% yield. Rf (hexane/EtOAc, 7:3) 0.28. IR (neat, cm-1)  3172 
(OH), 1722 (CON), 1681, 1618, 1541, 1484 (Ar).1H NMR (300 MHz, CDCl3)  3.36 (s, 3H, NCH3), 
3.94 (s, 3H, OCH3), 5.08 (s, 2H, CH2), 6.95 (d, 1H, J = 8.9 Hz, H3), 7.01 (d, 2H, J = 8.8 Hz, H2’, H6’), 
7.14-7.27 (m, 3H, H4, H3’, H5’), 7.35-7.46 (m, 5H, H2’’-H6’’), 7.57 (m, 1H, H6), 10.63 (br s, 1H, OH). 13C 
NMR (75 MHz, CDCl3)  37.8, 53.6 (2CH3), 70.7 (CH2), 110.7 (C), 113.7, 116.5, 120.4 (3CH), 125.4
(3CH), 125.4 (C), 125.9 (2CH), 126.5 (2CH), 127.4 (2CH), 134.2, 140.3, 151.0 (3C), 155.4 (2C), 
165.9 (C).
Synthesis of 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoic acid (28). To  a  
solution of benzyl ester 14 (120 mg, 0.3 mmol) in absolute EtOH (20 mL), 10% Pd(C) (50 mg) was
added and the mixture was hydrogenated at rt for 4 h, with an initial hydrogen pressure of 30 psi.
The reaction mixture was filtered through a pad of celite and washed with EtOH. The solvent was 
evaporated to afford the title pure compound as a solid in quantitative yield. Mp 157-158 ºC. Rf
(DCM/EtOH, 95:5) 0.20. IR (KBr, cm-1)  3071 (OH), 1699 (NCOO, COO), 1596, 1489 (Ar). 1H NMR 
(300 MHz, CDCl3) δ 3.44 (s, 3H, NCH3), 6.95 (d, 1H, J = 8.9 Hz, H3), 7.22-7.45 (m, 6H, H4, H2’-H6’),
7.61 (m, 1H, H6). 13C NMR (75 MHz, CDCl3) δ 38.4 (CH3), 114.2 (C), 118.8, 119.1, 126.1, 127.0, 
127.3 (5CH), 129.3 (3CH), 142.5, 142.7, 154.8, 159.2, 169.8 (5C). 
Synthesis of methyl 2-hydroxy-5-({[(4-hydroxyphenyl)-(methyl)amino]carbonyl}oxy) 
benzoate (10). To a solution of 26 (100 mg, 0.3 mmol) in EtOH (10 mL), 10% Pd(C) (39 mg) was 
added and the mixture was hydrogenated at rt for 5 h, with an initial hydrogen pressure of 57 psi.
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The reaction was filtered through celite and the solvent was evaporated to afford pure the title
compound as a solid in quantitative yield. Mp 54-56 ºC. Rf (hexane/EtOAc, 7:3) 0.23. IR (KBr, cm-1) 
 3352 (OH), 1687 (NCOO), 1619, 1515, 1485 (Ar). 1H NMR (300 MHz, CD3OD)  3.32 (s, 3H, NCH3), 
3.95 (s, 3H, OCH3), 6.82 (d, 2H, J = 8.7 Hz, H3’, H5’), 6.93 (d, 1H, J = 7.8 Hz, H3), 7.19 (d, 2H, J = 8.7
Hz, H2’, H6’), 7.36 (m, 1H, H4), 7.49 (m, 1H, H6).13C NMR (75 MHz, CD3OD)  39.1, 53.1 (2CH3), 
113.5 (C), 116.8 (2CH), 119.1 (2CH), 123.4, 128.7, 130.8 (3CH), 135.9, 144.7, 156.3, 157.7, 160.1,
171.1 (6C). Elemental analysis: calcd. for C16H15NO6: %C: 60.57, %H: 4.77, %N: 4.41; found, %C: 
60.29, %H: 4.98, %N: 4.25. 
Synthesis of 4-hydroxy-3-[(methylamino)carbonyl]phenyl methyl(phenyl)carbamate (13). 
To a solution of methyl ester 7 (200 mg, 0.7 mmol) in MeOH (2 mL), a solution of methylamine (40% 
in H2O) (0.5 mL, 10 mmol) was added dropwise at 0 ºC and the reaction mixture was stirred for 3 h 
at rt. The solvents were evaporated and the residue was purified by chromatography (hexane/EtOAc, 
7:3) to afford the title compound as a solid in 76% yield. Mp 69-70 ºC. Rf (DCM/EtOH, 95:5) 0.43. IR 
(KBr, cm-1) 3366 (NH, OH), 1705 (NCOO), 1647 (CON), 1602, 1552, 1494 (Ar).1H NMR (300 MHz,
CDCl3)  2.92 (d, 3H, J = 4.8 Hz, NHCH3), 3.43 (s, 3H, NCH3), 6.41 (br s, 1H, NH), 6.95 (d, 1H, J = 
8.8 Hz, H3), 7.10-7.44 (m, 7H, H4, H6, H2’-H6’), 12.22 (s, 1H, OH). 13C NMR (75 MHz, CDCl3)  26.5, 
38.4 (2CH3), 114.2 (C), 118.8, 119.1, 126.1, 127.0, 127.3 (5CH), 129.3 (3CH), 142.5, 142.7, 154.8, 
159.2, 169.8 (5C). Elemental analysis: calcd. for C17H18N2O4: %C: 63.99, %H: 5.37, %N: 9.33; found, 
%C: 63.70, %H: 5.39, %N: 9.26. 
General procedure for the synthesis of final compounds 19-23. To a solution of benzoic acid
28 (1 equiv) in anhydrous DMF (12 mL/mmol), EDC (1.5 equiv) and DMAP (0.3 equiv) were added
and the mixture was stirred at rt for 15 min. Then, a solution of the corresponding amine or alcohol 
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(1 equiv) in DMF (6 mL/mmol) was added at 0 ºC, and the reaction mixture was stirred for 2 h at this
temperature and at rt for 14 additional h. The mixture was evaporated and the residue was purified 
by column chromatography to give the title final compounds.
1-(Pyridin-3-yl)ethyl 2-hydroxy-5-({[methyl(phenyl)amino]carbonyl}oxy)benzoate (19).
Obtained from acid 28 (201 mg, 0.7 mmol) and 1-pyridin-3-ylethanol (86 mg, 0.7 mmol) in 52% yield.
The free amine was characterized (yield, Rf, IR, NMR), dissolved in anhydrous DCM (4 mL) and
treated with a commercial 1 M HCl(g)/Et2O solution (0.6 mL). The hydrochloride salts was isolated
by evaporation of the solvents and characterized (Melting point, elemental analysis). 
Chromatography: DCM/EtOH, 99:1. Mp 80-82 ºC. Rf (DCM/MeOH, 95:5) 0.20. IR (KBr, cm-1)  3177
(OH), 1723 (NCOO), 1677 (COO), 1620, 1596, 1487 (Ar). 1H NMR (300 MHz, CDCl3)  1.73 (d, 3H, 
J = 6.7 Hz, CH3), 3.44 (s, 3H, NCH3), 6.17 (q, 1H, J = 6.7 Hz, CH(CH3)2), 6.96 (d, 1H, J = 9.0 Hz, H3), 
7.25-7.45 (m, 7H, H4, H2’-H6’, H5’’), 7.61 (m, 1H, H6), 7.76 (d, 1H, J = 7.9 Hz, H4’’), 8.60 (dd, 1H, J = 
4.8, 1.6 Hz, H6’’), 8.73 (d, 1H, J = 2.1 Hz, H2’’). 13C NMR (75 MHz, CDCl3)  22.3, 38.7 (2CH3), 72.1
(CH), 112.4 (C), 118.8, 122.5, 124.0, 126.3, 127.1 (5CH), 129.5 (3CH), 130.5 (CH), 134.2 (C), 136.6
(CH), 143.2, 143.5 (2C), 148.4, 150.1 (2CH), 154.5, 159.8, 169.1 (3C). Elemental analysis: calcd. for 
C22H20N2O5·HCl·5/3H2O: %C: 57.58, %H: 5.34, %N: 6.10; found, %C: 57.42, %H: 5.53, %N: 5.99. 
(1-Methylpiperidin-3-yl)methyl (20).
Obtained from acid 28 (230 mg, 0.8 mmol) and (1-methylpiperidin-3-yl)methanol (0.1mL, 0.8 mmol)
in 34% yield. The free amine was characterized (yield, Rf, IR, NMR), dissolved in anhydrous DCM 
(4.5 mL) and treated with a commercial 1 M HCl(g)/Et2O solution (0.7 mL). The hydrochloride salts 
was isolated by evaporation of the solvents and characterized (Melting point, elemental analysis). 
Chromatography: DCM/EtOH, 9:1. Mp 75-77 ºC. Rf (DCM/EtOH, 8:2) 0.55. IR (KBr, cm-1)  3168
(OH), 1726 (NCOO), 1678 (COO), 1596, 1489 (Ar). 1H-NMR (300 MHz, CDCl3)  1.00-1.14 (m, 1H,
H4’’), 1.62-1.86 (m, 4H, H4’’, 2H5’’, H6’’), 1.99 (td, 1 H, J = 11.0, 2.7 Hz, H2’’), 2.10-2.23 (m, 1H, H3’’),
2.32 (s, 3H, NCH3), 2.81 (d, 1H, J = 10.9 Hz, H6’’), 2.94 (d, 1H, J = 10.1 Hz, H2’’), 3.44 (s, 3H, PhNCH3),
4.15-4.24 (m, 2H, CH2), 6.96 (d, 1H, J = 9.0 Hz, H2), 7.22-7.45 (m, 6H, H4, H2’-H6’), 7.54 (m, 1H, H6), 
10.67 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  24.7, 26.6 (2CH2), 35.8 (CH3), 38.3 (CH), 46.7
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(CH3), 56.1, 59.0, 68.2 (3CH2), 112.2 (C), 118.3, 122.2, 126.0, 126.8 (4CH), 129.1 (3CH), 129.8 (CH), 
142.8, 143.1, 154.2, 159.2, 169.5 (5C). Elemental analysis: calcd. for C22H26N2O5·HCl·2H2O: %C:
56.11, %H: 6.63, %N: 5.95; found, %C: 56.49, %H: 6.36, %N: 6.07. 
hexane/EtOAc, 8:2, oil. Rf (hexane/EtOAc, 95:5) 0.40. IR (neat, cm-1)  3358, 3068 (NH, OH), 1706
(NCOO), 1646 (CON), 1599, 1545, 1493 (Ar). 1H NMR (300 MHz, CDCl3)  3.45 (s, 3H, NCH3), 4.62 
(d, 2H, J = 5.6 Hz, CH2), 6.56 (br s, 1H, NH), 6.97 (d, 1H, J = 9.0 Hz, H3), 7.14-7.43 (m, 12H, H4, H6, 
H2’-H6’, H2’’-H6’’), 12.14 (br s, 1H, OH). 13C NMR (75 MHz, CDCl3)  38.3 (CH3), 43.6 (CH2), 114.1 (C), 
118.9, 125.8, 126.9, 127.5, 127.6 (5CH), 127.9 (3CH), 128.7 (2CH), 129.2 (3CH), 137.6, 142.5,
142.6, 154.5, 159.1, 169.1 (6C). MS (ESI): [(M-H)-] 375.1. 
yield. The free amine was characterized (yield, Rf, IR, NMR), dissolved in anhydrous DCM (4.5 mL) 
and treated with a commercial 1 M HCl(g)/Et2O solution (0.7 mL). The hydrochloride salts was
isolated by evaporation of the solvents and characterized (Melting point, elemental analysis). 
Chromatography: DCM/EtOH, 95:5. Mp 110-112 ºC. Rf (DCM/EtOH, 9:1) 0.32. IR (KBr, cm-1)  3348 
(NH, OH), 1719 (NCOO), 1646 (CON), 1599, 1545, 1492 (Ar). 1H-NMR (300 MHz, CDCl3)  3.35 (s, 
3H, NCH3), 4.40 (d, 2H, J = 5.7 Hz, CH2), 6.87 (d, 1H, J = 9.0 Hz, H3), 7.04-7.06 (m, 1H, H4), 7.19-
7.36 (m, 6H, H5’’, H2’-H6’), 7.41 (m, 1H, H6), 7.60 (d, 1H, J = 7.9 Hz, H4’’), 8.12 (br s, 1H, NH), 8.44 (br 
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3-[(Benzylamino)carbonyl]-4-hydroxyphenyl methyl(phenyl)carbamate (21). Obtained from
acid 28 (230 mg, 0.8 mmol) and benzyl amine (0.09 mL, 0.8 mmol) in 27% yield. Chromatography:
4-Hydroxy-3-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl methyl(phenyl)carbamate (22).
Obtained from acid 28 (228 mg, 0.8 mmol) and pyridin-3-ylmethylamine (87 mg, 0.8 mmol) in 37% 
 
	
	
 
  
     
 
    
    
 
 
  
  
  
  
    
 
 
 
 	
Experimental section
	
s, 2H, H2’’, H6’’). 13C NMR (75 MHz, CDCl3)  38.7 (CH3), 41.3 (CH2), 115.0 (C), 119.1, 120.2, 124.1,
126.3, 127.2, 127.8 (6CH), 129.5 (3CH), 134.3 (C), 136.5 (CH), 142.9, 143.0 (2C), 148.8, 149.3 
(2CH), 154.9, 159.0, 169.4 (3C). Elemental analysis: calcd. for C21H19N3O4·HCl·H2O: %C: 58.40,  
%H: 5.13, %N: 9.73; found, %C: 58.01, %H: 5.19, %N: 9.75. 
4-Hydroxy-3-{[methyl(pyridin-3-ylmethyl)amino]carbonyl}phenylmethyl(phenyl)-
carbamate (23). Obtained from acid 28 (144 mg, 0.5 mmol) and N-methyl-N-(pyridin-3-
yl)methylamine (61 mg, 0.5 mmol) in 64% yield. The free amine was characterized (yield, Rf, IR, 
NMR), dissolved in anhydrous DCM (2 mL) and treated with a commercial 1 M HCl(g)/Et2O solution
(0.3 mL). The hydrochloride salts was isolated by evaporation of the solvents and characterized
(Melting point, elemental analysis). Chromatography: DCM/EtOH, 95:5. Mp 207-209 ºC. Rf
(DCM/EtOH, 95:5) 0.14. IR (KBr, cm-1)  3062 (OH), 1721 (NCOO), 1629 (CON), 1601, 1493 (Ar).
1H NMR (300 MHz, CDCl3)  3.05 (s, 3H, NCH3), 3.39 (s, 3H, PhNCH3), 4.73 (s, 2H, CH2), 6.93 (d, 
1H, J = 8.7 Hz, H3), 7.02-7.09 (m, 2H, H4, H5’’), 7.26-7.41 (m, 6H, H6, H2’-H6’), 7.69 (d, 1H, J = 7.7 Hz, 
H4’’), 8.56 (d, 1H, J = 4.1 Hz, H6’’ ), 8.62 (m, 1H, H2’’). 13C NMR (75 MHz, CDCl3)  37.0, 38.7 (2CH3), 
60.8 (CH2), 118.3 (CH), 119.2 (C), 121.6, 124.3, 125.8, 126.3, 127.1 (5CH), 129.5 (3CH), 132.8 (C),
136.5 (CH), 143.2 (2C), 149.1, 149.4 (2CH), 154.5, 155.3, 171.4 (3C). Elemental analysis: calcd. for 
C22H21N3O4·HCl·1/2H2O: %C: 60.48, %H: 5.31, %N: 9.62; found, %C: 60.16, %H: 5.12, %N: 9.51. 
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4.2. Biological experiments 
4.2.1. Inhibition of bFGF-induced cell proliferation of HUVECs. HUVECs, obtained from
American Type Culture Collection (ATCC, Rockville, MD), were cultured in a humidified atmosphere
of 95% air and 5% CO2 at 37 C in M199 medium containing 10% fetal bovine serum (FBS) and 10
μg/mL heparin. Cells were incubated in the presence of bFGF (1 μg/mL) and the appropiate 
concentration of compound or vehicle (0.4% DMSO) for 2 days, and cell proliferation was quantified
spectrofluorimetrically. IC50 values are the mean from at least two independent experiments carried
out in triplicate. In all cases, the SEM is within a 10% of the mean value.
4.2.2. Determination of VEGF and bFGF levels. Cells were seeded in 12-well plates at a density 
of 5 x 104 cells per well and were grown for 24 h to obtain a 70-80% confluent monolayer. Then,
medium was replaced with fresh Dulbecco’s Modified Eagle Medium (DMEM) with or without 150 μM 
CoCl2. After 5 h, compound 22 or vehicle (DMSO) were added to the culture medium, and cells were
incubated for 4 h more. Supernatants were then collected and used straightaway or stored at -80 ºC 
for further use. Concentrations of VEGF and bFGF in the culture medium were measured using an
enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s instructions (VEGF 
human ELISA kit and FGF-basic human ELISA kit, Invitrogen, Carlsbad, CA). Absorbance was 
measured at 450 nm using an Asys UVM 340 (Biochrom Ltd., Cambridge, UK) microplate reader,
and data were normalized to the kit controls and the number of producing cells. Data from three to
five independent experiments carried out in triplicate were represented as mean fold ± SEM with bar
graphs. 
4.2.3. Nitric oxide (NO) quantification. Nitric oxide production was measured through
determination of nitrite concentration in the culture medium using the Griess test. Briefly, cells were 
seeded in 96-well plates at a density of 1 x 104 cells per well in DMEM with 10% FBS and incubated
for 24 h prior to treatments. The medium was then replaced with fresh DMEM with or without 150 μM 
CoCl2; after 5 h of incubation, compound 22 or vehicle was added, and incubation was continued for 
another 4 h. Then, 100 μL of supernatant from each condition was mixed with 100 μL of Griess 
reagent (1% sulphanilamide, 0.1% N-(1-naphthyl)ethylendiamine dihydrochloride, 2.5% phosphoric
acid). After 15 min at rt in the dark, absorbance was measured at 548 nm in an Asys UVM 340
(Biochrom Ltd., Cambridge, UK) microplate reader. The concentration of nitrite, a stable oxidized
derivative of NO in cell cultures, was determined from a sodium nitrite (NaNO2, Sigma-Aldrich) 
standard curve. Data from three independent experiments performed in triplicate were presented as 
mean ± SEM.
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4.2.4. Western blot analysis. MCF7 cells were plated at a density of 2 x 106 cells in 15-cm dishes
and allowed to grow 24 h in DMEM with 1% FBS, to a 80% confluent monolayer. The medium was 
then replaced by fresh DMEM with or without 150 μM CoCl2 and cells were incubated for 5 h to allow 
hypoxic response. After that, compound 22 or vehicle were added and cells were incubated during 4 
h. Cells were washed with phosphate buffered saline (PBS) and lysed with ice-cold RIPA buffer (50
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Igepal) containing protease and phosphatase inhibitors 
(Roche and Sigma-Aldrich, respectively). Lysates were clarified by centrifugation at 10000g for 10
min at 4 ºC and used straightaway or stored at -80 ºC until use. Protein concentration was measured
(DC protein assay kit, Bio-Rad), and samples with equal amounts of total protein were diluted into 
Laemmli reducing sample buffer (Bio-Rad) and denatured at 95 ºC for 5 min. Samples were then 
resolved on 4-20% SDS-PAGE gels (Bio-Rad), and proteins were transferred to nitrocellulose
membranes (GE Healthcare, Amersham). After 1 h of incubation in blocking buffer [10 mM Tris-HCl
pH 8.0, 150 mM NaCl, 0.05% Tween-20 (TBS-T) with 1% BSA], membranes were incubated 
overnight at 4 ºC with the corresponding primary antibody. Then, membranes were washed three 
times (5 min each) with TBS-T and incubated with the corresponding secondary antibody for 1 h at 
rt. Protein bands were visualized using enhanced chemiluminescence detection reagents (GE 
Healthcare, Amersham) in a Fujifilm LAS-3000 developer (Tokyo, Japan) and quantified by 
densitometry using ImageJ software (NIH).
Primary antibodies were from Cell Signaling and used at 1:1000 dilution (rabbit anti-phospho-AKT
(pS473), rabbit anti-AKT, rabbit anti-phospho-ERK1/2, rabbit anti-ERK1/2, rabbit anti-phospho-
MEK1/2, rabbit anti-MEK1/2, rabbit anti-VEGFR, rabbit anti-phospho-VEGFR, rabbit anti-FGFR, 
rabbit anti-phospho-FGFR) or from Santa Cruz Biotechnology and used at 1:200 dilution (mouse anti-
HIF-1α, mouse anti-HIF-2α, mouse anti-iNOS, rabbit anti-β-actin). Secondary antibodies used were 
goat anti-mouse or goat anti-rabbit IgG HRP conjugates (1:5000, Sigma-Aldrich) accordingly.
Relative phosphorylation levels from three independent experiments were presented as mean ± SEM 
with bar graphs.  
4.2.5. Migration or wound healing assay. Cells were seeded in 96-well plates at a density of 
1.5 x 104 cells per well in DMEM with 10% FBS and grown for 24 h at 37 ºC and 5% of CO2 to obtain
a 90-100% confluent monolayer. Wounds were made with a sterile p20 pipette tip and each well was 
washed twice with PBS to eliminate nonadherent cells and cell debris. Fresh DMEM with or without
150 μM CoCl2 was then added and after 5 h of incubation, compound 22 (50 μM) or vehicle was 
added. At this time (0 h) and after 48 h, cells were photographed under phase contrast with an 
Olympus FW1200 microscope. Empty area in each wound was quantified using ImageJ software 
(NIH) and compared with the corresponding area of the initial wound. The percentage of area from 
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three independent experiments performed in triplicate was presented as mean ± SEM with bar 
graphs.
4.2.6. RNA interference-mediated silencing of the HIF-1α gene. Cells were transfected with
specific siRNA duplexes using DharmaFECT 1 as transfection reagent according to the 
manufacturer’s instructions (Dharmacon-Thermo Scientific, Lafayette, CO). Selective siRNA against 
human HIF-1α was a smart pool from Dharmacon-Thermo Scientific, and the sequences were: 5'-
GAACAAAUACAUGGGAUUA-3'; 5'-AGAAUGAAGUGUACCCUAA-3'; 5'-
GAUGGAAGCACUAGACAAA-3'; 5'-CAAGUAGCCUCUUUGACAA-3'. The nontargeted control 
sequence, 5'-UUCUCCGAACGUGUCACGU-3’, was from Applied Biosystems-Ambion (Austin, TX). 
Twenty-four hours after transfection, cells were seeded for ELISA assays, which performed as 
described below.
4.2.7. Quantitive polymerase chain reaction (qPCR). RNA from cell cultures or tumor tissues 
was isolated with TRIzol reagent (Sigma-Aldrich). cDNA was subsequently obtained with Transcriptor 
reverse transcriptase (Roche). Real-time quantitative PCR assays were performed using the
FastStart master mix with Rox (Roche), and probes were obtained from the Universal Probe Library
(Roche). The primers used for human HIF-1α were as follows: sense, 5’-
GATAGCAAGACTTTCCTCAGTCG-3’; and antisense, 5’-TGGCTCATATCCCATCAATTC-3’. 
Amplifications were run in a 7900 HT-fast real-time PCR system (Applied Biosystems). Each value 
was normalized to human β-actin RNA levels as an internal control: sense, 5’-
CCAACCGCGAGAAGATGA-3’; and anti-sense, 5’-CCAGAGGCGTACAGGGATAG-3’.
4.2.8. Gene expresssion analysis. The RT2 profiler PCR array of human angiogenesis (Qiagen, 
Valencia, CA), which analyzes the expression of 84 key genes involved in modulating the biological 
processes of angiogenesis, was used. RNA from cell cultures was isolated with TRIzol reagent
(Sigma-Aldrich), including a DNA digestion step with genomic DNA elimination mix (Qiagen). cDNA 
was subsequently obtained with a RT2 first strand kit according to manufacturer’s instructions
(Qiagen). Real-time PCR assay was performed using the RT2 profiler PCR array of human
angiogenesis in combination with RT2 SYBR Green master mix (Qiagen). Amplifications were run in 
a 7900 HT-fast real-time PCR system (Applied Biosystems) and data were analyzed using the
SABiosciences PCR array data analysis template Excel (Qiagen). 
4.2.9. VEGF expression analysis. RNA was isolated from tumors with TRIzol reagent
(Invitrogen) with the real star kit (Durviz, Valencia, Spain), and cDNA was obtained with Transcriptor 
reverse transcriptase (Roche). The primers used for VEGF-A amplification were: sense, 5'-
GTCCTGTGTGCCGCTGAT-3'; antisense, 5'-AGGTTTGATCCGCATGATCT-3'. GAPDH was used 
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as reference (sense, 5'-GGGAAGCTCACTGGCATGGCCTTCC-3'; antisense, 5'-
CATGTGGGCCATGAGGTCCACCAC-3').  
4.2.10. Subcutaneous xenografts. All procedures involving animals were performed with the 
approval of the Complutense University Animal Experimentation Committee in compliance with
European official regulations. Five million MDA-MB-231 breast cancer cells in 100 µL of PBS were 
subcutaneously injected into the flank of 6-week-old athymic mice (Harlan Interfauna Iberica, 
Barcelona, Spain). Tumors were routinely measured with external caliper, and volume was calculated
as (4/3) x (width/2)2 x (length/2). When tumors reached ca. 200 mm3, the mice were treated
intraperitoneally three times a week with compound 22 (25 mg/kg) or vehicle (DMSO 0.2 mg/μL in
PBS) for 4 weeks. After treatment, animals were sacrificed, and tumors and organs were collected.
Tumors were divided into different portions for preparation of tissue sections for immunofluorescent
staining [frozen in Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, The Netherlands)] or snap
frozen for RNA extraction (and stored at -80 ºC until use). Organs collected were fixed in 
formaldehyde and stained with hematoxylin-eosin for analysis.
For immunofluorescence analysis, Tissue-Tek frozen sections were fixed in PFA 4% and were 
subjected to heat-induced antigen retrieval in citrate buffer. Then, sections were blocked with PBS 
containing 0.25% TritonX-100 and 10% goat serum, and incubated with anti-CD31 (Pharmingen/BD
Biosciences, San Jose, CA). Secondary anti-mouse antibodies conjugated with Alexa Flour 488 were
from Invitrogen (Carlsbad, CA). Cell nuclei were stained with DAPI (Invitrogen). Images were 
acquired using a Leica DM400B microscope (Leica, Wetzlar, Germany).
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CHAPTER II:
LEAD OPTIMIZATION PROCESS AND BIOLOGICAL CHARACTERIZATION OF 
A NOVEL INHIBITOR OF ICMT WITH ANTITUMOR ACTIVITY  
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1. INTRODUCTION AND OBJECTIVES 
The Ras protein family members are monomeric low-molecular-weight GTP-binding proteins that 
play a role in regulating cell differentiation, proliferation, and survival. To do so, Ras proteins act as 
binary molecular switches, exchanging guanosine 5’-triphosphate (GTP, active form) for guanosine 
5’-diphosphate (GDP, inactive form), or vice versa. GTP binding induces a marked conformational 
change in Ras that allows it to bind effectors via their Ras binding domains (RBD). This switch is 
regulated by guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs), 
which change the activation state of Ras without covalently modifying it (Figure 1).1 
Figure 1. The GTP/GDP cycle of Ras.
Single-point mutations of ras gene can lead to the production of constitutively activated Ras 
protein, with impaired GTPase activity. These activating mutations of ras result in continuous 
stimulation of cell proliferation and inhibition of apoptotic signaling, thus promoting cancer. In fact, 
intensive sequencing of the cancer genome has revealed that, despite the identification of more than
500 validated cancer genes, the three ras genes (hras, nras and kras) still constitute the most
frequently mutated oncogene family in human cancers. Considering also that mutations in ras are
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found in some of the most lethal cancers -they have been found in almost 30% of all cancers, 
including 50% of colon and up to 90% of pancreatic tumors-,2,3 it is easy to understand the interest 
that has been spurred in developing Ras inhibitors. However, despite more than three decades of 
intensive effort, no effective pharmacological inhibitors of the Ras oncoproteins have reached the 
clinic, prompting the widely held perception that Ras proteins are ‘undruggable’.4,5 Hence, the 
possibility of blocking Ras activity by interfering with the post-translational modifications responsible
for its activation has gained an increasing attention within the last years.
Ras is a member of a large class of proteins known as CAAX proteins, where C is cysteine, A is
usually an aliphatic amino acid and X is any amino acid. The primary translation product of CAAX 
protein genes ends with a CAAX sequence, which serves as a substrate for three enzymes that 
modify the sequence in a step-wise manner to create a lipidated, hydrophobic domain that mediates
the association with cellular membranes. First, unmodified CAAX sequences serve as substrates for 
prenylation by one of the cytosolic prenyltransferases: geranylgeranyltransferase type I (GGTase I) 
if the X amino acid is leucine or phenylalanine, or farnesyltransferase (FTase), for any other amino
acid.6 For Ras protein, this first modification means the addition of a farnesyl moiety, turning an
otherwise globular and hydrophilic protein into one that binds to the cytoplasmic leaflet of cellular 
membranes, which is an essential process required for Ras biological activation.1 However, it has
been demonstrated that upon inhibition of FTase, N-Ras and K-Ras (but not H-Ras) can also be 
geranylgeranylated.7 
The second step for prenylated proteins consists in a specific proteolytic removal of the last three
amino acids AAX, which is carried out by the Ras-converting enzyme 1 (Rce1), an integral membrane 
protease of the endoplasmic reticulum.8,9 Finally, the newly formed C-terminal prenylcysteine 
becomes a substrate for a specific protein carboxyl methyltransferase, isoprenylcysteine carboxyl 
methyltransferase (ICMT), also localized in the endoplasmic reticulum,10 which methylates the free 
carboxyl group, neutralizing the negative charge of the prenylcysteine and thereby increasing 
membrane affinity (Figure 2).6 
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Figure 2. Post-translational modifications of Ras. 
In absence of any of these post-translational modifications, Ras losses its ability to induce tumor 
transformation. Therefore, the blockade of the enzymes involved in these modifications represents 
an attractive strategy to inhibit Ras activity. However, thus far attempts to abrogate the plasma 
membrane binding of Ras by FTase11,12 have failed because N-Ras and K-Ras are also good
substrates for GGTase I.7 Meanwhile, inactivation of Rce1 has been shown to promote the 
development of lethal cardiomyopathy in mice,13 as well as to accelerate the growth of some 
malignancies, such as myeloproliferative disease.14 Besides, mammalian genomes encode only one
member of the ICMT class of methyltransferases and it lacks homology to other protein
methyltransferases,10 thus resulting in a more specific target than Rce1, and turning the inhibition of 
ICMT into a promising alternative for anticancer therapies.15 
Up to date, few structurally distinct inhibitors of ICMT have been disclosed and only two
compounds have been studied for their potential use as anticancer agents. First, cysmethynil (CYSM, 
Figure 3) was discovered in 2005 by high-throughput screening (HTS), and it has been characterized 
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as an ICMT inhibitor (IC50 = 2.4 μM) able to impact on tumor growth, but its in vitro antiproliferative
activity and in vivo antitumor efficacy are still quite modest.16,17 
More recently, and also from a HTS followed by structure-activity relationship (SAR) studies, some 
tetrahydropyrane derivatives have been described (general structure referred as THP, Figure 3).
However, none of the cellular effects observed using these ICMT inhibitors were very pronounced,18 
so no further biological characterization -either in vitro or in vivo- has been carried out regarding these
derivatives. 
Figure 3. Representative synthetic inhibitors of ICMT. 
Given the interest of ICMT and the paucity of inhibitors, in our research group we have started a
project aimed at the design, synthesis and development of new ICMT inhibitors. For the initial design, 
we built a 3D pharmacophore model that was subsequently refined by homology models based on
the ICMT prokaryotic ortologue,19 and followed by virtual screening of the Natural Cancer Institute 
database. This work first led us to the hit UCM-1310 (Figure 4),20 which showed 30% of ICMT 
inhibition at 50 μM. The subsequent hit to lead process yielded the lead UCM-1325 (Figure 4), with
54% of ICMT inhibition at 50 μM. 
Figure 4. Hit to lead process carried out in our research group. 
Thus, the main objectives of this work are: 
1. Optimization of the lead UCM-1325. 
2. Study of the mechanism of action of the selected compound(s). 
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2. RESULTS AND DISCUSSION 
2.1. Optimization of the lead compound UCM-1325
We have carried out an optimization process aimed at the improvement of the inhibitory capacity 
of lead compound UCM-1325, while keeping good pharmacokinetic properties. For this purpose, the
three types of structural modifications depicted in Figure 5 were carried out: substitution of the
cyclopropyl ring for different aromatic rings (compounds 1-15); modifications in the hydrophobic chain 
(compounds 16-27); and modifications in the amide group (compounds 28-30). 
Figure 5. Structural modifications in compound UCM-1325. 
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2.1.1. Modification of the cyclopropyl ring  
To start the exploration of compound UCM-1325 with the aim of increasing the ICMT inhibitory
capacity, we first designed compounds 1-3 (Scheme 1), where the cyclopropyl ring was substituted
by an aromatic moiety (pyridine or benzene). 
The synthesis of compounds 1-3 was carried out following the approach depicted in Scheme 1, 
starting from acryloyl chloride, which through reaction with the corresponding amine in the presence
of a base (triethylamine or pyridine) gave acrylamides 31-33. The aza-Michael reaction of 1
equivalent of acrylamide 33 with 3 equivalents of octylamine in the presence of 1,8-
diazabicycloundec-7-ene (DBU) for 5 h gave secondary amine 34, which through reaction with the
acrylamides 31 and 32 in the presence of DBU afforded the final compounds 1 and 2, respectively.
The aza-Michael reaction of 3 equivalents of acrylamide 33 with 1 equivalent of octylamine in the 
presence of DBU for 24 h gave final compound 3. 
Scheme 1. Reagents and conditions: a) 2- or 3-aminopyridine, Et3N, DCM, -78 to 0 ºC, 57-68%; b) aniline, 
pyridine, DCM, 0 ºC to rt, 2 h, 84%; c) CH3(CH2)7NH2, DBU, CH3CN, 60 ºC, 5 h, 79%; d) 31 or 32, DBU, CH3CN,
60 ºC, 24 h, 37-45%; e) CH3(CH2)7NH2, DBU, CH3CN, 60 ºC, 24 h, 83%. 
The synthetized compounds were screened for ICMT inhibitory capacity and for cell
antiproliferative effect in a panel of cancer cell lines (Table 1).  
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To determine the capacity of these new derivatives to inhibit the activity of ICMT, we used as a
source of enzyme membranes from Sf9 insect cells that overexpressed ICMT, biotinyl-S-
farnesylcysteine (BFC) as substrate, and [3H]-S-adenosylmethionine ([3H]-SAM) as cosubstrate. 
Incubation of the enzyme with BFC and [3H]-SAM in the presence of the compound under study 
allowed us to quantify the percentage of inhibition of the methyl esterification reaction, in which the
tritiated methyl group of [3H]-SAM was transferred to the substrate BFC. The incorporated
radioactivity was measured by liquid scintillation spectrometry.  
The antiproliferative effect of the compounds in breast cancer MCF7 and MDA-MB-231 cells, as 
well as in prostate cancer PC-3 cells, was measured through MTT assays. Cells were incubated with
different concentrations of the compounds for 48 h and then, the formation of formazan crystals by 
the remaining viable cells was measured and compared to the vehicle-treated cells. 
Table 1. Biological activity of compounds UCM-1325 and 1-3a 
UCM-1325 34 36 34 54
1 19 28 22 24
2 37 48 54 18
3 10 17 22 93
Antiproliferative effect (IC50, μM) ICMT inhibitionCpd R MCF7 MDA-MB-231 PC-3 (%, 50 μM) 
aData from three independent experiments performed in triplicate; the standard error of the mean (SEM) is in all
cases within a 10% of the mean value.
As can be deduced from the biological data obtained for compounds 1-3 (Table 1), while the 
introduction of pyridine rings does not improve the ICMT inhibitory capacity of derivatives 1 and 2, 
the opposite occurs when a phenyl ring is introduced (3). In this last case, we can observe a
significant increase in the inhibitory capacity (93% ICMT inhibition at 50 μM), which comes along with 
an improvement in the antiproliferative effect of the resulting derivative, compound 3. 
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Scheme 2. Reagents and conditions: a) acryloyl chloride, pyridine, DCM, 0 ºC to rt, 2 h, 35-93%; b) acryloyl
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We hence decided to keep the phenyl group and analyze the influence of the introduction of 
different substituents, which led to derivatives 4-15. The synthesis of the compounds was achieved 
following the conditions depicted in Scheme 2. The aza-Michael reaction between amine 34 and the 
corresponding acrylamide (37-47) in the presence of DBU afforded asymmetric amides 4-14. The
hydrolysis of the ethyl ester 14 with lithium hydroxide gave final compound 15. Synthesis of 
acrylamides (37-47) was carried out as previously described in Scheme 1, starting from acryloyl
chloride, which afforded the corresponding acrylamides by reaction with the adequate anilines in the 
presence of a base. 
chloride, Et3N, THF/DMF, 0 ºC to rt, o/n, 41%; c) N1-phenyl-N3-octyl-β-alaninamide (34), DBU, CH3CN, 77 ºC,
24 h, 32-100%; d) LiOH·H2O, THF/H2O, reflux, 3h, 28%. 
All the anilines used in Scheme 2 were commercial except for derivative 36, which was prepared
as described in Scheme 3. 
Scheme 3. Reagents and conditions: a) NHMe2·HCl, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
tetrafluoroborate (TBTU), Et3N, rt, 2 h, 75%; b) TFA/DCM, rt, 1 h, 93%.
We then determined the antiproliferative activity and the ICMT inhibitory capacity of compounds 
4-15 (Table 2). First, we analyzed the influence of the position of the substitution in the phenyl ring 
(ortho, meta or  para) for F and CF3 substituents (compounds 4-9). Regarding the antiproliferative
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effect, both meta and para positions led to similar biological activity (IC50 = 10-15 μM for F substituted
derivatives 5 and 6, and 8-22 μM for CF3 substituted compounds 8 and 9), better than the ortho
substitution (IC50 = 21-38  μM for F substituted derivative 4, and 25-36 μM for CF3 substituted
derivative 7). However, the inhibition of ICMT was much higher for the derivatives with the substituent 
at para position rather than for those with ortho or meta substitutions, as observed when comparing 
para substituted compounds 6 and 9 (with percentages of ICMT inhibition at 50 μM of 84% and 63%, 
respectively) with the meta substituted 5 and 8 (23% and 35%), or the ortho substituted 4 and 7 (23%
and 30%, respectively). Hence, the para position was chosen for the rest of substituents (compounds 
10-15). 
With respect to the influence of the electronic effects we could not observe any clear correlation
between the biological activity (antiproliferative activity and ICMT inhibitory capacity) and the electron
donor or acceptor character of the different substituents. In any case, none of the modifications
improved the 93% inhibition obtained with derivative 3, and their antiproliferative activity in cancer 
cells was clearly decreased (Table 2). 
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Table 2. Biological activity of compounds 3-15a 
Cpd R
Antiproliferative effect (IC50 μM) 
MCF7 MDA-MB-231 PC-3
ICMT 
Inhibition 
(%, 50 μM) 
3 H 10 17 23 93
4 o-F 22 38 21 23
5 m-F 14 13 10 23
6 p-F 15 14 14 84
7 o-CF3 36 25 30 30
8 m-CF3 15 20 22 35
9 p-CF3 11 8 12 63
10 p-NHCOCH3 32 38 31 40
11 p-CN 14 25 27 68
12 p-OCH3 16 25 25 53
13 p-CON(CH3)2 22 33 25 47
14 p-COOCH2CH3 17 21 15 21
15 p-COOH >50 48 >50 15
aData from three independent experiments performed in triplicate; the SEM is in all cases within a 10% of the
mean value.
2.1.2. Influence of the hydrophobic chain 
In order to study the influence of the hydrophobic chain, we designed a new series of compounds
(16-27) with lower calculated logarithm of the octanol/water partition coefficient (clogP) values by 
replacing the hydrophobic n-octyl chain by shorter alkyl chains or more polar substituents. First, the 
importance of the length of the alkyl chain was evaluated in order to check whether it is possible to
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Scheme 4. Reagents and conditions: a) 3-bromopropanoyl chloride, pyridine, DCM, rt, 2 h, 92%; b) NH3 (2 M in
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decrease the lipophilicity of compounds by shortening it, while keeping a good biological activity. This 
led us to compounds 16-18. Next, we analyzed the influence of the introduction of oxygen atoms in
the hydrophobic chain (19-22) or its replacement by more polar groups (23-27).
The synthesis of compounds 16-27 was carried out following the approach depicted in Scheme
4. The nucleophilic substitution of 48 with  NH3 gave compound 16, whereas its reaction with
piperidinyl or piperazinyl amines in the presence of triethylamine afforded compounds 26 and 27. 
Intermediate phenylamide 48 was obtained by nucleophilic substitution of 3-bromopropanoyl chloride 
and aniline using pyridine as a base. The aza-Michael reaction of acrylamide 33 (Scheme 1) with the
appropriate primary amine in the presence of DBU gave compounds 17-25. 
MeOH), DCM, rt, o/n, 15%; c) RNH2, Et3N, 10% KI, DCM, 60 ºC, 24 h, 48-54%; d) RNH2, DBU, CH3CN, 60 ºC
or 45 ºC, 24 h, 21-100%.
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This synthetic route involved the previous preparation of the non-commercial amines 6-
methoxyhexyl-1-amine (52), 2-(2-ethoxyethoxy)ethylamine (54), 3-(2-methoxyethoxy)propyl-1-amine 
(56), 2-(3-pentyloxetan-3-yl)ethylamine (59) and (4-ethylpiperazin-1-yl)ethylamine (61). 
Amines 52, 54, and 56, with oxygen atoms introduced in their alkyl chains, were synthetized as
depicted in Scheme 5. 6-Methoxyhexyl-1-amine (52) was obtained using 2-methoxycyclohexyl-1-one
as starting material. This ketone was transformed into the corresponding oxime (49) by reaction with
hydroxylamine, and further acetylated to give intermediate 50. Later reductive Beckman 
fragmentation and reduction with BH3 finally provided amine 52. 2-(2-Ethoxyethoxy)ethylamine (54) 
was prepared through Mitsunobu reaction of 2-(2-ethoxyethoxy)ethanol and phthalimide, in the 
presence of diisopropylazodicarboxylate (DIAD) and triphenylphosphine, followed by deprotection
with hydrazine and sodium borohydride. 3-(2-Methoxyethoxy)propyl-1-amine (56) was synthetized
starting from 2-methoxyethanol, by addition of acrylonitrile in the presence of KOH, followed by 
reduction of the resulting nitrile (55) with BH3. 
Scheme 5. Reagents and conditions: a) NH2OH·HCl, NaOAc, H2O, MeOH, 60 ºC, 24 h, 99%; b) Ac2O, pyridine, 
rt, 16 h, 95%; c) Et3SiH, CF3SO3SiMe3, DCM, 0 ºC, 6 h, 83%; d) BH3, THF, reflux, 3.5 h, 68-89%; e) DIAD, PPh3, 
phthalimide, MeOH, toluene, 0 ºC to rt, o/n, 58%; f) N2H4·H2O, NaBH4, MeOH, rt, o/n, 71%; g) acrylonitrile, KOH,
HCl, 0 ºC, 1.5 h, 100%.
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2-(3-Pentyloxetan-3-yl)ethylamine (59) was prepared as shown in Scheme 6. The intermediate 
nitrile 57, obtained by a Wittig reaction between oxetan-3-one and the appropriate phosphorane, was 
reacted with pentylmagnesium bromide in the presence of copper (I). Reduction of the resulting
product 58 with lithium aluminium hydride (LAH) gave the desired amine 59. 
Scheme 6. Reagents and conditions: a) Ph3P=CHCN, DCM, rt, 6 h, 79%; b) C5H11MgBr, CuI, Et2O, 0 ºC, 2 h,
26%; c) LAH, Et2O, 0 ºC, 2 h, 59%.
(4-Ethylpiperazin-1-yl)ethylamine (61) was obtained through formation of nitrile 60 by reaction of 
1-ethylpiperazine and bromoacetonitrile in the presence of K2CO3, followed by reduction with LAH,
as previously described in the literature (Scheme 7).21 
Scheme 7. Reagents and conditions: a) BrCH2CN, K CO2 3, CH3CN, rt, o/n, 100%; b) LAH, THF, 0 ºC, 4 h, 86%. 
The biological activity of compounds 16-27 was also determined. The obtained results (Table 3) 
show that a decrease in the length of the alkyl chain (compounds 16-18), despite it significantly 
improves cLogP values, involves important reductions in the inhibitory activity of the compounds, 
ranging from 0% to 30% inhibition. Neither the introduction of oxygen atoms in the alkyl chain (19-
22), nor the introduction of the oxetane group (23) allows to keep good inhibition values, compared
to the 93% inhibition induced by derivative 3 at the same concentration. Finally, replacement of the
n-octyl chain by cyclopropane, methylcyclopropane, (4-ethylpiperidin-1-yl)ethane or (4-
ethylpiperazin-1-yl)ethane (24-27) also implies an important decrease in the antiproliferative and
inhibitory activities of the resulting compounds. 
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Table 3. cLogP and biological activity of compounds 3 and 16-27
	
Antiproliferative effect 
(IC50 μM)b ICMT Cpd R cLogPa inhibitionb
MCF7 MDA-MB-231 PC-3 (%, 50 µM) 
3 -(CH2)7CH3 4.11 10 17 23 93 
16 -H 1.92  >50 >50 >50 30
17 -CH3 0.39 ND ND ND 0
18 -(CH2)5CH3 2.52  >50 >50 >50 9 
19 -(CH2)3O(CH2)3CH3 2.21  >50 40 >50 14
20 -(CH2)6OCH3 1.68  >50 >50 >50 30
21 -(CH2)2O(CH2)2OCH2CH3 0.26  >50 >50 >50 15
22 -(CH2)3O(CH2)2OCH3 0.26  >50 >50 >50 45
23 2.90 ND ND ND 0 
0.76 24 29 >50 3324
25 1.29 >50 >50 >50 36
26 2.83 39 >50 >50 13
0.41 >50 >50 >50 1527
aParameter calculated using ACD/Labs Percepta. bData from three independent experiments performed in
triplicate; the SEM is in all cases within a 10% of the mean value. ND, not determined. 
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Taken together, the data obtained suggest that a long hydrophobic chain attached to the nitrogen
atom is needed, so we decided to keep the n-octyl chain and continued with the exploration of the
amide group.
2.1.3. Influence of the amide group 
Previous experiments carried out in our research group have shown that the amide group present 
in both UCM-1325 and compound 3 is necessary for a good inhibitory activity. However, when we
studied the metabolic stability of derivative 3 in mouse serum, we observed that it was only moderate, 
with a half-life value (t1/2) of 27 min. Thus, we decided to introduce a methyl substituent in one of the
amide groups of compound 3 (derivative 28), since it has been described that tertiary amides tend to 
have increased metabolic stabilities. We also replaced the initial amide by a sulfonamide (29) or by
an oxadiazole heterocyclic ring (30), considering that they have been reported as more stable 
isosteres of the amide group.22 
Compounds 28-30 were obtained as described in Scheme 8, starting from secondary amine 34
and following a similar approach to the previously described (Scheme 1).
Scheme 8. Reagents and conditions: a) N-methyl-N-phenylacrylamide (62), DBU, CH3CN, 60 ºC, 24 h, 58%; b)
N-phenylethylensulfonamide (63), DBU, CH3CN, 60 ºC, 24 h, 12%; c) 2-(chloromethyl)-5-phenyl-1,3,4-
oxadiazole, Et3N, CH3CN, 60 ºC, 24 h, 62%.
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The reaction of secondary amine 34 with either N-methyl-N-phenylacrylamide (62), N-
phenylethylensulfonamide (63) or 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole in the presence of  a  
base (DBU or triethylamine), afforded final compounds 28-30. Intermediates 62 and 63 were obtained 
as previously described (Scheme 1). Thus, acrylamide 62 was prepared using N-methylaniline and
acryloyl chloride as starting materials, whereas sulfonamide 63 was obtained from aniline and 2-
chloroethanesulfonyl chloride. 
The biological evaluation of compounds 28-30 as ICMT inhibitors and antiproliferative agents in
the selected panel of cancer cell lines, suggested that none of these modifications in the amide group
improved the inhibitory capacity of the resulting derivatives in comparison to the reference compound
3, as can be observed in Table 4.  
Table 4. Biological activity of compounds 3 and 28-30a 
Cpd
3 
X 
NHCO
Antiproliferative effect (IC50 μM) 
MCF7 MDA-MB-231 PC-3
10 17 23
ICMT 
Inhibition 
(%, 50 μM) 
93
28 NCH3CO 6  7 8 68 
29 NHSO2 30  34  25  22 
30 >50  >50  >50  13 
aData from three independent experiments performed in triplicate; the SEM is in all cases within a 10% of the
mean value.
Taken together the inhibitory capacity, the antiproliferative effect, and the pharmacokinetic 
parameters of this derivative, compound 3 (UCM-1336) deserves special attention as a structurally 
new inhibitor of the ICMT enzyme that could be a promising lead for anticancer treatment, so it was
selected for its further biological characterization.  
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In order to compare the biological results obtained with compound 3, we decided to use 2-[5-(3-
methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil) as a positive control for ICMT inhibition. 
The synthesis of cysmethynil was carried out following the route previously described in the literature
(Scheme 9).16 
Scheme 9. Reagents and conditions: a) CH2O, (CH3)2NH, 1,4-dioxane, AcOH, H2O, 0 ºC to rt, o/n, 83%; b)
KCN, (CH3)2SO4, THF, 10 ºC to 60 ºC, 2h, 95%; c) KOH, t-BuOH, reflux, 1.5 h, 74%; d) m-tolylboronic acid,
Pd(PPh3)4, NaHCO3, toluene, EtOH, reflux, o/n, 23%; e) NaH , Br(CH2)7CH3, DMF, 55 ºC, o/n, 43%. 
Hence, we analyzed the ICMT inhibitory capacity and antiproliferative effect of compound 3 in 
comparison to the already validated ICMT inhibitor cysmethynil. As can be observed in Table 5, the
values obtained with compound 3 (UCM-1336) were very similar or even better than those of
cysmethynil, reinforcing the potential of compound 3 as an ICMT inhibitor.  
Table 5. Biological activity of cysmethynil (CYSM) and compound 3 (UCM-1336)a 
Cpd Antiproliferative effect (IC50, μM) MCF7 MDA-MB-231 PC-3
ICMT inhibition at 
50 μM (%) 
IC50 values of 
ICMT inhibition 
CYSM 24 24 23 90 2.4 µM 
3 (UCM-1336) 10 17 22 93 2 µM 
aData from three independent experiments performed in triplicate; SEM is in all cases within a 10% of the mean
value. 
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2.2. Biological evaluation of compound 3 (UCM-1336) 
Validation of the new lead 3 (UCM-1336) as an ICMT inhibitor required not only to check that it
effectively blocked the enzyme activity, but also to demonstrate its significant in vivo efficacy in cancer
cell lines through the blockade of the activity of downstream Ras protein. In order to confirm the 
mechanism of action of this compound and the relevance of ICMT inhibition for Ras inactivation, we 
assessed whether UCM-1336 affects specifically tumor cell lines characterized by oncogenic Ras 
activity, enhances programmed cell death, induces mislocalization of Ras protein, inactivates all Ras 
isoforms, blocks the downstream signaling pathways, and impairs cell migration.  
2.2.1. Determination of cytotoxicity in a panel of cancer cell lines 
First, we established the antiproliferative activity of UCM-1336 using the MTT assay. The panel 
of cells was chosen to include multiple examples of cell lines that express wild-type or oncogenic 
mutant K-Ras, which was selected for being the most frequently mutated Ras isoform in cancer. It is
remarkable that regardless of the origin of the tumor, UCM-1336 inhibited the proliferation of cells 
expressing oncogenic mutant K-Ras (breast cancer MDA-MB-231 cells, pancreatic cancer MIA
PaCa-2 and PANC-1 cells, and colon cancer SW620 cells) more potently than cells expressing wild-
type K-Ras (pancreatic cancer BxPC-3 cells, breast cancer MCF7 cells, prostate cancer PC-3 cells,
and melanoma SK-Mel-28 cells), as can be observed in Table 6. Interestingly, UCM-1336 did not 
induce significant cytotoxic effects at concentrations up to 100 µM in non tumoral cell lines such as 
NIH3T3 and 142BR fibroblasts, suggesting that the mechanism of action of the compound is specific 
for cancer cell lines.  
Table 6. Cytotoxicity of UCM-1336 in a panel of cancer cell lines
Mutant K-Rasa Wild-type K-Rasb 
Cell Line IC50c (µM) Cell Line IC50c (µM) 
MDA-MB-231 10 MCF7 17
MIA PaCa-2 2 BxPC-3 > 50 
PANC-1 7 PC-3 23 
SW620 3 SK-Mel-28 15 
aMutant K-Ras and wild-type H- and N-Ras; bwild-type H,K,N-Ras [Ras status according to the Catalog of
Somatic Mutations in Cancer (Wellcome Trust Sanger Institute)]; call errors are less than 10%. 
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2.2.2. Induction of autophagy and apoptosis
An important property of anticancer agents is the ability to induce cell death, and many current 
antitumoral drugs enhance either autophagy (eg. tamoxifen) or apoptosis (eg. rapamycin) in cancer 
cells.23,24 Besides, it has been recently reported that both knockdown of ICMT and treatment of cells 
with cysmethynil increase protein levels and aggregation of microtubule-associated protein light chain
3 (LC-3) into vesicular structures characteristic of autophagosomes; as well as elevation of cleaved 
poly(ADP-ribose) polymerase (cPARP) levels and caspase 3 activity, suggesting that the inhibition
of ICMT promotes both autophagy and apoptosis in cancer cell lines.17,25 Hence, we studied the cell 
death mechanism of action of UCM-1336.  
Autophagy was assessed by determining the vesicular accumulation of LC-3, using a fusion 
protein with mCherry in a live cell imaging assay. To do so, we chose two different cell lines: human 
embryonic kidney AD-293 cells, as they are easily transfected and were hence selected as our model
for transient transfections; and osteosarcoma U2OS cells, as they have been described in the 
literature as a model of cells that use autophagy as a protective mechanism to survive treatment with
antineoplasic drugs such as doxorubicin.26 Our results show that both UCM-1336 and cysmethynil 
used at 5 µM cause a dramatic increase in total abundance of LC-3, which also aggregates into
vesicular structures characteristic of autophagosome formation in AD-293 cells and in U2OS cells 
(Figure 6A). Noteworthy, the observed effect was greater for treatment with UCM-1336 than for
cysmethynil. This was further supported by immunoblot analysis of LC-3, which showed a significant 
elevation of this protein in PC-3 cells treated with 10 µM UCM-1336 or 25 µM cysmethynil, included
as a positive control (Figure 6B). 
Apoptosis was assessed by measurement of caspase 3 activation using a colorimetric assay, and
by the appearance of cPARP through immunoblot analysis (Figure 6C and D). Caspases are cysteine 
aspartyl proteases that serve as the central engine of apoptosis. In particular, caspase 3 is used as 
a control of the overall levels of apoptosis, as it is activated both by extrinsic and intrinsic pathways.27 
PC-3 cells were incubated in the presence of 10 µM UCM-1336 or 25 µM cysmethynil. Our results 
showed that exposure of cells to either UCM-1336 or cysmethynil increased caspase 3 activity in a
4-5 fold (Figure 6C). In addition, caspase 3 is responsible, either wholly or partially, for the proteolytic
cleavage of a large number of substrates during apoptosis, including PARP -a family of proteins 
involved in DNA repair and programmed cell death-,27 so we confirmed the previous results by 
measuring the levels of cPARP in cells treated with UCM-1336. Immunoblot analysis showed the
appearance of cPARP after 48 h in UCM-1336 or cysmethynil exposed cells (Figure 6D), whose
levels revealed a 4-8 fold increase. These data provide clear evidence that UCM-1336 treatment 
induces both apoptosis and autophagy. 
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Figure 6. Treatment with UCM-1336 induces autophagy and apoptosis in cancer cells. (A) Confocal images of
live AD-293 (upper) and U2OS (lower) cells transiently transfected with mChery-LC-3 plasmid and treated
overnight with vehicle (DMSO), 5 M cysmethynil (CYSM) or 5 M UCM-1336 (UCM). Images were taken using
an inverted Zeiss LSM 510 Meta laser scanning confocal microscope and are representative of two independent
transfections performed in triplicate. Bars, 10 µm. (B) Representative immunoblot analysis of LC-3. PC-3 cells
were treated with either vehicle (DMSO), 25 M cysmethynil (CYSM) or 10 M UCM-1336 (UCM) for 48 h. The
bar graphs represent the optical density of the LC-3 protein normalised to the tubulin (loading control), and
expressed as the percentage relative to DMSO. (C) Caspase 3 activity induction. PC-3 cells were treated for 48 
h with vehicle (DMSO), 25 M cysmethynil (CYSM) or 10 M UCM-1336 (UCM) before being harvested and
lysed. Lysates were assayed for caspase 3 activity and results are presented as the percentage relative to
DMSO. (D) Representative immunoblot analysis of cPARP. PC-3 cells were treated with either vehicle (DMSO), 
25 M cysmethynil (CYSM) or 10 M UCM-1336 (UCM) for 48 h. cPARP protein was quantified as the indication 
for the level of apoptosis and tubulin protein was used as loading control. In all cases, data correspond to the
average ± SEM of three independent experiments performed in triplicate. **, P<0.01; ***, P<0.001 vs DMSO
treated cells (Student’s t test). 
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2.2.3. Mislocalization of endogenous Ras in PC-3 cells 
Then, we determined whether inhibition of ICMT leads to Ras mislocalization in tumor cells. PC-
3 cells were incubated with increasing concentrations of compound UCM-1336 or cysmethynil for 96
h. This time frame was chosen to allow trafficking of newly synthesized Ras proteins and turnover of 
Ras proteins that were already present when treatments started. As expected, in the absence of 
compounds, Ras was localized along the plasma membrane (Figure 7, 0 µM). In contrast, a large 
fraction of Ras in the UCM-1336 or cysmethynil treated cells was trapped within the cytoplasm, and
fluorescence at the plasma membrane was reduced (Figure 7, 1-25 µM). Remarkably, this effect was
higher for UCM-1336 than for cysmethynil at the same concentration, and increased in a dose-
dependent manner. These data are consistent with previous observations of Ras mislocalization
caused by knockout of ICMT28 and by the ICMT inhibitor cysmethynil.16 
UCM (μM) 0 1 5 10 25
CYSM (μM) 0 1 5  10 25 
Figure 7. Compound UCM-1336 induces Ras mislocalization from the cellular membrane (far-left image) to
intracellular locations in PC-3 cells in a dose-dependent manner. The observed effect is higher for UCM-1336
than for cysmethynil at the same concentration. Immunofluorescence images show Ras in green stained using
an anti-Ras primary antibody followed by the appropriate secondary FITC-labelled antibody. Nuclei (in blue)
were stained with Hoechst 33258. Images were obtained in a Leica confocal microscope under the same 
conditions and are representative of three to five independent experiments. Bars, 30 µm.
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2.2.4. Mislocalization of the four isoforms of Ras 
There are three ras genes in mammals: hras, kras, and nras, but through alternative splicing of 
exon 4, the kras gene gives rise to two isoforms: K-Ras4A and K-Ras4B.1 To determine whether the
observed effects of UCM-1336 on the localization of Ras affected equally all isoforms, we used
confocal live cell fluorescent imaging of AD-293 cells transfected with the four Ras isoforms tagged 
with green fluorescent protein (GFP).  
DMSO CYSM UCM 
H-Ras-GFP
N-Ras-GFP
K-Ras4A-GFP 
K-Ras4B-GFP 
Figure 8. UCM-1336 impairs plasma localization of the four Ras isoforms in live cells. Confocal images of live
AD-293 cells that had been transiently transfected with H-Ras, K-Ras4A, K-Ras4B, and N-Ras GFP fusion
plasmids, and treated overnight with vehicle (DMSO), 5 µM cysmethynil (CYSM), or 5 µM UCM-1336 (UCM).
Live cells were imaged with an inverted Zeiss LSM 510 Meta laser scanning confocal microscope. Similar results
were obtained with three independent transfections performed in triplicate. Bars, 10 µm.
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Transfected cells were treated overnight with 5 µM cysmethynil or UCM-1336, or with DMSO. 
While the vehicle-treated cells showed a predominant localization of Ras in the plasma membrane, 
all four isoforms of Ras were substantially mislocalized to the cytosolic region after treatment with 
UCM-1336 (Figure 8). Furthermore, this effect was more significant for UCM-1336 than for 
cysmethynil, included for comparison, at the same concentration. 
2.2.5. Study of the specificity of the mechanism of action of UCM-1336
To confirm that the effect of mislocalization of the Ras isoforms is due to ICMT inhibition, and not 
to any other unspecific mechanism, we performed two additional sets of tranfections: with Fyn protein, 
to discard potential detergent-like effects; and with a geranylgeranylated K-Ras, to confirm that the 
mislocalization of Ras is not caused by inhibition of any other upstream enzyme rather than ICMT.  
As a control to discard any possible nonspecific detergent-like effects of the compounds, cells 
were transfected with GFP-tagged Fyn, a member of the Src family of tyrosine protein kinases that 
targets the plasma membrane after myristoylation and palmitoylation, but which is not processed by 
ICMT (Figure 9). In this case, neither UCM-1336 nor cysmethynil affected the localization pattern of 
Fyn. 
Fyn-GFP
DMSO CYSM UCM 
Figure 9. UCM-1336 does not affect Fyn localization. To discard any possible nonspecific detergent-like effects,
AD-293 cells were transfected with GFP-tagged Fyn, which is not processed by ICMT, and treated overnight
with vehicle (DMSO), 5 µM cysmethynil (CYSM), or 5 µM UCM-1336 (UCM). After treatments, GFP-tagged Fyn
showed the same localization pattern in all cases. Live cells were imaged with an inverted Zeiss LSM 510 Meta
laser scanning confocal microscope. Similar results were obtained with three independent transfections
performed in triplicate. Bars, 10 µm.
Furthermore, it has been previously demonstrated that CAAX proteolysis and carboxyl 
methylation by ICMT are required only for previously farnesylated Ras proteins to proper localize in 
the plasma membrane, but not for geranylgeranylated proteins. The substrate specificity for FTase
versus GGTase I is determined by the residue in the X position of the CAAX motif: S and M specifies 
farnesylation whereas L specifies geranylgeranylation.29 Using a GFP-tagged K-Ras4B protein with
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a CAAX motif point mutation expected to switch the chain length of the isoprenyl modification
(farnesylation for geranylgeranylation), we studied the effect of derivative UCM-1336 on its cellular 
localization. Geranylgeranylated K-Ras4B (K-Ras4B-CVIL-GFP) localized in the plasma membrane
of AD-293 cells with an indistinguishable pattern in both vehicle and compound treated cells, whereas 
farnesylated K-Ras4B-GFP was mislocalized to the cytosol in the presence of compound UCM-1336 
(Figure 10). This further confirmed the specific effect of UCM-1336 on farnesylated GTPases through
inhibition of ICMT, as geranylgeranylated Ras should not be affected by an ICMT inhibition.  
DMSO CYSM UCM
K-Ras4B-GFP 
K-Ras4B-CVIL-GFP
Figure 10. UCM-1336 affects the membrane association of farnesylated K-Ras, but not geranylgeranylated K-
Ras. Confocal images of live AD-293 cells transiently transfected with a GFP-tagged K-Ras4B plasmid with a
CAAX motif point mutation that switches farnesylation for geranylgeranylation, or with wild-type K-Ras4B-GFP. 
Geranylgeranylated K-Ras4B (K-Ras4B-CVIL-GFP) localizes in the plasma membrane with an indistinguishable
pattern in both vehicle and compound treated cells, whereas farnesylated K-Ras4B-GFP mislocalizes to the
cytosol in the presence of cysmethynil or compound UCM-1336. Live cells were imaged with an inverted Zeiss
LSM 510 Meta laser scanning confocal microscope. Images are representative of two to three independent 
experiments performed in triplicate. Bars, 10 µm.
These results supported the specificity of the mechanism of action of UCM-1336 through inhibition
of signaling pathways upstream of Ras.
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2.2.6. Study of the activation status of Ras
 As Ras signaling is dependent on membrane association, we next explored the ability of our 
compound to prevent Ras activation, by analysing the GTP loading capacity of Ras using a pulldown
assay, and studying its effects on the activation of the downstream MAP kinase pathways. Figure
11A shows that UCM-1336 at 10 µM significantly reduces pan-Ras GTP loading to a greater extent
than treatment with 25 µM cysmethynil. This reduction in Ras activation correlates closely with a
concomitant reduction in the phosphorylation of MEK/ERK and PI3K/AKT signaling pathways (Figure
11B). After activation of PC-3 cells with epidermal growth factor (EGF), the phosphorylated levels of 
MEK1/2 (p-MEK1/2), ERK1/2 (p-ERK1/2), and AKT (p-AKT) were decreased in cells treated with 10
μM UCM-1336, and this reduction was greater than the one produced by 25 µM cysmethynil. 
A B kDa 
Figure 11. Compound UCM-1336 significantly reduces the Ras-GTP (active form) levels and its downstream
MEK/ERK and PI3K/AKT signaling pathways. (A) Ras-GTP complex from PC-3 cells treated with DMSO, 25 M 
cysmethynil or 10 µM UCM-1336 were immunoprecipitated and visualized by western blot. The bar graph shows
the ratio Ras-GTP/total Ras, expressed as percentage relative to DMSO. (B) Representative western blots of
phosphorylated MEK1/2 (p-MEK1/2) and total MEK1/2 (T-MEK1/2), phosphorylated ERK1/2 (p-ERK1/2) and
total ERK1/2 (T-ERK1/2), and phosphorylated AKT (p-AKT) and total AKT (T-AKT). Lysates were obtained from
PC-3 cells treated with DMSO, 25 M cysmethynil (CYSM) or 10 M UCM-1336 (UCM). The bar graphs
represent the optical density of the immunoreactive phosphorylated protein normalised to the total corresponding 
protein, and expressed as the percentage relative to DMSO. White bars, DMSO; grey bars, 25 M cysmethynil;
black bars, 10 M UCM-1336. In all cases, data correspond to the average ± SEM of three to five independent
experiments. ns, not significant; *, P<0.05; **, P<0.01 vs DMSO (Student’s t test).
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Results and discussion
	
2.2.7. Study of the impairment of cellular migration 
Importantly, inhibition of Ras signaling pathways by compound UCM-1336 was accompanied by 
a reduced invasive phenotype as measured by in vitro wound-healing assays, where MDA-MB-231
cells expressing oncogenic mutant K-Ras treated with UCM-1336 or cysmethynil showed a 
significantly reduced capacity for wound closing at 48 h, which decreased in a dose-dependent 
manner and was much higher in cells treated with UCM-1336 than in those treated with the same 
concentrations of cysmethynil (Figure 12). However, the number of viable cells remained similar to 
the vehicle-treated cells (data not shown), meaning that the inhibition of cell migration was not simply
due to a cytotoxic effect caused by the compound.
Re
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) 
10 5 1 10 5 1Cpd (μM)
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* ns 
*** 
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-
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Figure 12. Compound UCM-1336 significantly impairs cellular migration in a dose-dependent manner. (A) After 
wound scratching, MDA-MB-231 cells were treated with vehicle or different concentrations of cysmethynil
(CYSM) or UCM-1336 (UCM), and after 48 h cells were visualized under the microscope. The percentage of the
remaining wound area was quantified and expressed as percentage of initial wound area. The bar graph
represents the average ± SEM of at least three independent experiments performed in triplicate and three
different fields. ns, not significant; *, P<0.05; **, P<0.01; ***, P<0.001 (vs DMSO treated cells at 48 h) (Student’s 
t test). (B) Representative images of at least three independent experiments performed in triplicate, taken at
time 0 h and after 48 h of treatment with vehicle (DMSO), 10 M cysmethynil (CYSM) or 10 M UCM-1336 
(UCM), under phase contrast with an Olympus FW1200 microscope. Bars, 250 m. 
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Results and discussion
	
The main effects of the activation of the Ras pathway include the induction of proliferation, 
migration, and antiapoptotic signals; so its inhibition should lead to an arrest of all these processes, 
and consequently, of tumor growth. All these promising results have prompted us to study the in vivo 
efficacy of compound UCM-1336 in a xenograft mouse model of pancreatic cancer, experiments that 
are currently ongoing in our laboratory.  
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3. CONCLUSIONS
In this work we have started the lead optimization process of UCM-1325 (54% inhibition of ICMT 
at 50 μM) that has led us to the new compound UCM-1336 (3), which showed an ICMT inhibition of 
93% at 50 μM (IC50 = 2 μM), hence being selected for in depth biological studies and characterization 
of its mechanism of action. This new compound enhances programmed cell death, affecting specially 
those cell lines expressing oncogenic mutant K-Ras; and induces mislocalization of all Ras isoforms. 
Besides, UCM-1336 (3) significantly reduces Ras activity, blocks the activation of the downstream
MEK/ERK and PI3K/AKT signaling pathways, and impairs the migratory capacity of tumor cells.
Noteworthy, UCM-1336 (3) has shown to be more potent than cysmethynil in all performed assays, 
suggesting that it could work as a new ICMT inhibitor that would help to definitively validate this
enzyme from a mechanistic standpoint as a therapeutic target of interest for the treatment of cancers 
characterized by high Ras overactivation, a current unmet clinical need. All these promising results 
have prompted us to study the in vivo efficacy of compound UCM-1336 in a xenograft mouse model
of pancreatic cancer, experiments that are currently ongoing. 
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4. EXPERIMENTAL SECTION 
4.1. Chemistry
Unless stated otherwise, starting materials, reagents and solvents were purchased as high-grade 
commercial products from Sigma-Aldrich, Acros, Fluorochem, Abcr, Scharlab or Panreac, and were
used without further purification. Dichloromethane (DCM) and tetrahydrofuran (THF) were dried using 
a Pure Solv™ Micro 100 Liter solvent purification system. All non-aqueous reactions were carried out
under an argon atmosphere in oven-dried glassware. Chromatography was performed on glass 
column using silica gel type 60 (Merck, particle 230-400 mesh) or using a VARIAN 971-FP system
with cartridges of silica gel (Varian, size particle 50 μm). Analytical thin-layer chromatography (TLC) 
was run on Merck silica gel plates (Kieselgel 60 F-254) with detection by UV light (254 nm), ninhydrin 
solution, or 10% phosphomolybdic acid solution in ethanol. Melting points (mp, uncorrected) were 
determined on a Stuart Scientific electrothermal apparatus. Infrared (IR) spectra were measured on
a Shimadzu-8300 or Bruker Tensor 27 instrument equipped with a Specac ATR accessory of 5200-
650 cm-1 transmission range; frequencies () are expressed in cm-1. Nuclear Magnetic Resonance 
(NMR) spectra were recorded on a Bruker Avance 300-AM (1H, 300 MHz; 13C, 75 MHz) at the UCM’s 
NMR facilities. Chemical shifts () are expressed in parts per million relative to internal 
tetramethylsilane; coupling constants (J) are in hertz (Hz). The following abbreviations are used to 
describe peak patterns when appropriate: app (apparent), s (singlet), d (doublet), t (triplet), q
(quartet), qt (quintet), m (multiplet), br (broad), dd (doublet of doublets), ddd (doublet of doublets of 
doublets), tt (triplet of triplets). 2D NMR experiments (HMQC and HMBC) of representative 
compounds were carried out to assign protons and carbons of the new structures. Elemental 
analyses (C, H, N) were obtained on a LECO CHNS-932 apparatus at the UCM’s analysis services 
and were within 0.4% of the theoretical values. High Performance Liquid Chromatography-Mass 
Spectrometry (HPLC-MS) analysis was performed using an Agilent 1200LC-MSD VL. LC separation
was achieved with an Eclipse XDB-C18 column (5 µm, 4.6 mm x 150 mm) together with a guard 
column (5 µm, 4.6 mm x 12.5 mm). The gradient mobile phases consisted of A (95:5 water/MeOH) 
and B (5:95 water/MeOH) with 0.1% ammonium hydroxide and 0.1% formic acid as the solvent 
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Experimental section
	
modifiers. MS analysis was performed with an ESI source. The capillary voltage was set to 3.0 kV 
and the fragmentor voltage was set at 70 eV. The drying gas temperature was 350 ºC, the drying gas
flow was 10 L/min, and the nebulizer pressure was 20 psi. Spectra were acquired in positive or 
negative ionization mode from 100 to 1000 m/z and in UV-mode at four different wavelengths (210, 
230, 254, and 280 nm). High resolution mass spectrometry (HRMS) was carried out on a FTMS 
Bruker APEX Q IV (UCM) spectrometer in electrospray ionization (ESI) mode at UCM’s spectrometry 
facilities. Spectroscopic data of all described compounds were consistent with the proposed
structures. Satisfactory HPLC chromatograms and elemental analyses (C, H, N) were obtained for 
the final compounds, confirming a purity of at least 95% for all tested compounds.  
4.1.1. Synthesis of asymmetric diamides 1, 2, 4-15 and 28-30
Synthesis of tert-butyl 4-[(dimethylamino)carbonyl]phenylcarbamate (35).30 To a solution of
4-(Boc-amino)benzoic acid (261 mg, 1.1 mmol), dimethylamine hydrochloride (269 mg, 3.3 mmol)
and TBTU (459 mg, 1.4 mmol) in DMF (1.3 mL) was added, under argon atmosphere, triethylamine
(0.92 mL, 6.6 mmol) and the reaction mixture was stirred for 2 h at rt. Then, the reaction crude was
washed with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The organic phase was dried over 
Na2SO4 and the solvent was evaporated under reduced pressure to obtain the title compound as an 
oil in 75% yield. Chromatography: hexane/EtOAc, 3:7; oil. Rf (EtOAc) 0.56. IR (ATR) 3256 (NH), 
1725, 1612 (CO), 1535, 1494, 1454 (Ar). 1H NMR (300 MHz, CD3OD) Mixture of rotamers A:B 1:1; 
1.52 (s, 9H, 3CH3C), 3.05, 3.07 (2br s, 6H, 2CH3N, rotamers A and B), 7.35 (d, J = 8.7 Hz, 2H, H3, 
H5), 7.49 (d, J = 8.6 Hz, 2H, H2, H6). 13C NMR (75 MHz, CD3OD) 28.6 (3CH3), 35.8, 40.2 (2CH3), 
81.2 (C), 119.0 (2CH), 129.1 (2CH), 130.7, 142.6, 154.9, 173.7 (4C). MS (ESI): [(M+H)+] 265.1.
Synthesis of 4-amino-N,N-dimethylbenzamide (36). A solution of 35 (216 mg, 0.8 mmol) in 
TFA/DCM 1:1 (8.7 mL) was stirred 1 h at rt under argon atmosphere. The reaction crude was washed 
with saturated solutions of NaHCO3 (2 x 10 mL) and NaCl (10 mL); dried over Na2SO4 and the solvent
was evaporated under reduced pressure to obtain the title compound as a white solid in 93% yield.
Chromatography: EtOAc. Mp 147-148 ºC (Lit.31 151-154 ºC) . Rf (EtOAc) 0.35. IR (ATR) 3462, 3344
(NH), 1604 (CO), 1525, 1490, 1444 (Ar). 1H NMR (300 MHz, CD3OD) 3.06 (s, 6H, 2CH3N), 6.69 (d, 
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Experimental section
	
J = 8.6 Hz, 2H, H3, H5), 7.22 (d, J = 8.6 Hz, 2H, H2, H6). MS (ESI): [(M+H)+] 165.1. The spectroscopic 
data are in agreement with those previously described.32 
General procedure for the synthesis of pyridinylacrylamides 31 and 32.33 A solution of the 
corresponding amine (1 equiv.) and triethylamine (1 equiv.) in anhydrous DCM (9 mL/mmol) was 
stirred, under argon atmosphere and at -78 ºC, for 10 min. Then was added dropwise the acryloyl 
chloride (1 equiv.). The mixture was stirred for 3 h, warming it up to 0 ºC, and the solvent was removed
under reduced pressure.  
N-Pyridin-2-ylacrylamide (31). Obtained following the general procedure for the synthesis of 
pyridinylacrylamides from acryloyl chloride (0.22 mL, 2.8 mmol) and 2-aminopyridine (260 mg, 2.8
mmol) in 68% yield. Chromatography: EtOAc. Mp 66-68 ºC (Lit.33 71 ºC). Rf (hexane/EtOAc, 1:1) 
0.44. 1H NMR (300 MHz, CDCl3) 5.84 (dd, J = 10.2, 1.2 Hz, 1H, 1/2CH2), 6.28 (dd, J = 16.9, 10.2
Hz, 1H, CHCO), 6.48 (dd, J = 16.9, 1.1 Hz, 1H, 1/2CH2), 7.08 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H, H5), 7.75 
(td, J = 7.9, 1.9 Hz, 1H, H4), 8.23 (br s, 1H, NH), 8.28-8.34 (m, 2H, H3, H6). MS (ESI): [(M+H)+] 149.0. 
The spectroscopic data are in agreement with those previously described.33 
N-Pyridin-3-ylacrylamide (32). Obtained following the general procedure for the synthesis of 
pyridinylacrylamides from acryloyl chloride (0.45 mL, 5.5 mmol) and 3-aminopyridine (520 mg, 5.5
mmol) in 57% yield. Chromatography: EtOAc/MeOH, 9:1. Mp 121-123 ºC  (Lit.33 118-121 ºC). Rf
(hexane/EtOAc, 1:1) 0.25. 1H NMR (300 MHz, CDCl3) 5.84 (dd, J = 10.1, 1.2 Hz, 1H, 1/2CH2), 6.29 
(dd, J = 16.9, 10.2 Hz, 1H, 1/2CH2), 6.49 (dd, J = 16.8, 1.2 Hz, 1H, CHCO), 7.31 (dd, J = 8.3, 4.8 Hz, 
1H, H5), 7.59 (br s, 1H, NH), 8.28 (d, J = 9.4 Hz, 1H, H4), 8.38 (dd, J = 4.7, 1.3 Hz, 1H, H6), 8.61 (d,
J = 2.5 Hz, 1H, H2). MS (ESI): [(M+H)+] 148.9. The spectroscopic data are in agreement with those
previously described.33 
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General procedure for the synthesis of phenylacrylamides 33, 37-47 and 62-63. To a solution
of the corresponding aniline (1 equiv) in anhidrous DCM (2 mL/mmol) was added, under argon
atmosphere and at 0 ºC, acryloyl chloride (1.1 equiv) and pyridine (1.1 equiv), consecutively. Then, 
the reaction mixture was stirred 2 h at rt. In the case of N-[4-(acetylamino)phenyl]acrylamide (43), 
triethylamine was used as the base, THF with the minimum volume required of DMF as the solvent, 
and the reaction was stirred overnight at rt. For the synthesis of N-phenylethylensulfonamide (63), 2-
chloroethanesulfanoyl chloride was added instead of acryloyl chloride, anhydrous acetone was used
as the solvent, and the reaction was stirred overnight at 0 ºC. In all cases, the reaction crude was 
washed with saturated solutions of NaHCO3, CuSO4 (when pyridine was used) and NaCl; dried over
Na2SO4, and the solvent was evaporated under reduced pressure to afford title compounds as white
solids. In some cases, the solid was purified by column chromatography (hexane/EtOAc). 
N-Phenylacrylamide (33). Obtained following the general procedure for the synthesis of 
phenylacrylamides from aniline (0.98 mL, 10.7 mmol) and acryloyl chloride (0.95 mL, 11.8 mmol) in 
84% yield. Chromatography: hexane/EtOAc, 7:3. Mp 107-108 ºC (Lit.34 105-106 ºC). Rf
(hexane/EtOAc, 7:3) 0.39. 1H NMR (300 MHz, CDCl3) 5.71 (dd, J = 9.6, 2.0 Hz, 1H, 1/2CH2), 6.31 
(dd, J = 16.9, 9.7 Hz, 1H, CHCO), 6.42 (dd, J = 16.9, 1.9 Hz, 1H, 1/2CH2), 7.10 (t, J = 7.4 Hz, 1H,
H4), 7.30 (t, J = 7.9 Hz, 2H, H3, H5), 7.60 (d, J = 7.9 Hz, 2H, H2, H6), 8.16 (br s, 1H, NH). MS (ESI):
[(M+H)+] 147.9. The spectroscopic data are in agreement with those previously described.35 
N-(2-Fluorophenyl)acrylamide (37).36 Obtained following the general procedure for the 
synthesis of phenylacrylamides from 2-fluoroaniline (0.5 mL, 5.2 mmol) and acryloyl chloride (0.46 
mL, 5.8 mmol) in 87% yield. Mp 102-103 ºC. Rf (hexane/EtOAc, 7:3) 0.53. IR (ATR) 3276, 3209 
(NH), 1669 (CO), 1616, 1547, 1490 (Ar). 1H NMR (300 MHz, CDCl3) 5.80 (dd, J = 10.0, 1.4 Hz, 1H,
1/2CH2), 6.30 (dd, J = 16.9, 10.1 Hz, 1H, CHCO), 6.45 (dd, J = 16.9, 1.4 Hz, 1H, 1/2CH2), 7.02-7.17 
(m, 3H, H3, H4, H6), 7.54 (br s, 1H, NH), 8.40 (t, J = 7.6 Hz, 1H, H5). 13C NMR (75 MHz, CDCl3) 114.9 
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(d, J = 19.2 Hz, CH), 122.0 (CH), 124.7 (d, J = 13.5 Hz, CH), 124.8 (d, J = 8.8 Hz, CH), 126.4 (d, J =
10.0 Hz, C), 128.5 (CH2), 131.0 (CH), 152.6 (d, J = 244.7 Hz, C), 163.6 (C). 19F NMR (282 MHz, 
CDCl3)  -131.9. MS (ESI): [(M+H)+] 166.1. 
N-(3-Fluorophenyl)acrylamide (38). Obtained following the general procedure for the synthesis 
of phenylacrylamides from 3-fluoroaniline (0.5 mL, 5.2 mmol) and acryloyl chloride (0.46 mL, 5.8 
mmol) in 70% yield. Mp 119-120 ºC (Lit.36 125-126 ºC). Rf (hexane/EtOAc, 7:3) 0.51. 1H NMR (300 
MHz, CDCl3)  5.79 (dd, J = 10.1, 1.3 Hz, 1H, 1/2CH2), 6.27 (dd, J = 16.9, 10.1 Hz, 1H, CHCO), 6.45
(dd, J = 16.8, 1.3 Hz, 1H, 1/2CH2), 6.79-6.86 (m, 1H, H4), 7.20-7.30 (m, 2H, H5, H6), 7.56 (d, J = 10.9
Hz, 1H, H2), 7.70 (br s, 1H, NH). MS (ESI): [(M+H)+] 166.1. The spectroscopic data are in agreement 
with those previously described.36 
N-(4-Fluorophenyl)acrylamide (39). Obtained following the general procedure for the synthesis 
of phenylacrylamides from 4-fluoroaniline (0.22 mL, 2 mmol) and acryloyl chloride (0.18 mL, 2.2 
mmol) in 35% yield. Mp 152-153 ºC. Rf (hexane/EtOAc, 7:3) 0.41. 1H NMR (300 MHz, CDCl3)  5.80
(dd, J = 10.2, 1.3 Hz, 1H, 1/2CH2), 6.24 (dd, J = 16.8, 10.2 Hz, 1H, CHCO), 6.46 (dd, J = 16.8, 1.3
Hz, 1H, 1/2CH2), 7.05 (t, J = 8.7 Hz, 2H, H3, H5), 7.24 (br s, 1H, NH), 7.53-7.58 (m, 2H, H2, H6). MS 
(ESI): [(M+H)+] 166.0. The spectroscopic data are in agreement with those previously described.37 
N-[2-(Trifluoromethyl)phenyl]acrylamide (40). Obtained following the general procedure for the 
synthesis of phenylacrylamides from 2-(trifluoromethyl)aniline (0.5 mL, 3.9 mmol) and acryloyl 
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chloride (0.35 mL, 4.3 mmol) in 62% yield. Chromatography: hexane/EtOAc, 7:3. Mp 115-116 ºC. Rf
(hexane/EtOAc, 7:3) 0.39. IR (ATR) 3275 (NH), 1664 (CO), 1634, 1613, 1591, 1534 (Ar). 1H NMR
(300 MHz, CDCl3) 5.82 (dd, J = 10.1, 1.2 Hz, 1H, 1/2CH2), 6.29 (dd, J = 16.9, 10.0 Hz, 1H, CHCO),
6.44 (dd, J = 16.9 Hz, 1.2 Hz, 1H, 1/2CH2), 7.25 (t, J = 7.7 Hz, 1H, H3), 7.56 (t, J = 7.8 Hz, 1H, H4), 
7.61 (d, J = 7.9 Hz, 1H, H5), 7.67 (br s, 1H, NH), 8.24 (d, J = 7.9 Hz, 1H, H6). 13C NMR (75 MHz, 
CDCl3)  120.3 (q, J = 28.9 Hz, C), 124.2 (q, J = 273.2 Hz, C), 124.5, 124.8 (2CH), 126.2 (q, J = 5.4
Hz, CH), 128.6 (CH2), 131.1, 133.1 (2CH), 135.2, 163.7 (2C). 19F NMR (282 MHz, CDCl3)  -60.8.
MS (ESI): [(M+H)+] 216.0.
N-[3-(Trifluoromethyl)phenyl]acrylamide (41).37 Obtained following the general procedure for 
the synthesis of phenylacrylamides from 3-(trifluoromethyl)aniline  (0.5 mL, 4 mmol) and acryloyl  
chloride (0.35 mL, 4.4 mmol) in 84% yield. Chromatography: hexane/EtOAc, 7:3. Mp 85-86 ºC. Rf
(hexane/EtOAc, 7:3) 0.38. IR (ATR)  3285 (NH), 1671 (CO), 1608, 1557, 1492, 1447 (Ar). 1H NMR
(300 MHz, CDCl3) 5.82 (dd, J = 10.2, 1.2 Hz, 1H, 1/2CH2), 6.26 (dd, J = 16.8, 10.2 Hz, 1H, CHCO),
6.48 (dd, J = 16.8 Hz, 1.2 Hz, 1H, 1/2CH2), 7.38 (d, J = 7.8 Hz, 1H, H4), 7.45 (t, J = 7.9 Hz, 1H, H5), 
7.51 (br s, 1H, NH), 7.79 (d, J = 8.1 Hz, 1H, H6), 7.88 (s, 1H, H2). 13C NMR (75 MHz, CDCl3)  116.9,
121.2, 123.3 (3CH), 123.9 (q, J = 272.5 Hz, C), 128.9 (CH2), 129.7, 130.8 (2CH), 131.5 (q, J = 32.6 
Hz, C), 138.3, 164.0 (2C). 19F NMR (282 MHz, CDCl3)  -63.1. MS (ESI): [(M+H)+] 215.9. 
N-[4-(Trifluoromethyl)phenyl]acrylamide (42). Obtained following the general procedure for the 
synthesis of phenylacrylamides from 4-(trifluoromethyl)aniline (0.3 mL, 2.4 mmol) and acryloyl 
chloride (0.21 mL, 2.6 mmol) in 64% yield. Chromatography: hexane/EtOAc, 7:3. Mp 171-172 ºC. Rf
(hexane/EtOAc, 7:3) 0.33. 1H NMR (300 MHz, CDCl3) 5.84 (dd, J = 10.2, 1.2 Hz, 1H, 1/2CH2), 6.25 
(dd, J = 16.8, 10.2 Hz, 1H, CHCO), 6.48 (dd, J = 16.8, 1.1 Hz, 1H, 1/2CH2), 7.35 (br s, 1H, NH), 7.60
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(d, J = 8.7  Hz, 2H, H3, H5), 7.72 (d, J = 8.7  Hz, 2H, H2, H6). MS (ESI): [(M+H)+] 216.1. The
spectroscopic data are in agreement with those previously described.37 
N-[4-(Acetylamino)phenyl]acrylamide (43).38 Obtained following the general procedure for the
synthesis of phenylacrylamides from 4-(acetylamino)aniline (1 g, 6.7 mmol) and acryloyl chloride
(0.94 mL, 11.7 mmol) in 41% yield. Rf (hexane/EtOAc, 1:1) 0.18. Mp >220 ºC (decomposed). IR 
(ATR) 3277 (NH), 1665 (CO), 1616, 1583, 1517 (Ar). 1H NMR (300 MHz, CDCl3) 2.02 (s, 3H, 
CH3), 5.73 (dd, J = 10.0, 2.2 Hz, 1H, 1/2CH2), 6.23 (dd, J = 17.0, 2.2 Hz, 1H, 1/2CH2), 6.42 (dd, J = 
17.0, 10.0 Hz, 1H, CHCO), 7.51 (d, J = 9.0 Hz, 2H, H2, H6 / H3, H5), 7.58 (d, J = 9.0 Hz, 2H, H2, H6 /
H3, H5), 9.90 (br s, 1H, NH), 10.08 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3) 23.9 (CH3), 119.3
(2CH), 119.7 (2CH), 126.5 (CH2), 131.9 (CH), 134.2, 135.1, 162.8, 168.0 (4C). MS (ESI): [(M)+] 204.8. 
N-(4-Cyanophenyl)acrylamide (44). Obtained following the general procedure for the synthesis 
of phenylacrylamides from 4-aminobenzonitrile (550 mg, 4.6 mmol) and acryloyl chloride (0.41 mL, 5
mmol) in 68% yield. Chromatography: hexane/EtOAc, 7:3. Mp 197-199 ºC. Rf (hexane/EtOAc, 7:3)
0.18. 1H NMR (300 MHz, CDCl3) 5.87 (dd, J = 10.2, 1.0 Hz, 1H, 1/2CH2), 6.26 (dd, J = 16.8, 10.2
Hz, 1H, CHCO), 6.50 (dd, J = 16.8, 1.0 Hz, 1H, 1/2CH2), 7.44 (br s, 1H, NH), 7.63 (d, J = 8.8 Hz, 2H,
H3, H5), 7.73 (d, J = 8.8 Hz, 2H, H2, H6). MS (ESI): [(M+H)+] 173.0. The spectroscopic data are in
agreement with those previously described.39 
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N-(4-Methoxyphenyl)acrylamide (45). Obtained following the general procedure for the
synthesis of phenylacrylamides from 4-methoxyaniline (680 mg, 5.5 mmol) and acryloyl chloride (0.49 
mL, 6 mmol) in 72% yield. Chromatography: hexane/EtOAc, 7:3. Mp 98-99 ºC (Lit.33 97-98 ºC). Rf
(hexane/EtOAc, 6:4) 0.27. 1H NMR (300 MHz, CDCl3) 3.78 (s, 3H, CH3), 5.71 (dd, J = 10.0, 1.4 Hz,
1H, 1/2CH2), 6.24 (dd, J = 16.8, 10.0 Hz, 1H, CHCO), 6.40 (dd, J = 16.8, 1.4 Hz, 1H, 1/2CH2), 6.85 
(d, J = 9.0 Hz, 2H, H3, H5), 7.48 (d, J = 8.9 Hz, 2H, H2, H6), 7.63 (br s, 1H, NH). MS (ESI): [(M+H)+] 
178.1. The spectroscopic data are in agreement with those previously described.35 
4-(Acryloylamino)-N,N-dimethylbenzamide (46). Obtained following the general procedure for 
the synthesis of phenylacrylamides from 36 (69 mg, 0.4 mmol) and acryloyl chloride (0.04 mL, 0.5
mmol) in 72% yield. Chromatography: hexane/EtOAc, 4:6. Mp 149-151 ºC. Rf (hexane/EtOAc, 6:4)
0.23. IR (ATR)  3265 (NH), 1688 (CO), 1608, 1532, 1492 (Ar). 1H NMR (300 MHz, CDCl3) 2.99 (s,
3H, CH3), 3.10 (s, 3H, CH3), 5.74 (dd, J = 9.8, 1.8 Hz, 1H, 1/2CH2), 6.32 (dd, J = 16.9, 9.8 Hz, 1H,
CHCO), 6.44 (dd, J = 16.9, 1.8 Hz, 1H, 1/2CH2), 7.29 (d, J = 8.5 Hz, 2H, H3, H5), 7.52 (d, J = 8.5 Hz,
2H, H2, H6), 8.45 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  35.7, 39.9 (2CH3), 120.0 (2CH), 128.1 
(2CH+CH2), 131.2 (CH), 131.7, 139.5, 164.1, 171.6 (4C). MS (ESI): [(M+H)+] 219.1. 
Ethyl 4-acrylamidobenzoate (47).40 Obtained following the general procedure for the synthesis 
of phenylacrylamides from ethyl 4-aminobenzoate (550 mg, 3.3 mmol) and acryloyl chloride (0.29
mL, 3.6 mmol) in 86% yield. Chromatography: hexane/EtOAc, 8:2. Mp 119-121 ºC. Rf
(hexane/EtOAc, 7:3) 0.31. IR (ATR) 3312 (NH), 1716, 1674 (CO), 1603, 1541, 1474 (Ar). 1H NMR
(300 MHz, CDCl3) 1.38 (t, J = 7.1 Hz, 3H, CH3), 4.35 (q, J = 7.1 Hz, 2H, CH2O), 5.79 (dd, J = 10.0, 
1.4 Hz, 1H, 1/2CH2), 6.31 (dd, J = 16.8, 10.0 Hz, 1H, CHCO), 6.46 (dd, J = 16.8, 1.4 Hz, 1H, 1/2CH2),
7.69 (d, J = 8.8 Hz, 2H, H2, H6), 8.00 (d, J = 8.8 Hz, 2H, H3, H5), 8.07 (br s, 1H, NH). 13C NMR (75 
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MHz, CDCl3)  14.5 (CH3), 61.1 (CH2), 119.2 (2CH), 126.2 (C), 128.8 (CH2), 130.9 (2CH), 131.0 (CH),
142.1, 164.0, 166.4 (3C). MS (ESI): [(M+H)+] 220.0.
N-Methyl-N-phenylacrylamide (62). Obtained following the general procedure for the synthesis 
of phenylacrylamides from methylaniline (0.5 mL, 4.5 mmol) and acryloyl chloride (0.4 mL, 5 mmol) 
in quantitative yield. Mp 75-76 ºC (Lit.41 74-76 ºC). Rf (hexane/EtOAc, 7:3) 0.26. 1H NMR (300 MHz, 
CDCl3) 3.37 (s, 3H, CH3N), 5.52 (dd, J = 10.3, 2.0 Hz, 1H, 1/2CH2), 6.08 (dd, J = 16.8, 10.4 Hz, 1H,
CHCO), 6.37 (dd, J = 16.8, 2.0 Hz, 1H, 1/2CH2), 7.19 (d, J = 7.1 Hz, 2H, H2, H6), 7.34 (t, J = 7.3 Hz,
1H, H4), 7.42 (t, J = 7.4 Hz, 2H, H3, H5). MS (ESI): [(M+H)+] 162.1. The spectroscopic data are in 
agreement with those previously described.41 
N-Phenylethylensulfonamide (63). Obtained following the general procedure for the synthesis
of phenylacrylamides from aniline (0.24 mL, 2.7 mmol) and 2-chloroethanesulfanoyl chloride (0.31
mL, 3 mmol) in 30% yield. Chromatography: hexane/ EtOAc, 6:4. Mp 67-68 ºC. Rf (hexane/EtOAc,
7:3) 0.29. IR (ATR) 3262 (NH), 1599, 1495 (Ar), 1338, 1147 (SO2). 1H NMR (300 MHz, CDCl3) 
5.94 (d, J = 10.0 Hz, 1H, ½CH2), 6.09 (d, J = 16.5 Hz, 1H, ½CH2), 6.66 (dd, J = 16.5, 10.0 Hz, 1H, 
CHCO), 7.06 (tt, J = 6.9, 1.8 Hz, 1H, H4), 7.21-7.32 (m, 4H, H2, H3, H5, H6), 8.69 (br s, 1H, NH). The 
spectroscopic data are in agreement with those previously described.42 
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Synthesis of N1-phenyl-N3-octyl-β-alaninamide (34). To a solution of acrylamide 33 (230 mg,
1.6 mmol) and octylamine (0.78 mL, 4.7 mmol) in anhidrous acetonitrile (0.8 mL) was added DBU
(0.71 mL, 4.7 mmol) and the reaction mixture was stirred 5 h at 60 ºC. Then, the solvent was removed 
under reduced pressure to give the secondary amine in 79% yield. Chromatography: EtOAc/MeOH, 
9:1; oil. Rf (EtOAc) 0.12. IR (ATR) 3297 (NH), 1667 (CO), 1601, 1551, 1497, 1444 (Ar). 1H NMR
(300 MHz, CDCl3)  0.86-0.88 (m, 3H, CH3), 1.29 (m, 10H, (CH2)5CH3), 1.54-1.58 (m, 2H, 
CH2(CH2)5CH3), 2.48 (t, J = 5.2 Hz, 2H, CH2CO), 2.69 (t, J = 6.8 Hz, 2H, (CH2)6CH2N), 2.97 (t, J =
5.4 Hz, 2H, NCH2CH2CO), 3.48 (br s, 1H, NH), 7.06 (t, J = 7.3 Hz, 1H, H4), 7.29 (t, J = 7.7 Hz, 2H,
H3, H5), 7.53 (d, J = 7.8 Hz, 2H, H2, H6). 13C NMR (75 MHz, CDCl3) 14.1 (CH3), 22.7, 27.5, 29.3, 
29.5, 30.1, 31.8, 36.1, 45.5, 49.3 (9CH2), 119.7 (2CH), 123.6 (CH), 128.9 (2CH), 138.8, 171.1 (2C).
MS (ESI): [(M+H)+] 277.2.
General procedure for the synthesis of asymmetric diamides 1, 2, 4-15 and 28-30. To a
solution of the corresponding or 2-(chloromethyl)-5-phenyl-1,3,4-
oxadiazole (1.5 equiv) and secondary amine 34 (1 equiv) in anhidrous acetonitrile (0.5 mL/mmol), 
was added DBU (1.5 equiv), and the reaction mixture was stirred 24 h at 60 ºC. Then, the solvent 
was removed under reduced pressure and the residue was purified by column chromatography to
give the title compounds. For the synthesis of N3-octyl-N1-phenyl-N3-[(5-phenyl-1,3,4-oxadiazol-2-
yl)methyl]-β-alaninamide (30) triethylamine was used as a base.
N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-pyridin-2-yl-β-alaninamide (1). Obtained following the
general procedure for the synthesis of asymmetric diamides from amine 34 (75 mg, 0.3 mmol) and 
acrylamide 31 (60 mg, 0.4 mmol) in 45% yield. Chromatography: EtOAc; oil. Rf (EtOAc/MeOH, 98:2) 
0.28. IR (ATR) 3274 (NH), 1665, 1540 (CO), 1600, 1436 (Ar). 1H NMR (300 MHz, CDCl3) 0.83 (t, 
J = 6.9 Hz, 3H, CH3), 1.04-1.34 (m, 10H, (CH2)5CH3), 1.51 (m, 2H, CH2(CH2)5CH3), 2.51-2.60 (m, 6H, 
(CH2)6CH2N , 2CH2CO), 2.90 (t, J = 6.0 Hz, 4H, 2NCH2CH2CO), 6.98-7.01 (m, 2H, H5, H4’), 7.20 (t, J
= 7.8 Hz, 2H, H3’, H5’), 7.47 (d, J = 7.8 Hz, 2H, H2’, H6’), 7.66 (t, J = 7.9 Hz, 1H, H4), 8.17-8.22 (m, 2H, 
H3, H6), 9.89 (br s, 1H, NH), 10.55 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  14.1 (CH3), 22.6, 26.7, 
27.5, 29.2, 29.5, 31.7, 34.1, 36.3, 50.0, 51.0, 54.1 (11CH2), 114.5, 119.7 (2CH), 120.0 (2CH), 123.9
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(CH), 128.8 (2CH), 138.5 (C), 138.6, 147.5 (2CH), 151.6, 170.9, 171.0 (3C). HRMS (ESI): [(M)+] 
calcd. for C25H36N4O2, 424.2833; found, 424.2832.
N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-pyridin-3-yl-β-alaninamide (2). Obtained following the
general procedure for the synthesis of asymmetric diamides from amine 34 (100 mg, 0.4 mmol) and
acrylamide 32 (80 mg, 0.5 mmol) in 37% yield. Chromatography: EtOAc/MeOH, 9:1; oil. Rf
(EtOAc/MeOH, 9:1) 0.28. IR (ATR) 3265 (NH), 1664, 1546 (CO), 1600, 1489, 1444 (Ar). 1H NMR
(300 MHz, CDCl3) 0.84 (t, J = 6.8 Hz, 3H, CH3), 1.07-1.34 (m, 10H, (CH2)5CH3), 1.51 (m, 2H, 
CH2(CH2)5CH3), 2.50-2.59 (m, 6H, (CH2)6CH2N, 2CH2CO), 2.82 (t, J = 6.4 Hz, 2H, NCH2CH2CO), 
2.84 (d, J = 6.4 Hz, 2H, NCH2CH2CO), 6.99 (t, J = 7.4 Hz, 1H, H4’), 7.10 (dd, J = 8.3, 4.8 Hz, 1H, H5), 
7.15 (t, J = 7.8 Hz, 2H, H3´, H5´), 7.41 (d, J = 7.8 Hz, 2H, H2´, H6´), 7.99 (d, J = 8.5 Hz, 1H, H4), 8.21
(d, J = 5.8 Hz, 1H, H6), 8.54 (d, J = 2.4 Hz, 1H, H2), 9.52 (br s, 1H, NH), 9.98 (br s, 1H, NH). 13C NMR 
(75 MHz, CDCl3)  14.1 (CH3), 22.6, 26.7, 27.7, 29.3, 29.5, 31.8 (6CH2), 34.3 (2CH2), 49.6, 49.8, 53.7 
(3CH2), 119.9 (2CH), 123.7, 124.1, 127.1 (3CH), 128.8 (2CH), 135.4, 138.0 (2C), 140.9, 144.4 (2CH), 
170.6, 171.4 (2C). HRMS (ESI): [(M)+] calcd. for C25H36N4O2, 424.2833; found, 424.2831. 
N3-{3-[(2-Fluorophenyl)amino]-3-oxopropyl}-N3-octyl-N1-phenyl-β-alaninamide (4).
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(60 mg, 0.2 mmol) and acrylamide 37  (54 mg, 0.2 mmol) in 85% yield. Chromatography:
EtOAc/MeOH, 95:5; oil. Rf (EtOAc/hexane, 7:3) 0.38. IR (ATR) 3287 (NH), 1663 (CO), 1600, 1543, 
1497, 1449 (Ar). 1H NMR (300 MHz, CDCl3) 0.84 (t, J = 6.8  Hz, 3H, CH3), 1.19-1.25 (m, 10H, 
(CH2)5CH3), 1.53 (m, 2H, CH2(CH2)5CH3), 2.52-2.59 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.83-2.92 (m,
4H, 2NCH2CH2CO), 6.95-7.07 (m, 4H, H3, H4, H6, H4’), 7.18 (t, J = 7.8 Hz, 2H, H3’, H5’), 7.43 (d, J =
7.7 Hz, 2H, H2’, H6’), 8.25 (t, J = 7.9 Hz, 1H, H5), 8.80 (br s, 1H, NH), 9.61 (br s, 1H, NH). 13C NMR 
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(75 MHz, CDCl3) 14.2 (CH3), 22.7, 26.5, 27.7, 29.4, 29.6, 31.9, 34.3, 34.7, 49.7, 49.8, 53.7 (11CH2),
114.9 (d, J = 19.3 Hz, CH), 119.8 (2CH), 122.1, 124.1 (2CH), 124.3 (d, J = 34.5 Hz, CH), 124.4 (d, J
= 30.5 Hz, CH), 126.6 (d, J = 10.4 Hz, C), 128.9 (2CH), 138.1 (C), 152.6 (d, J = 243.0 Hz, C), 170.3, 
171.7 (2C). 19F NMR (282 MHz, CDCl3)  -130.4. HRMS (ESI): [(M+Na)+] calcd. for C26H36FN3O2Na,
464.26892; found, 464.27185. 
N3-{3-[(3-Fluorophenyl)amino]-3-oxopropyl}-N3-octyl-N1-phenyl-β-alaninamide (5).
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(80 mg, 0.3 mmol) and acrylamide 38  (72 mg, 0.4 mmol) in 88% yield. Chromatography:
EtOAc/MeOH, 8:2; oil. Rf (EtOAc/MeOH, 95:5) 0.50. IR (ATR)  1685 (CO), 1604, 1543, 1492, 1443 
(Ar). 1H NMR (300 MHz, CDCl3)  0.83 (t, J = 6.8 Hz, 3H, CH3), 1.16-1.27 (m, 10H, (CH2)5CH3), 1.49 
(m, 2H, CH2(CH2)5CH3), 2.47-2.51 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.77-2.81 (m, 4H, 2NCH2CH2CO), 
6.65-6.72 (m, 1H, H4), 6.99-7.06 (m, 3H, H5, H6, H4’), 7.17 (t, J = 7.8 Hz, 2H, H3’, H5’), 7.41-7.47 (m, 
3H, H2, H2’, H6’), 9.32 (br s, 1H, NH), 9.65 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3) 14.1 (CH3), 
22.7, 26.8, 27.7, 29.4, 29.6, 31.9, 34.2, 34.4, 49.6, 49.9, 53.6 (11CH2), 107.3 (d, J = 26.2 Hz, CH),
110.6 (d, J = 21.3 Hz, CH), 115.2 (d, J = 2.6 Hz, CH), 120.1 (2CH), 124.2 (CH), 128.9 (2CH), 129.9 
(d, J = 9.4 Hz, CH), 138.0 (C), 139.8 (d, J = 10.8 Hz, C), 162.9 (d, J = 244.1 Hz, C), 170.7, 171.0
(2C). 19F NMR (282 MHz, CDCl3)  -112.0. HRMS (ESI): [(M+H)+] calcd. for C26H37FN3O2, 442.28698;
found, 442.28703.
. 
N3-{3-[(4-Fluorophenyl)amino]-3-oxopropyl}-N3-octyl-N1-phenyl-β-alaninamide (6).
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(44.8 mg, 0.3 mmol) and acrylamide 39 (50 mg, 0.2 mmol) in 58% yield. Chromatography: 
EtOAc/MeOH, 8:2. Mp 79-80 ºC. Rf (EtOAc) 0.32. IR (ATR)  3290 (NH), 1659 (CO), 1604, 1550, 
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1508, 1445 (Ar). 1H NMR (300 MHz, CD3OD)  0.87 (t, J = 7.0 Hz, 3H, CH3), 1.08-1.41 (m, 10H, 
(CH2)5CH3), 1.51 (m, 2H, CH2(CH2)5CH3), 2.52-2.61 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.85-2.90 (m,
4H, 2NCH2CH2CO), 6.90 (t, J = 8.8 Hz, 2H, H3’, H5’), 7.07 (t, J = 7.4 Hz, 1H, H4’), 7.23 (t, J = 7.9 Hz,
2H, H3, H5), 7.43-7.50 (m, 4H, H2, H6, H2’, H6’). 13C NMR (75 MHz, CD3OD) 14.4 (CH3), 23.7, 28.3, 
28.8, 30.5, 30.8, 33.0, 35.5, 37.9, 51.0, 51.1, 54.7 (11CH2), 116.1 (d, J = 22.4 Hz, 2CH), 121.4 (2CH), 
123.1 (d, J = 7.8 Hz, 2CH), 125.1 (CH), 129.7 (2CH), 135.8 (d, J = 2.8 Hz, C), 139.6 (C), 160.5 (d, J
= 240.0 Hz, C), 173.2, 173.3 (2C). 19F NMR (282 MHz, CD3OD)  -121.2. Elemental analysis: calcd. 
for C26H36FN3O2: %C: 70.72, %H: 8.22, %N: 9.52; found, %C: 70.23, %H: 8.23, %N: 9.29. 
N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-[2-(trifluoromethyl)phenyl]-β-alaninamide (7). 
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(50 mg, 0.2 mmol) and acrylamide 40  (58 mg, 0.3 mmol) in 89% yield. Chromatography:
EtOAc/MeOH, 9:1; oil. Rf (EtOAc) 0.35. IR (ATR)  3301 (NH), 1663 (CO), 1600, 1546, 1499, 1456 
(Ar). 1H NMR (300 MHz, CDCl3) 0.84 (t, J = 6.8 Hz, 3H, CH3), 1.20-1.27 (m, 10H, (CH2)5CH3), 1.49
(m, 2H, CH2(CH2)5CH3), 2.49-2.60 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.87-2.92 (m, 4H, 2NCH2CH2CO), 
6.99 (t, J = 7.4 Hz, 1H, H4’), 7.14-7.21 (m, 3H, H3’, H5’, H6), 7.38-7.47 (m, 3H, H5, H2’, H6’), 7.55 (d, J
= 7.8 Hz, 1H, H3), 7.96 (d, J = 8.1 Hz, 1H, H4), 8.80 (br s, 1H, NH), 9.02 (br s, 1H, NH). 13C NMR (75 
MHz, CDCl3)  14.2 (CH3), 22.7, 26.0, 27.7, 29.3, 29.6, 31.9, 34.1, 34.2, 49.1, 49.7, 53.3 (11CH2),
119.8 (2CH), 121.2 (q, J = 28.3 Hz, C), 123.9 (CH), 124.0 (q, J = 273.3 Hz, C), 124.8, 125.8 (2CH),
126.1 (q, J = 5.5 Hz, CH), 128.9 (2CH), 132.8 (CH), 135.1, 138.2, 170.5, 170.8 (4C). 19F NMR (282 
MHz, CDCl3)  -60.9. HRMS (ESI): [(M+H)+] calcd. for C27H37F3N3O2: 492.28324; found, 492.28235.
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N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-[3-(trifluoromethyl)phenyl]-β-alaninamide (8). 
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(50 mg, 0.2 mmol) and acrylamide 41  (26 mg, 0.2 mmol) in 49% yield. Chromatography:
EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH, 9:1) 0.50. IR (ATR)  3299 (NH), 1661 (CO), 1601, 1554, 
1498, 1446 (Ar). 1H NMR (300 MHz, CDCl3) 0.83 (t, J = 6.8  Hz, 3H, CH3), 1.17-1.25 (m, 10H, 
(CH2)5CH3), 1.51 (m, 2H, CH2(CH2)5CH3), 2.49-2.56 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.78-2.84 (m,
4H, 2NCH2CH2CO), 6.99 (t, J = 7.4 Hz, 1H, H4’), 7.12-7.25 (m, 4H, H3’, H5’, H5, H6), 7.40 (d, J = 7.8
Hz, 2H, H2’, H6’), 7.52 (d, J = 7.3 Hz, 1H, H6), 7.87 (s, 1H, H2), 9.22 (br s, 1H, NH), 9.70 (br s, 1H,
NH). 13C NMR (75 MHz, CDCl3)  14.2 (CH3), 22.7, 26.7, 27.7, 29.4, 29.6, 31.9, 34.2, 34.4, 49.6,
49.9, 53.8 (11CH2), 116.5 (d, J = 3.9 Hz, CH), 120.0 (2CH), 120.4 (d, J = 3.8 Hz, CH), 122.9 (CH), 
124.0 (q, J = 272.7 Hz, C), 124.3 (CH), 129.0 (2CH), 129.4 (CH), 131.1 (q, J = 32.2 Hz, C), 137.9, 
138.8, 170.7, 171.1 (4C). 19F NMR (282 MHz, CDCl3)  -63.0. HRMS (ESI): [(M+H)+] calcd. for
C27H37F3N3O2: 492.28324; found, 492.28379.
N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-[4-(trifluoromethyl)phenyl]-β-alaninamide (9). 
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(94 mg, 0.3 mmol) and acrylamide 42 (110 mg, 0.5 mmol) in quantitative yield. Chromatography: 
EtOAc/MeOH, 7:3. Mp 77-78 ºC. Rf (EtOAc/MeOH, 8:2) 0.58. IR (ATR)  3286 (NH), 1660 (CO), 
1603, 1544, 1499, 1444 (Ar). 1H NMR (300 MHz, CDCl3) 0.84 (t, J = 6.8 Hz, 3H, CH3), 1.15-1.28
(m, 10H, (CH2)5CH3), 1.46-1.51 (m, 2H, CH2(CH2)5CH3), 2.50-2.57 (m, 6H, 2CH2CO, (CH2)6CH2N),
2.81-2.89 (m, 4H, 2NCH2CH2CO), 7.05 (t, J = 7.4 Hz, 1H, H4’), 7.20 (t, J = 7.8 Hz, 2H, H3’, H5’), 7.33 
(d, J = 8.6 Hz, 2H, H3, H5), 7.38 (d, J = 8.1 Hz, 2H, H2’, H6’), 7.50 (d, J = 8.6 Hz, 2H, H2, H6), 8.32 (br
s, 1H, NH), 9.44 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  14.1 (CH3), 22.7, 26.7, 27.8, 29.4, 29.6, 
31.8, 34.3, 34.5, 49.6, 50.0, 53.6 (11CH2), 119.5 (2CH), 120.1 (2CH), 124.2 (q, J = 271.5 Hz, C),
124.4 (CH), 125.4 (q, J = 32.6 Hz, C), 126.0 (q, J = 3.9 Hz, 2CH), 128.9 (2CH), 137.9, 141.3, 170.7, 
171.3 (4C). 19F NMR (282 MHz, CDCl3)  -62.4. Elemental analysis: calcd. for C27H36F3N3O2: %C:
65.97, %H: 7.38, %N: 8.55; found, %C: 66.43, %H: 7.36, %N: 8.45. 
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N3-(3-{[4-(Acetylamino)phenyl]amino}-3-oxopropyl)-N3-octyl-N1-phenyl-β-alaninamide (10).
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(36 mg, 0.13 mmol) and acrylamide 43  (40 mg, 0.2 mmol) in 32% yield. Chromatography:
EtOAc/MeOH, 8:2; oil. Rf (EtOAc/MeOH, 9:1) 0.33. IR (ATR)  3291 (NH), 1664 (CO), 1600, 1550, 
1515, 1499, 1444 (Ar). 1H NMR (300 MHz, CDCl3)  0.84 (t, J = 6.8 Hz, 3H, CH3), 1.13-1.28 (m, 10H, 
(CH2)5CH3), 1.51 (m, 2H, CH2(CH2)5CH3), 2.12 (s, 3H, CH3CO), 2.52-2.55 (m, 6H, 2CH2CO,
(CH2)6CH2N), 2.82-2.86 (m, 4H, 2NCH2CH2CO), 7.01 (t, J = 7.4 Hz, 1H, H4’), 7.19 (t, J = 7.8 Hz, 2H, 
H3’, H5’), 7.26 (d, J = 8.9 Hz, 2H, H2, H6/ H3, H5), 7.32 (d, J = 8.9 Hz, 2H, H2, H6/ H3, H5), 7.44 (d, J = 
7.4 Hz, 2H, H2’, H6’), 7.74 (br s, 1H, NH), 9.32 (br s, 1H, NH), 9.37 (br s, 1H, NH). 13C NMR (75 MHz,
CDCl3)  14.2 (CH3), 22.7 (CH2), 24.5 (CH3), 26.6, 27.7, 29.4, 29.6, 31.9, 34.1, 34.4 (7CH2), 49.9
(2CH2), 53.7 (CH2), 120.0 (2CH), 120.7 (2CH), 121.0 (2CH), 124.1 (CH), 129.0 (2CH), 134.1, 134.6, 
138.2, 168.8 (4C), 170.6 (2C). HRMS (ESI): [(M+Na)+] calcd. for C28H40N4O3Na: 503.29981; found, 
503.30008.
N3-(3-Anilino-3-oxopropyl)-N1-(4-cyanophenyl)-N3-octyl-β-alaninamide (11). Obtained 
following the general procedure for the synthesis of asymmetric diamides from amine 34 (80 mg, 0.3
mmol) and acrylamide 44 (75 mg, 0.4 mmol) in 59% yield. Chromatography: EtOAc/MeOH, 95:5. Mp 
99-100 ºC. Rf (EtOAc) 0.24. IR (ATR)  3294 (NH), 2926 (CN), 1664 (CO), 1597, 1531, 1500, 1444
(Ar). 1H NMR (300 MHz, CDCl3)  83 (t, J = 6.9 Hz, 3H, CH3), 1.14-1.25 (m, 10H, (CH2)5CH3), 1.48 
(m, 2H, CH2(CH2)5CH3), 2.47-2.57 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.77-2.85 (m, 4H, 2NCH2CH2CO), 
7.07 (t, J = 7.3 Hz, 1H, H4’), 7.20 (t, J = 7.8 Hz, 2H, H3’, H5’), 7.31 (d, J = 8.7 Hz, 2H, H3, H5), 7.38 (d, 
J = 7.9 Hz, 2H, H2’, H6’), 7.52 (d, J = 8.6 Hz, 2H, H2, H6), 8.66 (br s, 1H, NH), 9.83 (br s, 1H, NH). 13C 
NMR (75 MHz, CDCl3)  14.2 (CH3), 22.7, 26.8, 27.8, 29.4, 29.6, 31.9, 34.4, 34.8, 49.4, 50.3, 53.7 
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(11CH2), 106.2, 119.2 (2C), 119.6 (2CH), 120.2 (2CH), 124.6 (CH), 129.1 (2CH), 133.0 (2CH), 137.7, 
142.5, 170.5, 171.5 (4C). HRMS (ESI): [(M+Na)+] calcd. for C27H36N4O2Na: 471.27359; found, 
471.27339.
N3-(3-Anilino-3-oxopropyl)-N1-(4-methoxyphenyl)-N3-octyl-β-alaninamide (12). Obtained 
following the general procedure for the synthesis of asymmetric diamides from amine 34 (85 mg, 0.3
mmol) and acrylamide 45 (82 mg, 0.5 mmol) in 59% yield. Chromatography: EtOAc/MeOH, 95:5; oil.
Rf (EtOAc/MeOH) 0.26. IR (ATR)  3279 (NH), 1658 (CO), 1601, 1544, 1510, 1464, 1443 (Ar). 1H 
NMR (300 MHz, CDCl3)  0.82 (t, J = 6.8 Hz, 3H, CH3), 1.16-1.26 (m, 10H, (CH2)5CH3), 1.48 (m, 2H, 
CH2(CH2)5CH3), 2.45-2.50 (m, 6H, 2CH2CO, (CH2)6CH2N), 2.78 (t, J = 6.0 Hz, 4H, 2NCH2CH2CO), 
3.71 (s, 3H, CH3O), 6.67 (d, J = 9.0 Hz, 2H, H3, H5), 7.00 (t, J = 7.4 Hz, 1H, H4’), 7.16 (t, J = 7.8 Hz,
2H, H3’, H5’), 7.32 (d, J = 9.0 Hz, 2H, H2, H6), 7.43 (d, J = 7.6 Hz, 2H, H2’, H6’), 9.30 (br s, 1H, NH), 
9.45 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  14.1 (CH3), 22.7, 26.8, 27.7, 29.4, 29.6, 31.8, 34.1, 
34.3 (8CH2), 49.8 (2CH2), 53.6 (CH2), 55.4 (CH3), 114.0 (2CH), 119.9 (2CH), 121.7 (2CH), 123.9
(CH), 128.8 (2CH), 131.4, 138.3, 156.1, 170.5, 170.8 (5C). HRMS (ESI): [(M+H)+] calcd. for
C27H39N3O3Na: 454.30696; found, 454.30446.
N3-(3-Anilino-3-oxopropyl)-N3-octyl-N1-[4-(dimethylbenzamide)phenyl]-β-alaninamide (13). 
Obtained following the general procedure for the synthesis of asymmetric diamides from amine 34
(42 mg, 0.15 mmol) and acrylamide 46  (33 mg, 0.23 mmol) in 56% yield. Chromatography:
EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH/NH3, 9:1:0.1) 0.35. IR (ATR)  3302 (NH), 1683, 1605 (CO), 
1542, 1496, 1446, 1401 (Ar). 1H NMR (300 MHz, CDCl3) 0.83 (t, J = 6.6 Hz, 3H, CH3CH2), 1.18-
1.24 (m, 10H, (CH2)5CH3), 1.51 (m, 2H, CH2(CH2)5CH3), 2.50-2.53 (m, 6H, 2CH2CO, (CH2)6CH2N),
2.83 (t, J = 5.3 Hz, 4H, 2NCH2CH2CO), 2.94 (s, 3H, CH3N), 3.06 (s, 3H, CH3N), 6.99 (t, J = 7.3 Hz,
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1H, H4’), 7.17 (m, 4H, H3, H5, H3’, H5’), 7.41 (m, 4H, H2, H6, H2’, H6’), 9.39 (br s, 1H, NH), 9.70 (br s,
1H, NH). 13C NMR (75 MHz, CDCl3)  14.2 (CH3), 22.7, 26.7, 27.7, 29.4, 29.6, 31.9, 34.3, 34.4 (8CH2),
35.6, 39.8 (2CH3) 49.8, 49.9, 53.6 (3CH2), 119.4 (2CH), 120.0 (2CH), 124.0 (CH), 128.1 (2CH), 128.9
(2CH), 131.0, 138.3, 138.8, 170.7, 171.0, 171.6 (6C). HRMS (ESI): [(M+H)+] calcd. for C29H43N4O3: 
495.33351; found, 495.33450.
Ethyl 4-{[N-(3-anilino-3-oxopropyl)-N-octyl-β-alanyl]amino}benzoate (14). Obtained following
the general procedure for the synthesis of asymmetric diamides from amine 34 (190 mg, 0.7 mmol) 
and acrylamide 47 (226 mg, 1 mmol) in 84% yield. Chromatography: EtOAc/MeOH, 9:1; oil. Rf
(EtOAc/MeOH, 9:1) 0.50. IR (ATR)  3309 (NH), 1712, 1664 (CO), 1599, 1537, 1444, 1409 (Ar). 1H 
NMR (300 MHz, CDCl3) 0.83 (t, J = 6.8 Hz, 3H, CH3), 1.17-1.28 (m, 10H, (CH2)5CH3), 1.38 (t, J =
7.1 Hz, 3H, CH3CH2O), 1.47-1.54 (m, 2H, CH2(CH2)5CH3), 2.50-2.58 (m, 6H, 2CH2CO, (CH2)6CH2N),
2.83-2.90 (m, 4H, 2NCH2CH2CO), 4.34 (q, J = 7.1 Hz, 2H, CH2O), 7.05 (t, J = 7.4 Hz, 1H, H4’), 7.21 
(t, J = 7.9 Hz, 2H, H3’, H5’), 7.41 (d, J = 7.7 Hz, 2H, H2, H6), 7.49 (d, J = 8.7 Hz, 2H, H2’, H6’), 7.83 (d, 
J = 8.7 Hz, 2H, H3, H5), 8.47 (br s, 1H, NH), 9.39 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  14.1, 
14.4 (2CH3), 22.7, 26.8, 27.7, 29.3, 29.6, 31.8, 34.2, 34.5, 49.6, 49.9, 53.5, 60.8 (12CH2), 118.9
(2CH), 120.0 (2CH), 124.2 (CH), 125.4 (C), 128.9 (2CH), 130.6 (2CH), 138.0, 142.5, 166.3, 170.7,
171.1 (5C). HRMS (ESI): [(M+H)+] calcd. for C29H42N3O4: 496.31753; found, 496.31665.
N3-{3-[Methyl(phenyl)amino]-3-oxopropyl}-N3-octyl-N1-phenyl-β-alaninamide (28). Obtained
following the general procedure for the synthesis of asymmetric diamides from amine 34 (100 mg, 
0.24 mmol) and acrylamide 62 (87 mg, 0.54 mmol) in 58% yield. Chromatography: EtOAc/MeOH,
9:1; oil. Rf (EtOAc/MeOH, 9:1) 0.31. IR (ATR)  3306 (NH), 1658 (CO), 1599, 1547, 1497 (Ar). ). 1H 
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NMR (300 MHz, CDCl3) 0.88 (t, J = 6.8 Hz, 3H, CH3CH2), 1.23 (m, 10H, (CH2)5CH3), 1.47 (m, 2H, 
CH2(CH2)5CH3), 2.30 (t, J = 6.8 Hz, 2H, CH2CO), 2.39 (t, J = 7.5 Hz, 2H, (CH2)6CH2N), 2.46 (app t, 
2H, CH2CO), 2.63 (app t, 2H, NCH2CH2CO), 2.84 (t, J = 6.8 Hz, 2H, NCH2CH2CO), 3.18 (s, 3H, 
CH3N), 7.07 (t, J = 7.4 Hz, 1H, H4), 7.10 (d, J = 6.7 Hz, 2H, H2´, H6´), 7.27-7.42 (m, 5H, H3, H5, H3´-
H5´), 7.50 (d, J = 7.9 Hz, 2H, H2, H6), 10.40 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3)  14.1 (CH3), 
22.6, 26.6, 27.6, 29.3, 29.5, 31.5, 31.8, 33.9 (8CH2), 37.3 (CH3), 49.1, 50.3, 53.4 (3CH2), 119.8 (2CH), 
123.5 (CH), 127.1 (2CH), 128.0 (CH), 128.8 (2CH), 129.9 (2CH), 138.7, 143.7, 170.9, 171.2 (4C).
HRMS (ESI): [(M+H)+] calcd. for C27H39N3O2: 437.3042; found, 437.3041.
N3-[2-(Anilinosulfonyl)ethyl]-N3-octyl-N1-phenil-β-alaninamide (29). Obtained following the
general procedure for the synthesis of asymmetric diamides from amine 34 (151 mg, 0.8 mmol) and
sulfonamide 63 (150 mg, 0.8 mmol) in 12% yield. Chromatography: hexane/EtOAc, 7:3; oil. Rf 
(hexane/EtOAc, 7:3) 0.35. IR (ATR)  3253 (NH), 1661, 1545 (CO), 1599, 1498, 1466 (Ar), 1376, 
1148 (SO2). 1H NMR (300 MHz, CDCl3)  0.81 (t, J = 6.8 Hz, 3H, CH3), 1.04-1.29 (m, 10H, (CH2)5CH3), 
1.36 (m, 2H, CH2(CH2)5CH3), 2.35 (app t, J = 7.7  Hz, 2H, (CH2)6CH2N), 2.44 (t, J = 5.8  Hz, 2H,  
CH2CO), 2.71 (t, J = 5.7 Hz, 2H, NCH2CH2CO), 2.96 (t, J = 6.5 Hz, 2H, CH2SO2), 3.21 (t, J = 6.5 Hz,
2H, NCH2CH2SO2), 6.99-7.12 (m, 4H, H4, H2´, H4´, H6´), 7.19-7.32 (m, 5H, H3, H5, H3´, H5´, NH), 7.48 
(d, J = 7.7 Hz, 2H, H2, H6), 9.12 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3) 14.1 (CH3), 22.6, 26.3, 
27.5, 29.2, 29.4, 31.8, 34.6, 47.4, 48.1, 50.5, 53.7 (11CH2), 119.9 (2CH), 120.5 (2CH), 124.1, 125.0
(2CH), 128.9 (2CH), 129.6 (2CH), 136.9, 138.1, 170.8 (3C). HRMS (ESI): [(M+H)+] calcd. for 
C25H38N3O3S: 460.26284; found, 460.26383.
Synthesis of N3-octyl-N1-phenyl-N3-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-β-alaninamide 
(30). Obtained following the general procedure for the synthesis of asymmetric diamides from amine 
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34 (200 mg, 0.73 mmol) and 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole (117 mg, 0.6 mmol) in 62% 
yield. Chromatography: DCM/EtOAc, 8:2; oil. Rf (DCM/EtOAc, 8:2) 0.40. IR (ATR) 3304 (NH), 1728 
(CO), 1599, 1550, 1499, 1444 (Ar). 1H NMR (300 MHz, CDCl3)  0.85 (t, J = 6.9 Hz, 3H, CH3), 1.25-
1.30 (m, 10H, (CH2)5CH3), 1.50-1.60 (m, 2H, CH2(CH2)5CH3), 2.63 (t, J = 6.3 Hz, 2H, CH2CO), 2.70
(app t, J = 7.3 Hz, 2H, NCH2), 3.00 (t, J = 6.3 Hz, 2H, NCH2CH2CO), 4.10 (s, 2H, NCH2Chet), 7.07 (tt, 
J = 7.7 Hz, 1.8, 1H, H4), 7.28 (t, J = 7.2 Hz, 2H, H3, H5), 7.44 (t, J = 7.7 Hz, 2H, H3´, H5´), 7.50 (d, J = 
7.3 Hz, 1H, H4´), 7.57 (d, J = 8.6 Hz, 2H, H2, H6), 7.93 (d, J = 8.6 Hz, 2H, H2´, H6´), 10.17 (br s, 1H, 
NH). 13C NMR (75 MHz, CDCl3)  14.5 (CH3), 23.0, 27.2, 27.8, 29.6, 29.8, 32.1, 34.2, 47.7, 51.0, 54.4
(10CH2), 120.3 (2CH), 123.8, 124.3 (2CH), 127.3 (2CH), 129.3 (2CH), 129.5 (2CH), 132.3, 138.8,
163.8, 165.9, 170.4 (5C). HRMS (ESI): [(M+H)+] calcd. for C26H35N4O2: 435.2755; found, 435.2752.
Synthesis of 4-{[N-(3-anilino-3-oxopropyl)-N-octyl-β-alanyl]amino}benzoic acid (15).43 To a 
solution of 14 (34 mg, 0.07 mmol) in THF/H2O 2:1 (1.2 mL) was added LiOH·H2O (6.5 mg, 0.3 mmol)
and the reaction mixture was stirred at reflux for 3 h. Then, the solvent was removed under reduced
pressure, and the residue was taken up in EtOAc and washed with saturated solution of NaCl (3 x 
10 mL). The organic phase was dried over Na2SO4 and the solvent was evaporated under reduced
pressure to obtain the title compound in 28% yield. Chromatography: EtOAc/MeOH, 1:1; oil. Rf
(EtOAc/MeOH/NH3, 7:3:0.2) 0.34. IR (ATR) 3275, 3193, 3057 (NH, OH), 1685 (CO), 1602, 1544,
1502, 1446 (Ar). 1H NMR (300 MHz, CD3OD) 0.86 (t, J = 6.7 Hz, 3H, CH3), 1.25-1.29 (m, 10H,
(CH2)5CH3), 1.67-1.72 (m, 2H, CH2(CH2)5CH3), 2.52 (q, J = 6.3 Hz, 4H, 2CH2CO), 3.00 (t, J = 7.5 Hz,
2H, (CH2)6CH2N), 3.34 (m, 4H, 2NCH2CH2CO), 7.07 (t, J = 7.4 Hz, 1H, H4’), 7.24 (t, J = 7.4 Hz, 2H,
H3’, H5’), 7.51 (d, J = 7.6 Hz, 2H, H2, H6), 7.62 (d, J = 8.6 Hz, 2H, H2’, H6’), 7.89 (d, J = 8.6 Hz, 2H, H3, 
H5). 13C NMR (75 MHz, CD3OD)  14.4 (CH3), 23.7, 26.3, 28.0, 30.3, 30.4, 30.8, 32.5, 32.9 (8CH2), 
51.1 (2CH2), 55.1 (CH2), 120.2 (2CH), 121.3 (2CH), 124.3 (C), 125.4 (CH), 129.8 (2CH), 131.7 (2CH), 
139.5, 143.4, 170.5, 171.6, 171.8 (5C). HRMS (ESI): [(M-H)-] calcd. for C27H36N3O4: 466.27058; 
found, 466.27198.
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4.1.2. Synthesis of symmetric diamides 3 and 16-27
Synthesis of 3-bromo-N-phenylpropanamide (48). To a solution of aniline (4.1 mL, 45 mmol) 
in anhidrous DCM (225 mL) was added, under argon atmosphere and at 0 ºC, 3-bromopropanoyl 
chloride (5 mL, 50 mmol) and pyridine (4 mL, 50 mmol), consecutively. The reaction mixture was
stirred for 1 h at rt, and the crude was washed with saturated solution of NaHCO3, H2O and saturated
solution of NaCl, sequentially. The aqueous phase was dried over Na2SO4 and the solvent was 
evaporated at reduced pressure, giving the compound as a solid in 71% yield. Rf (DCM/MeOH, 95:5) 
0.56. Mp: 118-122 ºC (Lit.44 123-124 ºC). 1H NMR (300 MHz, CDCl3) 2.96 (t, J = 6.5  Hz, 2H,  
CH2CO), 3.65 (t, J = 6.5 Hz, 2H, CH2Br), 7.10 (t, J = 7.4 Hz, 1H, H4), 7.27 (t, J = 7.8 Hz, 2H, H3, H5), 
7.55 (d, J = 7.8 Hz, 2H, H2, H6), 8.63 (br s, 1H, NH). The spectroscopic data are in agreement with
those previously described.44 
Synthesis of (1E)-N-hydroxy-2-methoxycyclohexylimine (49). To a solution of sodium acetate 
(192 mg, 2.3 mmol) and hydroxylamine hydrochloride (163 mg, 2.3 mmol) in H2O (5.8 mL) previously
heated at 60 ºC, was added a solution of 2-methoxycyclohexyl-1-one (0.15 mL, 1.1 mmol) in methanol
(0.6 mL) under argon atmosphere. The reaction mixture was stirred overnight at 60 ºC, and the crude
was washed with H2O  (5.5 mL) and  extracted  with Et2O. The organic phase was washed with 
saturated aqueous solutions of NaHCO3 and NaCl, dried over Na2SO4, and the solvent was removed 
under reduced pressure to obtain the title compound in quantitative yield. Chromatography: 
hexane/EtOAc, 7:3; oil. Rf (hexane/EtOAc, 7:3) 0.40. 1H NMR (300 MHz, CDCl3) 1.35-1.94 (m, 5H, 
2CH2, 1/2CH2), 2.03-2.14 (m, 2H, CH2), 3.01-3.05 (m, 1H, 1/2CH2), 3.27 (s, 3H, CH3), 3.75 (m, 1H, 
CH), 6.05 (br s, 1H, OH). MS (ESI): [(M+H)+] 143.9. The spectroscopic data are in agreement with 
those previously described.45 
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Synthesis of 1-{[(E)-(2-methoxycyclohexylidene)amino]oxy}bethanone (50). A solution of 
ketoxime 49 (166 mg, 1.2 mmol), pyridine (0.34 mL, 4.2 mmol) and acetic anhydride (0.68 mL, 7.2
mmol) was stirred overnight under argon atmosphere at rt. The solvent was removed under reduced
pressure and coevaporated with toluene to obtain the title compound in 85% yield. Chromatography: 
hexane/EtOAc, 7:3; oil. Rf (hexane/EtOAc, 7:3) 0.42. IR (ATR)  1769 (COO), 1702 (CN), 1193
(COC). 1H NMR (300 MHz, CDCl3) 1.34-1.70 (m, 5H, 2CH2, 1/2CH2), 1.73-2.02 (m, 2H, CH2), 2.07-
2.26 (m, 5H, CH2, CH3CO), 3.03-3.08 (m, 1H, 1/2CH2), 3.30 (s, 3H, OCH3), 3.95 (m, 1H, CH). 13C 
NMR (75 MHz, CDCl3)  19.3 (CH3 diastereomers), 19.4 (CH2 diastereomers), 19.4 (CH3
diastereomers), 19.6, 23.2, 25.5, 26.8, 28.0, 31.8, 32.7 (7CH2 diastereomers), 56.0, 56.2 (CH3
diastereomers), 70.1, 77.0 (CH diastereomers), 166.9, 167.4, 168.3, 168.5 (2C diastereomers). MS
(ESI): [(M-OCOCH3)+] 125.9. 
Synthesis of 6-methoxyhexanenitrile (51).46 A solution of 50 (120 mg, 0.7 mmol), 
trimethylsilane (0.12 mL, 0.8 mmol) and catalytic quantities of trimethylsilyl trifluoromethanesulfonate
(TMSOTf) (12 μL, 70.0 nmol) was stirred at 0 ºC for 6 h. Then, the solvent was removed under 
reduced pressure to give the title compound in 87% yield. Chromatography: hexane/EtOAc, 8:2; oil. 
Rf (hexane/EtOAc, 8:2) 0.33. IR (ATR) 2246 (CN), 1120 (CO). 1H NMR (300 MHz, CDCl3) 1.47-
1.75 (m, 6H, (CH2)3CH2CN), 2.36 (t, J = 7.1 Hz, 2H, CH2CN), 3.34 (s, 3H, CH3), 3.39 (t, J = 6.1 Hz,
2H, CH2O). 13C NMR (75 MHz, CDCl3)  17.3, 25.4, 25.6, 29.0 (4CH2), 58.8 (CH3), 72.3 (CH2), 119.8 
(C). MS (ESI): [(M-CH3+H)+] 113.0. 
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Synthesis of 6-methoxyhexyl-1-amine (52). To a solution of nitrile 51 (100 mg, 0.8 mmol) in 
anhydrous THF (1 mL) was added under argon atmosphere a solution of 1M BH3 in THF (3.2 mL,
3.2 mmol) and the mixture was stirred at reflux for 3.5 h. Once at rt, the reaction was quenched by 
slow addition of MeOH (1.8 mL) and concentrated HCl (0.2 mL), and the product was extracted with 
DCM, dried over Na2SO4, and the solvent was removed under reduced pressure. The title amine was 
obtained in 66% yield. Chromatography: EtOAc/MeOH, 9:1; oil. Rf (hexane/EtOAc, 1:1) 0.13. IR 
(ATR)  3332 (NH). 1H NMR (300 MHz, CDCl3) 1.34-1.49 (m, 4H, 2CH2), 1.56 (qt, J = 6.6 Hz, 2H,
CH2), 1.79 (qt, J = 7.4 Hz, 2H, CH2), 2.99 (t, J = 7.7 Hz, 2H, CH2N), 3.32 (s, 3H, CH3), 3.37 (t, J = 6.4
Hz, 2H, CH2O). 13C NMR (75 MHz, CDCl3)  25.7, 26.4, 27.6, 29.4, 40.0 (5CH2), 58.6 (CH3), 72.6
(CH2). MS (ESI): [(M+H)+] 132.0.
Synthesis of 2-[2-(2-ethoxyethoxy)ethyl]-1H-isoindol-1,3(2H)-dione (53). To a solution of 2-
(2-ethoxyethoxy)ethanol (0.5 mL, 3.7 mmol), phthalimide (549 mg, 3.7 mmol) and triphenylphosphine
(977 mg, 3.7 mmol) in anhydrous toluene (11 mL) was added, under argon atmosphere and at 0 ºC, 
DIAD (0.8 mL, 4 mmol). The reaction mixture was stirred at 0 ºC for 50 min and at rt for 1 h. Then, 
was added methanol (2.9 mL) and the mixture was stirred overnight at rt. Solvent was removed under 
reduced pressure and precipitate was washed with hexane, filtered and dried over Na2SO4, to obtain
the title compound in 58% yield. Chromatography: hexane/EtOAc, 7:3; oil. Rf (hexane/EtOAc, 7:3) 
0.22. 1H NMR (300 MHz, CDCl3) 1.13 (t, J = 7.0 Hz, 3H, CH3), 3.45 (q, J = 7.0 Hz, 2H, CH3CH2O), 
3.52-3.55 (m, 2H, CH2N), 3.62-3.65 (m, 2H, CH2O), 3.74 (t, J = 5.8 Hz, 2H, CH2O), 3.90 (t, J = 5.8
Hz, 2H, CH2O), 7.70 (m, 2H, 2H3), 7.84 (m, 2H, 2H2). MS (ESI): [(M+H)+] 264.0. The spectroscopic 
data are in agreement with those previously described.47 
Synthesis of 2-(2-ethoxyethoxy)ethylamine (54). To a solution of 53 (295 mg, 1.1 mmol) in dry 
methanol (4.9 mL) was added, under argon atmosphere, hydrazine (0.1 mL, 2.2 mmol) and  the  
reaction mixture was stirred for 2 h. Then, NaBH4 (42 mg, 1.1 mmol) and a second portion of 
hydrazine (0.1 mL, 2.2 mmol) were added and stirring was continued overnight at rt. The suspension
was filtered and the solvent was removed under reduced pressure. The residue was dissolved in
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EtOAc (20 mL), warmed to 50 °C, sonicated, and filtered. The filtrate was evaporated, redissolved in 
Et2O (20 mL), filtered, and the solvent was removed under reduced pressure to  afford the title  
compound as a yellowish oil in quantitative yield. Rf (EtOAc/MeOH, 9:1) 0.35. 1H NMR (300 MHz, 
CDCl3) 1.20 (t, J = 7.0 Hz, 3H, CH3), 1.95 (br s, 2H, NH2 ), 2.85 (t, J = 5.2 Hz, 2H, CH2N), 3.42-3.53 
(m, 4H, 2CH2O), 3.56-3.62 (m, 4H, 2CH2O). The spectroscopic data are in agreement with those
previously described.47 
Synthesis of 3-(2-methoxyethoxy)propanenitrile (55). A solution of 2-methoxyethanol (2 mL, 
26 mmol) in acrylonitrile (15 mL, 229 mmol) was stirred under argon atmosphere at 0 ºC for 10 min. 
Then, KOH (133 mg, 2.4 mmol) was added and the mixture was stirred at 0 ºC for 1.5 h. Four drops
of an aqueous solution of concentrated HCl were added and the solvent was removed under reduced 
pressure. The residue was dissolved in chloroform, filtered and the solvent was removed under 
reduced pressure to obtain the title nitrile as a colorless oil in 94% yield. Rf (hexane/EtOAc, 7:3) 0.28. 
1H NMR (300 MHz, CDCl3) 2.64 (t, J = 6.5 Hz, 2H, CH2CN), 3.40 (s, 3H, CH3), 3.55-3.58 (m, 2H, 
CH2O), 3.66-3.69 (m, 2H, CH2O), 3.73 (t, J = 6.5 Hz, 2H, CH2O). MS (ESI): [(M+H)+] 130.0. The
spectroscopic data are in agreement with those previously described.48 
Synthesis of 3-(2-methoxyethoxy)propyl-1-amine (56). To a solution of nitrile 55 (440 mg, 31.8
mmol) in anhydrous THF (41.6 mL) was added, dropwise and under argon atmosphere, a solution of 
1M BH3 in THF (7.7 mL, 7.7 mmol) and the mixture was stirred at reflux for 3.5 h. Once at rt, the
reaction was quenched by slow addition of MeOH (73 mL) and concentrated HCl (8 mL), the product 
was extracted with DCM, dried over Na2SO4, and the solvent was removed under reduced pressure
to obtain the title amine as an oil in 89% yield. Rf (hexane/EtOAc, 9:1) 0.25. 1H NMR (300 MHz, 
CDCl3) 1.74 (qt, J = 6.5 Hz, 2H, CH2CH2N), 2.78 (t, J = 6.8 Hz, 2H, CH2N), 3.38 (s, 3H, CH3), 3.52-
3.60 (m, 6H, 3CH2O). MS (ESI): [(M+H)+] 134.1. The spectroscopic data are in agreement with those
previously described.48 
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Synthesis of (oxetan-3-ylidene)acetonitrile (57). To a solution of oxetan-3-one (0.67 mL, 10.4 
mmol) in dry DCM (3 mL) was added, dropwise and under an argon atmosphere, a solution of 
Ph3P=CHCN (3.14 g, 10.4 mmol) in dry DCM (15 mL). The mixture was stirred for 6 h at rt, and the 
solvent was evaporated under reduced pressure. The residue was dissolved in hexane/Et2O (3:2), 
filtered over a plug of silica gel and washed with Et2O (2 x 50 mL). The solvents were removed under
reduced pressure to give the nitrile in 79% yield. Chromatography: hexane/EtOAc, 8:2; oil. Rf
(hexane/EtOAc, 7:3) 0.40. IR (ATR) 2218 (CN), 1690 (C=C). 1H NMR (300 MHz, CDCl3) 5.30 (m,
1H, CH), 5.25-5.28 (m, 2H, CH2O), 5.29-5.32 (m, 2H, CH2O). 
Synthesis of (3-pentyloxetan-3-yl)acetonitrile (58). To a suspension of CuI (200 mg, 1 mmol) 
in anhydrous Et2O (1 mL), pentylmagnesium bromide (2 M in Et2O, 1.3 mL) was added dropwise
under argon atmosphere. The mixture was cooled to 0 ºC before a solution of nitrile 57 (210 mg, 2.2 
mmol) in Et2O (4 mL) was added within 15 min. The reaction mixture was stirred at this temperature
for 2 h, quenched with saturated NH4Cl, and extracted with EtOAc (2 x 50 mL). The organic layers 
were washed with saturated aqueous solution of NaCl and dried over Na2SO4. The solvent was
removed under reduced pressure to give the title compound in 26% yield. Chromatography: 
hexane/EtOAc, 8:2; oil. Rf (hexane) 0.20. IR (ATR) 2245 (CN). 1H NMR (300 MHz, CDCl3) 0.84 
(t, J = 6.7 Hz, 3H, CH3), 1.16-1.29 (m, 6H, (CH2)3CH3), 1.74 (m, 2H, CH2C), 2.75 (s, 2H, CH2CN),
4.43 (d, J = 6.4 Hz, 2H, CH2O), 4.51 (d, J = 6.4 Hz, 2H, CH2O). 13C NMR (75 MHz, CDCl3)  14.0
(CH3), 22.5, 23.9, 25.0, 31.9, 35.7 (5CH2), 41.1 (C), 79.9 (2CH2), 118.3 (C).
Synthesis of 2-(3-pentyloxetan-3-yl)ethylamine (59). To a suspension of LAH (96 mg, 2.5 
mmol) in anhydrous Et2O, nitrile 58 (200 mg, 1.2 mmol) was added dropwise at 0º C and under argon
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atmosphere. The reaction was stirred for 2 h at this temperature and the crude was quenched by 
adding H2O (2.5 mL), NaOH 1 M (2.5 mL), and H2O (5 mL). The reaction mixture was extracted with 
EtOAc (2 x 50 mL) and the organic layers were washed with saturated aqueous solution of NaCl and 
dried over Na2SO4. Then, the solvent was removed under reduced pressure to obtain the amine as 
an oil in 59% yield. Rf (EtOAc/MeOH, 85:15) 0.10. IR (ATR) 3360 (NH). 1H NMR (300 MHz, CDCl3) 
0.90 (t, J = 6.7 Hz, 3H, CH3), 1.18-1.35 (m, 6H, (CH2)3CH3), 1.54 (br s, 2H, NH2), 1.65 (app t, J =
7.3, 2H, CH2C), 1.84 (app t, J = 8.1 Hz, 2H, CH2CH2N), 2.69 (t, J = 7.3 Hz, 2H, CH2N), 4.40 (AB 
system, J = 5.7 Hz, 4H, 2CH2O). 13C NMR (75 MHz, CDCl3)  14.1 (CH3), 22.6, 23.7, 31.0 (3CH2), 
32.3 (C), 34.3, 35.9, 41.5 (3CH2), 81.9 (2CH2). MS (ESI): [(M+H)+] 172.1. 
Synthesis of (4-ethylpiperazin-1-yl)acetonitrile (60).21 A mixture of 1-ethylpiperazine (0.7 mL,
5.4 mmol), bromoacetonitrile (0.43 mL, 6.0 mmol) and K2CO3 (1.7 g, 12 mmol) in anhidrous 
acetonitrile (0.5 mL/mmol) was stirred overnight at rt. The product was isolated by filtration with celite, 
washed with acetonitrile, and the solvent was evaporated under reduced pressure to give the title
compound as a pure orange oil in quantitative yield. Rf (EtOAc/MeOH, 8:2) 0.28. IR (ATR)  2231 
(CN). 1H NMR (300 MHz, CDCl3) 1.08 (t, J = 7.2 Hz, 3H, CH3), 2.42 (q, J = 7.2 Hz, 2H, CH3CH2), 
2.51 (m, 4H, 2CH2N), 2.64 (t, J =  4.6  Hz, 4H, 2CH2N),  3.50 (s, 2H, CH2CN). 13C NMR (75 MHz, 
CDCl3) 11.9 (CH3), 45.7 (CH2), 51.7 (2CH2), 52.0 (CH2), 52.1 (2CH2), 114.7 (C). MS (ESI): [(M+H)+] 
154.1.
Synthesis of (4-ethylpiperazin-1-yl)ethylamine (61).21 A mixture of nitrile 60 (465 mg, 3 mmol)
in THF (3 mL/mmol) was treated with LAH (242 mg, 6 mmol) at 0 ºC for 4 h. After completion, the
reaction was quenched with Na2SO4·10H2O (8.4 g, excess) and stirred for 30 min. The product was 
isolated by filtration with celite, washed with THF and dried under reduced pressure to give the title
compound as a pure orange oil in 86% yield. IR (ATR)  3311 (NH2). 1H NMR (300 MHz, CDCl3) 
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1.07 (t, J = 7.2 Hz, 3H, CH3), 2.36-2.48 (m, 12H, CH2CH3+4CH2N+CH2CH2NH2), 2.78 (t, J = 6.3 Hz,
4H, CH2NH2). 13C NMR (75 MHz, CDCl3) 12.1 (CH3), 38.9, 52.4 (2CH2), 52.9 (2CH2), 53.3 (2CH2), 
61.3 (CH2). MS (ESI): [(M+H)+] 158.2. 
General procedure A for the synthesis of symmetric diamides 3 and 17-25. To a solution of 
N-phenylacrylamide 33 (3 equiv) and the corresponding amine (1 equiv) in anhidrous acetonitrile (0.5
mL/mmol), was added DBU (3 equiv), and the reaction mixture was stirred 24 h at 60 ºC (except for 
24). The solvent was removed under reduced pressure and the crude was purified by column 
chromatography (EtOAc/MeOH) to obtain the title compounds as yellowish oils. 
N3-(3-Anilino-3-oxopropyl)-N1-phenyl-N3-octyl-β–alaninamide (3). Obtained following the
general procedure A for the synthesis of symmetric diamides from acrylamide 33 (500 mg, 3.4 mmol) 
and octylamine (0.18 mL, 1.1 mmol) in 83% yield. Chromatography: hexane/EtOAc, 1:1; oil. Rf
(hexane:EtOAc, 1:1) 0.45. IR (ATR)  3294 (NH), 1659 (CO), 1601, 1546, 1497 (Ar). 1H NMR (300
MHz, CDCl3)  0.85 (t, J = 6.7 Hz, 3H, CH3), 1.08 (m, 2H, CH2CH3), 1.19-1.25 (m, 8H, (CH2)4CH2CH3), 
1.52 (m, 2H, CH2(CH2)5CH3), 2.53 (t, J = 6.3 Hz, 6H, 2CH2CO, (CH2)6CH2N), 2.85 (t, J = 6.2 Hz, 4H, 
2NCH2CH2CO), 7.02 (t, J = 7.3 Hz, 2H, 2H4), 7.20 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.43 (d, J = 7.8 Hz,
4H, 2H2, 2H6), 8.90 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  14.0 (CH3), 22.6, 26.8, 27.7, 29.3,
29.5, 31.8 (6CH2), 34.5 (2CH2), 49.9 (2CH2), 53.7 (CH2), 119.9 (4CH), 124.0 (2CH), 128.9 (4CH),
138.1 (2C), 170.4 (2C). HRMS (ESI): [(M+H)+] calcd. for C26H38N3O2, 424.2959; found, 424.2959.
general procedure A for the synthesis of symmetric diamides from acrylamide 33 (500 mg, 3.4 mmol) 
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and methylamine (2 M solution in THF, 1.1 mmol) in 95% yield. Chromatography: DCM/MeOH, 95:5;
oil. Rf (DCM/MeOH, 95:5) 0.13; IR (ATR) 3298 (NH), 1660 (CO), 1600, 1547, 1497, 1443 (Ar). 1H 
NMR (300 MHz, CDCl3)  2.30 (s, 3H, CH3), 2.52 (t, J = 5.9 Hz, 4H, 2CH2CO), 2.75 (t, J = 5.9 Hz,
4H, 2CH2N), 7.01 (t, J = 7.2 Hz, 2H, 2H4), 7.17 (t, J = 7.6 Hz, 4H, 2H3, 2H5), 7.46 (d, J = 7.8 Hz, 4H, 
2H2, 2H6), 9.36 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  34.3 (2CH2), 41.3 (CH3), 53.0 (2CH2),
120.1 (4CH), 124.0 (2CH), 128.8 (4CH), 138.2 (2C), 170.5 (2C). HRMS (ESI): [(M+H)+] calcd. for 
C19H24N3O2, 326.1863; found, 326.1866.
N3-(3-Anilino-3-oxopropyl)-N3-hexyl-N1-phenyl-β-alaninamide (18). Obtained following the
general procedure A for the synthesis of symmetric diamides from acrylamide 33 (500 mg, 3.4 mmol) 
and hexylamine (111 mg, 1.1 mmol) in 76% yield. Chromatography: EtOAc/MeOH, 9:1; oil. Rf
(EtOAc/MeOH, 9:1) 0.21. IR (ATR)  3298 (NH), 1660 (CO), 1601, 1547, 1498, 1443 (Ar). 1H NMR
(300 MHz, CDCl3)  0.82 (t, J = 6.9 Hz, 3H, CH3), 1.20-1.28 (m, 6H, (CH2)3CH3), 1.50-1.54 (m, 2H, 
CH2(CH2)3CH3), 2.52 (t, J =  6.2 Hz, 6H, 2CH2CO, (CH2)4CH2N), 2.83 (t, J = 6.2  Hz, 4H,  
2NCH2CH2CO), 7.02 (t, J = 7.4 Hz, 2H, 2H4), 7.19 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 7.9 Hz,
4H, 2H2, 2H6), 9.08 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  14.4 (CH3), 23.0, 27.1, 27.7, 32.1
(4CH2), 34.7 (2CH2), 50.1 (2CH2), 54.0 (CH2), 120.2 (4CH), 124.4 (2CH), 129.3 (4CH), 138.5 (2C),
170.9 (2C). HRMS (ESI): [(M+H)+] calcd. for C24H34N3O2, 396.2646; found, 369.2648.
N3-(3-Anilino-3-oxopropyl)-N3-(3-butoxypropyl)-N1-phenyl-β-alaninamide (19). Obtained 
following the general procedure A for the synthesis of symmetric diamides from acrylamide 33 (336
mg, 2.3 mmol) and 3-butoxypropyl-1-amine (0.1 mL, 0.76 mmol) in 25% yield. Chromatography: 
EtOAc; oil. Rf (EtOAc) 0.30. IR (ATR) 3287 (NH), 1661 (CO), 1600, 1547, 1498, 1443 (Ar). 1H NMR
(300 MHz, CDCl3)  0.76 (t, J = 7.3 Hz, 3H, CH3), 1.10-1.37 (m, 4H, (CH2)2CH3), 1.64 (qt, J = 6.6 Hz,
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2H, NCH2CH2CH2O), 2.44-2.52 (m, 6H, 2CH2CO, NCH2(CH2)2O), 2.75 (t, J = 6.3 Hz, 4H,  
2NCH2CH2CO), 3.13 (t, J = 6.6 Hz, 2H, CH2O), 3.30 (t, J = 6.4 Hz, 2H, CH2O), 6.93 (t, J = 7.4 Hz,
2H, 2H4), 7.10 (t, J = 7.9 Hz, 4H, 2H3, 2H5), 7.37 (dd, J = 8.8, 1.0 Hz, 4H, 2H2, 2H6). 13C NMR (75
MHz, CDCl3)  14.4 (CH3), 20.4, 28.3, 32.9 (3CH2), 35.6 (2CH2), 51.2 (2CH2), 51.3, 69.8, 71.7 (3CH2),
121.3 (4CH), 125.1 (2CH), 129.8 (4CH), 139.7 (2C), 173.4 (2C). HRMS (ESI): [(M+Na)+] calcd. for
C25H35N3O3Na, 448.25761; found, 448.25641.
N3-[3-(Phenylamino)-3-oxopropyl]-N3-[6-(methoxyhexyl)]-N1-phenyl-β-alaninamide (20). 
Obtained following the general procedure A for the synthesis of symmetric diamides from acrylamide 
33 (168 mg, 1.1 mmol) and amine 52 (60 mg, 0.46 mmol) in 21% yield. Chromatography: 
EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH, 9:1) 0.42. IR (ATR) 3238 (NH), 1678, 1645 (CO), 1601, 
1548, 1495, 1443 (Ar). 1H NMR (300 MHz, CDCl3)  1.18-1.58 (m, 8H, OCH2(CH2)4), 2.51 (t, J = 7.1 
Hz, 2H, (CH2)5CH2N), 2.53 (t, J = 5.9 Hz, 4H, 2CH2CO), 2.83 (t, J = 6.1 Hz, 4H, 2NCH2CH2CO), 3.29-
3.33 (m, 5H, CH2OCH3), 7.02 (t, J = 7.4 Hz, 2H, 2H4), 7.18 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 
7.8 Hz, 4H, 2H2, 2H6), 9.20 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  25.9, 26.6, 27.2, 29.5 (4CH2), 
34.6 (2CH2), 50.0 (2CH2), 53.4 (CH2), 58.6 (CH3), 72.8 (CH2), 119.9 (4CH), 124.0 (2CH), 128.9 (4CH), 
138.3 (2C), 170.7 (2C). HRMS (ESI): [(M-H)-] calcd. for C25H34N3O3, 424.26001; found, 424.26106. 
N3-(3-Anilino-3-oxopropyl)-N3-[2-(2-ethoxyethoxy)ethyl]-N1-phenyl-β-alaninamide (21). 
Obtained following the general procedure A for the synthesis of symmetric diamides from acrylamide 
33 (332 mg, 2.3 mmol) and amine 54 (100 mg, 0.8 mmol) in 53% yield. Chromatography:
EtOAc/MeOH, 8:2; oil. Rf (EtOAc/MeOH, 9:1) 0.30. IR (ATR) 3303 (NH), 1660, 1547 (CO), 1601, 
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1496, 1443 (Ar). 1H NMR (300 MHz, CDCl3)  1.14 (t, J = 7.0 Hz, 3H, CH3), 2.53 (t, J = 6.0 Hz, 4H,
2CH2CO), 2.74 (t, J = 4.9 Hz, 2H, NCH2CH2O), 2.87 (t, J = 6.0 Hz, 4H, 2NCH2CH2CO), 3.44-3.49 (m, 
4H, NCH2CH2O, OCH2CH3), 3.54-3.59 (m, 4H, O(CH2)2O), 6.98 (t, J = 7.4 Hz, 2H, 2H4), 7.13 (t, J =
7.8 Hz, 4H, 2H3, 2H5), 7.43 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 9.24 (br s, 2H, 2NH). 13C NMR (75 MHz, 
CDCl3)  15.0 (CH3), 35.2 (2CH2), 51.4 (2CH2), 54.7, 66.6, 69.3, 69.6, 70.3 (5CH2), 120.0 (4CH), 
123.8 (2CH), 128.7 (4CH), 138.3 (2C), 171.0 (2C). HRMS (ESI): [(M+Na)+] calcd. for C24H33N3O4Na,
450.23688; found, 450.23663. 
33 (332 mg, 2.3 mmol) and amine 56 (100 mg, 0.8 mmol) in 39% yield. Chromatography:
EtOAc/MeOH, 8:2; oil. Rf (EtOAc/MeOH, 9:1) 0.29. IR (ATR) 3305 (NH), 1662, 1545 (CO), 1600, 
1497, 1443 (Ar). 1H NMR (300 MHz, CDCl3)  1.59 (qt, J = 5.7 Hz, 2H, NCH2CH2CH2O), 2.51 (app t,
4H, 2CH2CO), 2.54 (t, J = 5.4 Hz, 2H, NCH2CH2CH2O), 2.75 (t, J = 5.4 Hz, 4H, NCH2CH2CO), 3.28 
(t, J = 5.5 Hz, 2H, NCH2CH2CH2O), 3.39-3.42 (m, 2H, OCH2CH2O), 3.45 (s, 3H, CH3), 3.60-3.63 (m,
2H, OCH2CH2O), 6.98 (t, J = 7.3 Hz, 2H, 2H4), 7.11 (t, J = 7.7 Hz, 4H, 2H3, 2H5), 7.39 (d, J = 8.1 Hz,
4H, 2H2, 2H6), 8.89 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  27.1 (CH2), 35.5 (2CH2), 49.3 (CH2),
50.6 (2CH2), 58.9 (CH3), 67.2, 69.4, 72.5 (3CH2), 119.8 (4CH), 123.6 (2CH), 128.7 (4CH), 138.4 (2C),
171.9 (2C). HRMS (ESI): [(M+H)+] calcd. for C24H34N3O4, 428.25493; found, 428.25429. 
N3-(3-Anilino-3-oxopropyl)-N3-[3-(2-methoxyethoxy)propyl]-N1-phenyl-β-alaninamide (22). 
Obtained following the general procedure A for the synthesis of symmetric diamides from acrylamide 
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N3-(3-Anilino-3-oxopropyl)-N3-[(3-pentyloxetan-3-yl)ethyl]-N1-phenyl-β-alaninamide (23). 
Obtained following the general procedure A for the synthesis of symmetric diamides from acrylamide 
33 (275 mg, 1.9 mmol) and amine 59 (98 mg, 0.62 mmol) in 21% yield. Chromatography: 
EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH, 95:5) 0.60. IR (ATR) 3304 (NH), 1657 (CO), 1598, 1542, 
1498, 1442 (Ar). 1H NMR (300 MHz, CDCl3)  0.88 (t, J = 7.1 Hz, 3H, CH3), 1.15-1.31 (m, 6H, 
(CH2)3CH3), 1.56 (app t, J = 7.3 Hz, 2H, CH2C), 1.78 (t, J = 7.1 Hz, 2H, CCH2CH2N), 2.56 (t, J = 5.8
Hz, 4H, 2CH2CO), 2.63 (t, J = 7.1 Hz, 2H, CCH2CH2N), 2.87 (t, J = 5.8 Hz, 4H, 2NCH2CH2CO), 4.30 
(d, J = 5.9 Hz, 2H, CH2O), 4.45 (d, J = 5.9 Hz, 2H, CH2O), 7.02 (t, J = 7.5 Hz, 2H, 2H4), 7.16 (t, J = 
7.5 Hz, 4H, 2H3, 2H5), 7.38 (d, J = 8.1 Hz, 4H, 2H2, 2H6), 8.63 (br s, 2H, 2NH). 13C NMR (75 MHz, 
CDCl3)  14.1 (CH3), 22.6, 23.8, 31.6, 32.2 (4CH2), 35.1 (2CH2), 36.9 (CH2), 41.4 (C), 49.2 (CH2), 
50.1 (2CH2), 80.9 (2CH2), 119.8 (4CH), 124.0 (2CH), 128.8 (4CH), 138.0 (2C), 170.6 (2C). HRMS 
(ESI): [(M+H)+] calcd. for C28H39N3O2, 466.3025; found, 466.3050.
N3-(3-Anilino-3-oxopropyl)-N3-cyclopropyl-N1-phenyl-β-alaninamide (24). Obtained following
the general procedure A for the synthesis of symmetric diamides from acrylamide 33 (100 mg, 0.7 
mmol) and cyclopropylamine (16 μL, 0.2 mmol) at 45 ºC in 27% yield. Chromatography:
EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH, 9:1) 0.51. IR (ATR)  3296 (NH), 1659 (CO), 1598, 1546, 
1498, 1443 (Ar). 1H NMR (300 MHz, CDCl3) 0.50-0.55 (m, 2H, CH2cyc), 0.58-0.61 (m, 2H, CH2cyc), 
1.78-1.83 (m, 1H, CHcyc), 2.63 (t, J = 6.2 Hz, 4H, 2CH2CO), 3.02 (t, J = 6.2 Hz, 4H, 2CH2N), 7.03 (t, 
J = 7.4 Hz, 2H, 2H4), 7.19 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.41 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 8.70 (br s, 
2H, 2NH). 13C NMR (75 MHz, CDCl3)  6.9 (2CH2), 34.5 (2CH2), 37.2 (CH), 51.7 (2CH2), 119.6 (4CH), 
124.1 (2CH), 129.0 (4CH), 138.1 (2C), 170.6 (2C). HRMS (ESI): [(M+Na)+] calcd. for C21H25N3O2Na:
374.18445; found, 374.17157. 
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N3-(3-Anilino-3-oxopropyl)-N3-(cyclopropylmethyl)-N1-phenyl-β-alaninamide (25). Obtained
following the general procedure A for the synthesis of symmetric diamides from acrylamide 33 (100
mg, 0.7 mmol) and aminomethylcyclopropane (0.02 mL, 0.2 mmol) in quantitative yield.
Chromatography: EtOAc/MeOH, 9:1; oil. Rf (EtOAc/MeOH, 9:1) 0.42. IR (ATR)  3306 (NH), 1658
(CO), 1599, 1548, 1498, 1444 (Ar). 1H NMR (300 MHz, CDCl3) 0.13 (q, J = 5.0 Hz, 2H, CH2cyc), 
0.49-0.55 (m, 2H, CH2cyc), 0.88-0.94 (m, 1H, CHcyc), 2.43 (d, J = 6.7 Hz, 2H, CHCH2N), 2.52 (t, J =
6.3 Hz, 4H, 2CH2CO), 2.90 (t, J = 6.3 Hz, 4H, 2NCH2CH2CO), 7.01 (t, J = 7.4 Hz, 2H, 2H4), 7.18 (t, 
J = 7.8 Hz, 4H, 2H3, 2H5), 7.46 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 9.53 (br s, 2H, 2NH). 13C NMR (75 MHz, 
CDCl3)  4.3 (2CH2), 8.6 (CH), 34.3 (2CH2), 49.7 (2CH2), 58.5 (CH2), 119.9 (4CH), 124.1 (2CH), 128.9 
(4CH), 138.3 (2C), 170.7 (2C). HRMS (ESI): [(M+Na)+] calcd. for C22H27N3O2Na: 388.20010; found, 
388.19619.
2.2 mmol), and the mixture was stirred overnight at rt. The solvent was removed under reduced 
pressure, and the residue was dissolved in DCM, washed in saturated aqueous solutions of NaHCO3
and NaCl, dried over Na2SO4, and the solvent removed under reduced pressure to give final
compound 16 in 15% yield. Chromatography: EtOAc/MeOH 95:5; oil. Rf (DCM/MeOH, 95:5) 0.18. IR 
(ATR) 3285 (NH), 1733 (CO), 1668, 1602 (Ar).1H NMR (300 MHz, CDCl3) 2.59 (t, J = 6.3 Hz, 4H,
2CH2CO), 2.89 (t, J = 6.3 Hz, 4H, 2CH2N), 6.97 (t, J = 7.4 Hz, 2H, 2H4), 7.10 (t, J = 7.7 Hz, 4H, 2H3, 
2H5), 7.37 (d, J = 7.7 Hz, 4H, 2H2, 2H6). 13C NMR (75 MHz, CDCl3) 35.6 (2CH2), 50.9 (2CH2), 121.5
(4CH), 125.0 (2CH), 129.7 (4CH), 139.5 (2C), 173.3 (2C). HRMS (ESI): [(M+H)+] calcd. for
C18H22N3O2: 312.1706; found, 312.1706.
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Synthesis of N3-(3-anilino-3-oxopropyl)-N1-phenyl-β-alaninamide (16). To a solution of 48
(500 mg, 2.2 mmol) in anhydrous DCM (4 mL) was added a 2 M solution of NH3 in methanol (1.1 mL, 
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General procedure B for the synthesis of symmetric diamides 26 and 27. To a solution of 3-
bromo-N-phenylpropanamide 48 (3 equiv) and the corresponding amine (1 equiv) in DCM (0.5
mL/mmol), was added triethylamine (2.5 equiv) and 10% of KI, and the reaction mixture was stirred 
24 h at 60 ºC. The solvent was removed under reduced pressure and the crude was purified by 
column chromatography (EtOAc/MeOH/NH3) to give the title compounds as colorless oils.
N3-(3-Anilino-3-oxopropyl)-N3-[2-(4-ethylpiperidin-1-yl)ethyl]-N1-phenyl-β-alaninamide (26). 
Obtained following the general procedure B for the synthesis of symmetric diamides from 48 (185
mg, 0.8 mmol) and 2-(4-ethylpiperidin-1-yl)ethanamine (42 mg, 0.3 mmol) in 48% yield.
Chromatography: EtOAc/MeOH/NH3, 9:1:0.2; oil. Rf (EtOAc/MeOH/NH3, 9:1:0.2) 0.43. IR (ATR) 
3310 (NH), 1675 (CO), 1602, 1551, 1498, 1445 (Ar). 1H NMR (300 MHz, CDCl3) 0.76 (t, J = 7.3
Hz, 3H, CH3), 1.04-1.12 (m, 5H, CH2CH3+CH+2x1/2CH2cyc), 1.48 (d, J = 11.2 Hz, 2H, 2x1/2CH2cyc), 
1.92 (t, J = 11.1 Hz, 2H, 2x1/2CH2cycN), 2.52-2.54 (m, 6H, NcycCH2CH2N+ 2CH2CO), 2.71 (t, J = 6.1
Hz, 2H, NcycCH2CH2N), 2.85 (t, J =  6.0 Hz, 4H, 2NCH2CH2CO), 2.95 (d, J = 11.3 Hz, 2H, 
2x1/2CH2cycN), 7.01 (t, J = 7.4 Hz, 2H, 2H4), 7.17 (t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 7.9 Hz,
4H, 2H2, 2H6), 8.84 (br s, 2H, 2NH). 13C NMR (75 MHz, CDCl3)  14.3 (CH3), 29.2 (CH2), 31.6 (2CH2),
35.2 (2CH2), 37.3 (CH), 50.8 (2CH2), 51.5 (CH2), 54.9 (2CH2), 56.8 (CH2), 120.2 (4CH), 124.1 (2CH),
128.9 (4CH), 138.2 (2C), 170.8 (2C). HRMS (ESI): [(M+H)+] calcd. for C27H39N4O2: 451.30730; found, 
451.30714.
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N3-(3-Anilino-3-oxopropyl)-N3-[2-(4-ethylpiperazin-1-yl)ethyl]-N1-phenyl-β-alaninamide 
(27). Obtained following the general procedure B for the synthesis of symmetric diamides from 48
(218 mg, 0.9 mmol) and amine 61 (50 mg, 0.3 mmol) in 54% yield. Chromatography: 
EtOAc/MeOH/NH3, 7:3:0.2. Mp 70-72 ºC. Rf (EtOAc/MeOH/NH3, 8:2:0.2) 0.22. IR (ATR) 3276 (NH), 
1664 (CO), 1601, 1548, 1498, 1445 (Ar). 1H NMR (300 MHz, CDCl3) 0.96 (t, J = 7.2 Hz, 3H, CH3), 
2.23 (q, J = 7.2 Hz, 2H, CH2CH3), 2.19-2.53 (m, 14H, 2CH2CO+4CH2cyc+NcycCH2CH2N), 2.64 (t, J =
5.9 Hz, 2H, NcycCH2CH2N), 2.80 (t, J = 6.1 Hz, 4H, 2NCH2CH2CO), 7.00 (t, J = 7.4 Hz, 2H, 2H4), 7.16
(t, J = 7.8 Hz, 4H, 2H3, 2H5), 7.44 (d, J = 7.7 Hz, 4H, 2H2, 2H6), 9.24 (br s, 2H, 2NH). 13C NMR (75 
MHz, CDCl3) 11.9 (CH3), 34.8 (2CH2), 50.6 (2CH2), 50.8, 52.2 (2CH2), 52.4 (2CH2), 53.8 (2CH2),
56.3 (CH2), 120.3 (4CH), 124.1 (2CH), 128.9 (4CH), 138.3 (2C), 170.7 (2C). HRMS (ESI): [(M+H)+] 
calcd. for C26H38N5O2: 452.30255; found, 452.30104. 
4.1.3. Synthesis of cysmethynil 
Synthesis of N-[(5-bromo-1H-indol-3-yl)methyl]-N,N-dimethylamine (64). To a solution of 1,4-
dioxane (10.4 mL) and acetic acid (10.4 mL), were added sequentially at 0 ºC, formaldehyde (0.8
mL, 11.1 mmol), H2O (0.8 mL), NHMe2 (1.4 mL, 11.1 mmol), and 5-bromoindole (2 g, 10.1 mmol) 
previously solved in 10.4 mL of 1,4-dioxane. The reaction mixture was stirred at 0 ºC for 2 h after
which time it was removed from the ice bath and allowed to stir overnight at rt. Then, the reaction 
crude was diluted with H2O (130 ml), and active charcoal (0.6 g) and celite (0.6 g) were added. The
mixture was stirred for 10 min, filtered, and a 20% solution of NaOH (200 mL) was added to the filtrate 
to precipitate it. The resulting precipitate was filtered in vacuo, washed with H2O (3 x 50 mL), and 
dried under reduced pressure to give a white solid in 83% yield. Mp 149-150 ºC (Lit.16 149-152 ºC).
1H NMR (300 MHz, CDCl3) 2.27 (s, 6H, 2CH3), 3.57 (s, 2H, CH2), 7.06 (d, J = 2.0 Hz, 1H, CHAr),
7.20-7.29 (m, 2H, 2CHAr), 7.84 (d, J = 0.8 Hz, 1H, CHAr), 8.24 (br s, 1H, NH). The spectroscopic data
are in agreement with those previously described.16 
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Synthesis of (5-bromo-1H-indol-3-yl)acetonitrile (65). To a solution of Me2SO4 (7.6 mL, 39.5
mmol) in THF (5.4 mL) and acetic acid (0.16 mL) under argon atmosphere, was added dropwise the
bromoindol 64 (2 g, 7.9 mmol), previously solved in THF (13.8 mL) and acetic acid (0.16 mL). The
reaction mixture was stirred for 1 h at 10 ºC, and the crude was filtered in vacuo, washed with Et2O 
and dried under reduced pressure. Then, the precipitate was solved in a solution of KCN (1.5 g, 23.7
mmol) in H2O (20 mL); and the mixture was stirred vigorously for 1 h at 60-70 ºC, and then allowed 
to cool down to rt. The product was extracted with Et2O (2 x 50 mL) and dried under reduced pressure 
to give a pale solid in 95% yield. Mp 100-101 ºC (Lit.16 100-102 ºC). 1H NMR (300 MHz, CDCl3) 3.80 
(s, 2H, CH2), 7.23-76 (m, 3H, 3CHAr), 7.75 (s, 1H, CHAr), 8.23 (br s, 1H, NH). The spectroscopic data 
are in agreement with those previously described.16 
Synthesis of 2-(5-bromo-1H-indol-3-yl)acetamide (66). To a solution of nitrile 65 (1.77 g, 7.53
mmol) refluxed in t-BuOH (16 mL), was added under argon atmosphere KOH (3.98 g, 60.2 mmol),
and the reaction mixture was stirred at reflux for 1.5 h. Then, the reaction crude was cooled down to 
rt, diluted with H2O (16 mL), and acidified with 1N HCl (65 mL) in order precipitate the product as a
brown solid. The resulting suspension was filtered, washed with H2O (16 ml) and dried under reduced 
pressure to give the title compound in 74% yield. 1H NMR (300 MHz, DMSO-d6) 3.44 (s, 2H, CH2), 
6.86 (s, 1H, CHAr), 7.15-7.38 (m, 4H, 2CHAr+NH2), 7.73 (s, 1H, CHAr), 11.08 (br s, 1H, NH). The 
spectroscopic data are in agreement with those previously described.16 
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2-[5-(3-methylphenyl-1H-indol-3-yl]acetamideSynthesis of (67). To a suspension of
bromoindole 66 (1.36 g, 5.37 mmol) in anhydrous toluene (107 ml) was added Pd(PPh3)4 (0.35 g, 
0.31 mmol) and the reaction mixture was stirred for 1 h at rt under argon atmosphere. Hence, were
added a solution of m-tolylboronic acid (1.13 g, 8 mmol) in ethanol (20 mL), and a saturated aqueous 
solution of NaHCO3 (50 mL). The mixture was refluxed overnight, the reaction crude was washed
with saturated aqueous solution of NaCl (2 x 50 mL), and the organic fraction was extracted with 
EtOAc (3 x 100 mL), dried over Na2SO4, and the solvent was removed under reduced pressure. The 
product appeared as a yellow solid in 23% yield. Chromatography: DCM/MeOH, 1:1. 1H NMR (300 
MHz, CDCl3)  2.40 (s, 3H, CH3), 3.70 (s, 2H, CH2), 5.49 (br s, 1H, NH), 5.62 (br s, 1H, NH), 7.05-
7.42 (m, 7H, 7CHAr), 7.68 (s, 1H, CHAr), 8.23 (br s, 1H, NH). The spectroscopic data are in agreement
with those previously described.16 
Synthesis of 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil). To a 
suspension of NaH (25 g, 0.63 mmol) in DMF (0.8 mL) was added dropwise indol 67 (139 mg, 0,53 
mmol) in DMF (1.1 mL) and the mixture was stirred for 1.5 h at rt under argon atmosphere. Then 1-
bromooctane (309 mg, 1.6 mmol) was added dropwise and the reaction was stirred overnight at 55 
ºC. The reaction crude was poured into ice water (23 mL) and was stirred for 10 min. The product
was extracted with Et2O (6 x 10mL), washed with saturated aqueous solution of NaCl (4 x 15 mL), 
and dried over Na2SO4. The solvent was evaporated under reduced pressure to give the title
compound as a yellowish oil in 43% yield. Chromatography: DCM/MeOH, 95:5; oil. 1H NMR (300 
MHz, CDCl3) 0.85 (t, J = 6.7 Hz, 3H, CH3CH2), 1.25-1.34 (m, 10H, (CH2)5CH3), 1.86 (m, 2H, 
CH2(CH2)5CH3), 2.44 (s, 3H, CH3C), 3.76 (s, 2H, CH2CO), 4.11 (t, J = 7.1 Hz, 2H, (CH2)6CH2N), 5.60
(br s, 1H, NH), 5.71 (br s, 1H, NH), 7.08 (s, 1H, CHAr), 7.14 (d, J = 7.1 Hz, 1H, CHAr), 7.31-7.53 (m,
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5H, 5CHAr), 7.76 (s, 1H, CHAr). HRMS (ESI): [(M+Na)+] calcd. for C25H32N2ONa, 399.24123; found, 
399.24078.
4.2. Biological experiments
4.2.1. ICMT activity assay. ICMT activity was determined as previously described49 with slight 
modifications. Briefly, membranes that overexpress ICMT enzyme were incubated in the presence of
the corresponding concentration of the compound under study in assay buffer (100 mM Hepes, 5 mM 
MgCl2, pH 7.4) for 10 min, with shaking, at rt. Then, BFC and [3H]-SAMt were added at final 
concentrations of 5 and 2 μM, respectively (final volume 45 μL). Reactions were carried out for 30
min at 37 ºC after which they were terminated by addition of 5 μL of 10% Tween 20 in phosphate
buffered saline (PBS). Then, the reaction mixture was transferred to a 96-well plate containing
streptavidin beads (10 μL of packed beads, Thermofisher, suspended in 500 μL of PBS), and mixed
by gentle shaking overnight at 4 °C. Finally, the radioactivity bound to the beads was counted in a
Microbeta TopCount instrument (Perkin-Elmer). The percentage of inhibition was determined with 
respect to the 100% activity obtained in the absence of compounds. For the determination of IC50
values, the percentage of ICMT activity was plotted against log concentration of the compound on
GraphPad Prism (Version 5.0, GraphPad Software, San Diego, CA). In all cases, the reported data 
corresponded to the average obtained from three independent experiments carried out in duplicate. 
4.2.2. Cell lines and culture. MDA-MB-231, MIA PaCa-2, PANC-1, SW620, MCF7, SK-Mel-28, 
NIH3T3, AD-293, and U2OS cells from American Type Culture Collection (ATCC, Rockville, MD) and 
142BR fibroblasts from Sigma-Aldrich, were grown in Dulbecco’s Modified Eagle medium (DMEM, 
Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone), 1% L-
glutamine (Invitrogen), 1% sodium pyruvate (Invitrogen), 50 U/mL penicillin and 50 μg/mL
streptomycin (Invitrogen). BxPC-3 and PC-3 cells were obtained from ATCC and maintained in 
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% heat-inactivated FBS, 1% 
L-glutamine, 1% sodium pyruvate, 50 U/mL penicillin, and 50 μg/mL streptomycin. Cells were
incubated in a humidified atmosphere at 37 ºC in the presence of 5% of CO2. 
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4.2.3. MTT citotoxicity assay. The sensitivity of MDA-MB-23, MIA PaCa-2, PANC-1, SW620,
BxPC-3, PC-3, MCF7, SK-Mel-28, NIH3T3, and 142BR cell lines to compounds was tested through
a standard MTT assay. Briefly, cells were seeded in 96-well plates at a density of 5 or 10 x 103 cells 
per well in the corresponding medium with 10% FBS for 24 h prior to treatments. The medium was
then replaced by fresh medium containing different concentrations of compounds or the equivalent 
volume of DMSO. Cells were treated for 48 h, when medium was replaced by fresh medium with 2
mg/mL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich) and
cells were incubated for 4 h at 37 ºC in the dark. Once supernatants were removed, formazan crystals 
previously formed by viable cells were dissolved in DMSO (100 μL/well) and absorbance was
measured at 570 nm (OD570-630) using an Asys UVM 340 microplate reader (Biochrom Ltd., 
Cambridge, UK). Background absorbance from blank wells containing only media with compound or 
vehicle were substracted from each test well. For the determination of the IC50 values, the percentage
of absorbance was plotted against log concentration of the compound on GraphPad Prism (Version 
5.0, GraphPad Software, San Diego, CA). Results were reported as IC50 from three independent 
experiments carried out in triplicate.
4.2.4. Serum stability assay. To 900 µL of mouse serum (Europa Bioproducts) previously 
warmed at 37 ºC, were added 300 µL of a 2 mM solution of the compound in phosphate buffered
saline (PBS), and the mixture was incubated at 37 ºC for different times (0, 5, 10, 20, 40 and 60 min). 
Then, 200 µL of each mixture were added over 200 µL of cold acetonitrile, mixed, and incubated for
10 min on ice to precipitate proteins. Supernatants were separated by centrifugation at 39000g for
10 min, filtered (0.22 µm); and 50 µL of each filtered supernatant were analyzed by HPLC-MS in an
spectrometer Agilent 1200LC-MSD VL, using a column Eclipse XDB-C18 (5 µm, 4.6 mm x 150 mm) 
together with a guard column (5 µm, 4.6 mm x 12.5 mm). The gradient mobile phases consisted of A
(95:5 water/MeOH) and B (5:95 water/MeOH), with 0.1% ammonium hydroxide and 0.1% formic acid
as the solvent modifiers. In all cases, a constant flow of 0.5 mL/min was used for a total time of 15 
min. MS analysis was performed with an ESI source. The capillary voltage was set to 3.0 kV and the 
fragmentor voltage was set at 70 eV. The drying gas temperature was 350 ºC, the drying gas flow 
was 10 L/min, and the nebulizer pressure was 20 psi.  
4.2.5. Intracellular imaging of endogenous pan-Ras in PC-3 fixed cells. PC-3 cells were
seeded at a density of 2 x 104 cells per well on 12-mm coverslips previously treated with poly-D-
lysine hydrobromide (Sigma-Aldrich) and grown for 24 h at 37 ºC and 5 % of CO2 in RPMI medium
with 10% FBS. Medium was replaced with fresh medium with the indicated concentrations of 
compounds or DMSO and cells were incubated for 96 h, replacing the medium after the first 48 h. 
Cells were washed twice with PBS, fixed with 4% paraformaldehyde (Sigma-Aldrich) and
permeabilized with PBS-T (PBS with 0.1% Triton X-100, Sigma-Aldrich). Incubation with primary
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antibody mouse anti-Ras (1:200, Thermo Scientific) in PBS with 4% normal goat serum (NGS) was
performed at rt with gentle shaking for 2 h. Then, cells were washed twice with PBS-T and incubated
for 1 h in the dark with Alexa Fluor 488 goat anti-mouse (1:1500, Life Technologies) diluted in PBS 
with 1% NGS. Afterwards cells were washed twice with PBS-T and incubated with 5 µg/mL Hoechst 
33258 (Sigma-Aldrich) in PBS for 10 min at rt to visualize cell nuclei. Finally, cells were washed thrice 
with PBS-T and coverslips were carefully mounted with Immumount (Thermo Scientific). Visualization
was performed using an Olympus IX83 inverted confocal microscope fitted with the appropriate
excitation and emission filters and a 60X oil immersion objective. Images shown are representative 
of three to five independent experiments. 
4.2.6. Plasmid constructs. The coding sequences of K-Ras4A, K-Ras4B, N-Ras and H-Ras 
cDNAs were amplified by polymerase chain reaction (PCR) and cloned in-frame into pEGFPC1
(Clontech, Mountain View, CA), producing a fusion between the Ras proteins and a monomeric form
of green fluorescent protein (GFP), as previously described.50 Point mutation in CAAX motif in order
to obtain the K-Ras-CVIL-GFP plasmid was generated by PCR with primers incorporating the desired
mutation, and the resulting DNA was cloned into pEGFP-C3 (BD Biosciences Clontech, PaloAlto, 
CA).29 The coding sequence of LC-3 was amplified by PCR and cloned in-frame into mCherry 
(Clontech, Mountain View, CA).51 All plasmid constructs were verified by bidirectional DNA
sequencing.
4.2.7. Transfection of cells and live cell imaging. AD-293 and U2OS cells were seeded at 2 x
105 cells in 35-mm plastic dishes with a 1-cm round glass coverslip (MatTek, Ashland, MA) 24 h 
before transfection. Transient transfections were performed with Lipofectamine Plus (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. In all cases, 2 µg of DNA total was used
for each 35-mm dish. After 4 h of incubation at 37 ºC, media was replaced by fresh DMEM 
supplemented with 10% FBS containing 5 µM cysmethynil, UCM-1336 or an equivalent volume of 
DMSO, and incubated overnight. Live cells were imaged the next day with an inverted Zeiss LSM 
510 Meta laser scanning confocal microscope (63 Plan-Neofluar 1.25-numerical-aperture oil).  
4.2.8. Active Ras pulldown assay. PC-3 cells were plated at a density of 2 x 106 cells in 15-cm 
dishes and grown in RPMI medium with 10% FBS at 37 ºC and 5% of CO2. After 24 h, medium was 
replaced by fresh medium with 25 µM cysmethynil, 10 µM UCM-1336 or an equivalent volume of 
DMSO for vehicle control, and cells were incubated for 48 h at 37 ºC and 5% of CO2. At this point, 
medium was replaced once again by fresh medium with compounds or DMSO, and the incubation
was kept for additional 48 h. After 5 min of stimulation with EGF (10 ng/mL), cells were washed with 
PBS and lysed with ice-cold lysis buffer provided by the manufacturer. Lysates were clarified by 
centrifugation at 16000g for 15 min and protein concentration was measured using bicinchoninic acid 
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method (Thermo Scientific). Before performing the assay, 50 µL of each lysate were separated to 
analyze the total Ras expression. For the analysis of active Ras, a Ras-GTP pulldown assay kit 
(Thermo Scientific) was used following manufacturer’s instructions. Briefly, lysates were incubated 
with a glutathione S-transferase fusion of the RBD of Raf1 along with glutathione agarose resin to
pull down active Ras. The entire samples obtained after the pulldown assay were boiled for 5 min
and loaded onto 4-20% SDS-PAGE gels (Bio-Rad). Ras proteins were visualized by immunoblotting 
on nitrocellulose membranes using a mouse anti-Ras antibody provided by the manufacturer. Blots 
were analyzed by densitometry using ImageJ software (NIH). Data from four independent 
experiments were presented as mean ± SEM with bar graphs. 
4.2.9. Western blot analysis. PC-3 cells were plated at a density of 2 x 106 cells in 15-cm dishes 
and allowed to grow for 24 h in RPMI medium with 10% FBS, to obtain a 80% confluent monolayer. 
The medium was then replaced by fresh RPMI with 10 µM cysmethynil or UCM-1336, or an equivalent 
volume of DMSO, and cells were incubated overnight, except for LC-3 and PARP immunoblots, 
where the incubation times were prolonged up to 48 h following previously described results.25 Five
minutes prior to lysis, cells were stimulated with EGF (10 ng/mL). Cells were washed with PBS and 
lysed with ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Igepal) containing
protease and phosphatase inhibitors (Roche and Sigma-Aldrich, respectively). Lysates were clarified
by centrifugation at 16000g for 10 min at 4 ºC and used immediately or stored at -80 ºC until use. 
Protein concentration was measured (DC Protein Assay Kit, Bio-Rad) and samples with equal 
amounts of total protein were diluted into a Laemmli reducing sample buffer (Bio-Rad) and denatured
at 95 ºC for 5 min. Samples were then resolved on 4-20% SDS-PAGE gels (Bio-Rad) and proteins 
transferred to nitrocellulose membranes (GE Healthcare, Amersham). After 1 h of incubation in a
blocking buffer [10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween-20 (TBS-T) with 1% BSA],
membranes were incubated overnight at 4 ºC with the corresponding primary antibody. Then, 
membranes were washed three times (5 min each) with TBS-T and incubated with the corresponding
secondary antibody for 1 h at rt. Protein bands were visualized using enhanced chemiluminescence 
detection reagents (GE Healthcare, Amersham) in a Fujifilm LAS-3000 developer (Tokyo, Japan) and 
quantified by densitometry using ImageJ software (NIH). 
Primary antibodies used were rabbit anti-phospho-AKT, rabbit anti-AKT, rabbit anti-phospho-
ERK1/2, rabbit anti-ERK1/2, rabbit anti-phospho-MEK1/2, rabbit anti-MEK1/2, rabbit anti-PARP, 
rabbit anti-α/β tubulin (1:1000, Cell Signalling), rabbit anti-LC-3 (1:1000, Abgent), or mouse anti-Ras
(1:1000, Thermo Scientific). Secondary antibodies used were goat anti-mouse or goat anti-rabbit IgG
HRP conjugates (1:5000, Sigma-Aldrich). Relative phosphorylation levels from at least three 
independent experiments performed in triplicate were presented as mean ± SEM with bar graphs.  
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4.2.10. Migration or wound healing assay. MDA-MB-231 cells were seeded in 96-well plates at 
a density of 1.5 x 104 cells per well in DMEM with 10% FBS for 24 h at 37 ºC and 5% of CO2 to a 90-
100% confluent monolayer. Wounds were made with a sterile p20 pipette tip and each well was
washed twice with PBS to eliminate non adherent cells and cell debris. Fresh DMEM with indicated
concentrations of cysmethynil or UCM-1336, or with an equivalent volume of DMSO was then added.
At this time (0 h) and after 48 h, cells were photographed under phase contrast with an Olympus 
FW1200 microscope. Empty area in each wound was quantified using ImageJ software (NIH) and 
compared with the corresponding initial wound. Percentage of the areas from three independent 
experiments performed in triplicate was presented as mean ± SEM with bar graphs.  
4.2.11. Caspase 3 enzyme activity assay. PC-3 cells were seeded at 5 x 104 cells per well in a
24-well plate and grown for 24 h before treatments in RPMI medium with 10% FBS. The medium was
then replaced by fresh RPMI with 10 µM cysmethynil or UCM-1336, or an equivalent volume of
DMSO, and cells were incubated for 48 h. After this time, cells were washed with ice-cold PBS, 
counted and harvested by centrifugation at 400g for 5 min. The activity of caspase 3 was determined
by a caspase colorimetric assay kit (Clontech, Mountain View, CA), according to the manufacturer's 
protocol. Briefly, the protease activity was tested using a caspase 3 specific peptide, conjugated to 
the color reporter molecule p-nitroaniline (p-NA). The chromophore p-NA, cleaved by caspase 3, was 
quantified with a spectrophotometer at a wavelength of 405 nm. The caspase enzymatic activities in 
cell lysates are directly proportional to the color reaction. Data from three independent experiments 
performed in triplicate were presented as mean ± SEM with bar graphs.
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